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SUMMARY 
The use of supercritical fluid extraction (SFE) was evaluated for the determination of drugs 
of Forensic interest. Three matrices were investigated. The first two (blood and vitreous 
humor) were compared to SPE and LLE methodology currently in use at the Department of 
Forensic Science and Medicine. The third matrix, hair, was assessed to determine its 
usefulness as a marker of past drug use. 
Three types of drugs were investigated by SFE namely, benzodiazepines, morphine and 
methadone. These drugs were chosen due to their high frequency of occurrence in post- 
mortem cases in the West of Scotland. Successful methodology was developed for all 
three matrices and all three drug types, providing an efficient, reproducible alternative 
method to SPE and LLE, which reduced the environmental risks from organic solvents. 
The developed methods were applied to the analysis of authentic forensic samples. In 
addition to comparing well with the results obtained with the conventional techniques, 
good correlation was obtained between blood and vitreous humor results for temazepam, 
diazepam, methadone and morphine. Thus, in cases where a body is badly decomposed or 
burned, vitreous humor can be used as an alternative post-mortem sample. 
In addition to the determination of morphine, 6-monoacetyl morphine (6MAM) was used 
as a marker of heroin abuse. 6MAM was detected in all three samples matrices, thus 
confirming the use of heroin prior to death. 
Hair analysis for all three types of drugs was carried out using a single extraction method. 
A wide range of concentrations was found for all drug types. As with blood and vitreous 
humor, 6MAM was detected and used as a marker of heroin abuse. From this, 61% of 
known heroin users were confirmed. 
On the whole, the developed extraction methodologies provided an efficient alternative 
approach to drug analysis in Forensic Toxicology. 
from 'Little QcIcnd: T S. C-IIiot 
Chapter One: Introduction to Supercritical Fluids Pagel 
1. SUPERCRITICAL FLUIDS 
1.1 INTRODUCTION 
One hundred and seventy five years ago Baron Charles Cagniard de la Tour discovered that 
above certain temperatures and pressures, some substances can no longer be classified as 
either liquids or gases but share the properties of both. ' The ability to manipulate these 
properties for a variety of applications, by regulating pressure and temperature, is now 
being exploited by the analytical chemist. The most commonly used analytical tools which 
have resulted from the discovery of supercritical fluids are, supercritical fluid extraction 
(SFE) and supercritical fluid chromatography (SFC). 
It is possible to describe a supercritical fluid (SF) by reference to Figure 1.1.2 The areas of 
solid, liquid and gas are well defined by boundaries. Moving along the gas liquid 
boundary, both temperature and pressure increase. The liquid becomes less dense due to 
thermal expansion and as a result of increasing pressure, the gas becomes more dense. 3 At 
the critical point (C. P. ) the densities of the two phases are identical and there is no 
distinction between the gas and liquid phases. The substance can now only be described as 
a fluid. 
The critical point has co-ordinates of temperature and pressure as seen in Figure 1.1. These 
points are specific to a substance and are referred to as the critical temperature (Tc) and 
critical pressure (pc). Other important critical parameters are the critical density (pc) and 
the critical volume (Vc) for one mole of substance. The term supercritical fluid is used to 
describe substances above their critical temperature and pressure. Critical parameters of 
some of the substances used as supercritical fluids are shown in Table I. I. Of these 
substances, the most commonly used supercritical fluid in analysis is carbon dioxide 
(CO2) 4 This is due to its convenient supercritical temperature and pressure, its cheapness, 
its non-explosive nature and its non-toxicity. 
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Supercritical 
Fluid 









Figure 1.1: Phase Diagram for Carbon Dioxide 
Table 1.1: Physical Properties of Selected Supercritical Fluids 
Substance T (°C) pc (atm) (g cm-3) 
CO 31.3 79.2 0.47 
N, 20 36.5 72.5 0.45 
SF6 45.5 37.1 0.74 
NH 132.5 112.5 0.24 
H-20 374 227 0.34 
n-C H 152 37.5 0.23 
n-C H 197 33.3 0.23 
Xe 16.6 58.4 1.10 
CC17 7F 112 40.7 0.56 
CHF 25.9 46.9 0.52 
1.1.1 PROPERTIES OF SUPERCRITICAL FLUIDS 
From a historical viewpoint, the solvating power of a supercritical fluid (SF) was first 
discovered more than a century ago by Hannay and Horgarth. However, it is only in the s 
past thirty years that their use as an analytical tool has been developed. 
Supercritical fluids have several analytically desirable properties. Table 1.2 gives a 
comparison between gas, liquid and supercritical fluid phases for density, diffusivity and 
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dynamic viscosity 4 It can be seen that SF's have densities comparable to liquids, dynamic 
viscosities comparable to gases and diffusivities between liquids and gases. 
Table 1.2: Comparison of Properties of Gases, Liquids and SCFs4 
Phase Density 
p (g m1'1) 
Diffusivity 
D (cm2 s') 
Dynamic viscosity 
71 (g cm'ls'1) 
Gas =10-3 0.01-1.0 0.5-3.5(x10-4) 
SCF 0.2-0.9 3.3-0.1(x10-4) 0.2-1.0(x10-3) 
Liquid 0.8-1.0 0.5-2.0(x10-5) 0.3-2.4(x10-2) 
The combined gas-like mass transfer and liquid-like solvating characteristics of 
supercritical fluids, first led analytical chemists to use them as chromatographic mobile 
phases (supercritical fluid chromatography (SFC))6 and later as fluids capable of removing 
species from solid samples (supercritical fluid extraction (SFE)). In both these techniques, 
probably the most important factor for consideration is the ability of the mobile phase (in 
SFC) or extractant (in SFE) to solubilise the analytes of interest. The solvent strength of a 
liquid is essentially constant regardless of the extraction conditions. However, the solvent 
strength of a supercritical fluid is dependant on the temperature and pressure used for the 
extraction. 7 
1.1.1.1 SOLUBILITY 
By using supercritical fluid technology it is possible to exploit the unusual variations in 
solubility with pressure and temperature, which occur immediately above the critical point 
of a volatile solvent. 8 As stated previously, the solvent strength of a SF depends on the 
pressure and temperature used for the extraction. At constant temperature, extraction at 
lower pressures will favour less polar analytes and extraction at higher pressure will favour 
more polar and higher molecular weight analytes. This variation in solvent strength is 
highlighted in Figure 1.2 which shows the dependence of the Hildebrand solubility 
parameter on temperature and pressure for supercritical carbon dioxide (SF-CO2). 
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Figure 1.2: Effect of Temperature and Pressure on the Hildebrand Solubility Parameter 
for SF-CO 78 
It is essential that the analyte of interest dissolves in the supercritical fluid and thus without 
any knowledge of analyte solubility, the optimisation of analysis conditions can only be 
carried out on a trial and error basis. However, there are many models available which 
describe the solubility of analytes in SF's. The simplest of these is the solubility parameter. 
1.1.1.2 SOLUBILITY PARAMETER 
The dissolution of a solute in a supercritical fluid is a complicated phenomenon thus, the 
theoretical prediction of equilibrium solubility is often difficult. The maximum solubility 
which a solute can attain in a SF can be approximated by relating the solubility parameter 
(8) of the gas to its critical and reduced state properties using Giddings equation: 9 
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S =1.25p, 1/2 
Pr8 
P rl 
where: pc = critical pressure 
p, g = reduced density of gas 
p, ý = reduced density of liquid 
For maximum solubility, the solubility parameters of the fluid and the solute should be 
identical. Therefore, by using the above expression we can estimate which supercritical 
fluid could be used, and at what density for a given solute. 
Other methods which have been used to predict solubility data include equations of state, 
10 
Hildebrand solubility parameters" and the virial coefficient. 12 These approaches require 
some experimental data to compute unknown parameters and often utilise complicated 
equations. ' A simple empirical method was developed by Mitra and Wilson13 which 
predicts solubility as a function of the prevailing temperature, pressure and density based 
on the fact that solubility is determined by a combination of temperature and density. 
However, other properties such as viscosity, diffusivity and polarity also change with 
temperature and pressure and these may affect the equilibrium solubility. Mitra and 
Wilsons' theory is based on a negative gradient linear relationship existing between 
temperature and density, i. e. if the density is raised, the temperature has to be lowered to 
keep the pressure constant. 
1.1.2 PHASE BEHAVIOUR FOR SUPERCRTTICAL FLUID-SOLUTE MIXTURES 
Interpreting and extrapolating high pressure phase behaviour data can be a relentless task. 
This is a result of the complexity of high pressure phase behaviour of substances at or near 
their critical points, even in simple binary mixtures, where the components are chemically 
similar. 14 For a given practical application of SF technology, it is likely that not only will 
the mixture components be different in molecular size, but they will also differ in shape, 
structure and polarity. When the mixture components are so diverse, or when the mixture 
has numerous components, the resultant phase behaviour can be very complex. 
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The addition of polar modifiers to CO2 is well documented. 15 The modifier acts in two 
ways, firstly by interacting with the analyte/matrix complex to facilitate rapid desorption 
into the supercritical fluid and secondly by enhancing the solubility properties of SF-C02. 
The phase behaviour of binary systems is highly varied and much more complex than 
single component systems. Even simple binary compositions can undergo complicated 
phase transitions near the critical region. Gas-liquid or gas-gas immiscibility can occur at 
conditions exceeding the Tc or pc of either pure component. As a result, inhomogeneous 
phases can occur. For mixed phases, the critical constants of temperature and pressure for 
the mixture can be approximated as the arithmetic mean of the critical temperatures and 
pressure i. e.: 
Tc = XaTa + XbTb 
Pc = XaPa + XbPb 
where xa and Xb are the mole fractions, TA and Tb are the critical temperature of a and b and 
pa and Pb the critical pressures of components a and b respectively. More elaborate 
methods are based on the method of Cheuh and Prausnitz16 for the critical temperature and 
Kreglewski and Kay17 for the critical pressure. 
A comprehensive treatment of phase diagrams as well as phase behaviour in binary and 
ternary systems has been published by McHugh and Krukonis. 18 Of the systems described, 
the simplest is concerned with a binary mixture of a single SF solvent and a single solute. 19 
In 1970, Scott and van Konynenburg2° demonstrated that virtually all experimentally 
observed binary phase diagrams can be qualitatively described using the van der Waals 
equation of state. From this, five classes of possible binary phase diagrams were derived as 
indicated in Figure 1.3. Points C1 and C2 represent the critical points of components 1 and 
2 respectively. The dashed line depicts the critical mixture curve for the binary mixture, 
and the open triangles, represent the critical end points. Figure 1.3a is the simplest binary 
phase diagram. The critical-mixture curve runs continuously from the critical point of the 
heavier component to the critical point of the lighter component. 





















Figure 1.3: Five Classes of Possible Binary Phase Diagrams18 
The use of these phase diagrams provides the basis for an understanding of the phase- 
equilibrium principles that are operative during SF solvent extraction of mixtures, and for 
simplicity they are drawn as two-dimensional p-T plots. By looking at the general three- 
dimensional p-T-x plot where x denotes the composition of the heavier component for type 
I binary mixtures (Figure 1.4), it can be seen how these p-T plots are formed. The p-T-x 
diagram is constructed by compiling a number of isothermal p-x plots as shown in figures 
1.4c and 1.4d. Figure 1.4c is a plot at a temperature which is below the critical temperature 
of the two components. A vapour-liquid envelope is observed which intersects the 
pressure axis at two points: the vapour pressure of pure component 1 and the vapour 
pressure of pure component 2. At a fixed overall composition (denoted by x*) a single 
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vapour phase exists at low pressures. As the pressure is isothermally increased, the two- 
phase vapour-liquid envelope is intersected and a liquid phase now appears. The locus of 
points which separates the two-phase vapour-liquid region from the one phase vapour 
region is called the "dew-point curve". The concentration of the equilibrium vapour and 
liquid phases within the two-phase boundary of the vapour-liquid envelope is determined 
by a horizontal tieline. 
As the pressure is increased further, the amount of liquid phase in the mixture increases 
and the amount of vapour decreases until only a small bubble of vapour exists. As the 
pressure is increased still further, the bubble of vapour disappears and only a liquid 
remains. The locus of points which separates the two-phase vapour-liquid region from the 
one phase liquid region is called the "bubble-point curve". This vapour-liquid envelope is 
shown at the front of the three-dimensional p-T-x plot (1.4a). 
If the temperature is now increased to a temperature above the critical temperature of the 
component 1 (Tc1), the behaviour shown in figure 1.4d is observed. The vapour-liquid 
envelope is similar to that in figure 1.4c, however the envelope intersects the pressure axis 
only at the vapour pressure of component 2. As the temperature is greater than Tcl, the 
vapour-liquid equilibrium line for component 1 is never crossed. If an experiment is 
performed at an overall composition of x**, the vapour-liquid envelope is first intersected 
along the dew-point curve at low pressures and then at its highest pressure. The second 
intersection corresponds to the critical mixture point for this temperature and composition. 
If the overall composition is to the right of x** and the pressure is decreased, a bubble 
point is observed and if the overall composition is to the left of this point a dew point is 
observed. Again the three-dimensional plot at this temperatre (T2) is shown in figure 1.4a. 
In order to create the full critical curve, p-x diagrams are produced at higher and higher 
temperatures to determine the critical mixture points. These p-x diagrams are then 
assembled to form the three-dimensional p-T-x representation and the critical mixture 
curve plotted by joining the critical mixture points. Figure 1.3a is created from this by 
projecting the three-dimensional p-T-x diagram onto a two-dimensional p-T diagram. 












Figure 1.4: P-T-x p-T and y-x Diagrams for a Type I Binary Mixture 
The same principles apply when creating the other four binary phase diagrams. An in 
depth description of all five classes of binary mixture behaviour is provided by McHugh 
and Krukonis. '8 
1.2 SUPERCRITICAL FLUID EXTRACTION 
The first step in biological sample analysis involves separating the compounds of interest 
from the matrix (e. g. blood, tissue, urine). At present, this is done mainly by liquid 
extraction techniques such as solid-phase extraction (SPE) and liquid-liquid extraction 
(LLE). These can prove to be time consuming and costly as they require. high . purity 
organic solvents. 2' The use of high purity solvents also means that there is a significant 
amount of toxic waste produced. Supercritical fluid extraction (SFE) which is a quicker, 
more convenient alternative method to liquid extraction techniques offers the following 
advantages. 22 
" Improved efficiency 
" Non-toxicity and cost effectiveness of extraction fluid 
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" Extraction of thermally labile compounds 
" Easy control of conditions 
" Ease of separation of analytes from the supercritical fluid 
" Possibility of direct analysis of complex matrices and thus reduced risk of sample 
contamination 
" Potential of fractionation 
" Compatibility with on-line methods 
" Possibility of class sensitive extraction by choosing fluid polarity and density and/or the 
use of a modifier 
1.2.1 METHOD DEVELOPMENT IN SFE 
Before developing a method for SFE, it is essential that the analyst has an understanding of 
the composition of the matrix and the properties of the analytes. 23 Solubility data and 
correlations as discussed earlier, provide useful information for choosing initial SFE 
conditions. However, the determination of the optimum extraction conditions has been 
largely experimental for two reasons. 8 Firstly, analytical SFE often involves the recovery 
of a complex mixture of analytes rather than a single analyte. In such cases, the extraction 
must be optimised for several groups of compounds which complicates the prediction of 
conditions. Secondly, consideration of solubility only addresses part of the extraction 
problem. As the extraction of an analyte depends on its distribution between the SF and 
the sorptive sites on the sample matrix, the ability of the SF to compete with the analyte for 
the sorptive sites may be more significant than solubility considerations in determining the 
optimum extraction conditions. 
Most SFE methods concentrate on the use of CO2 due to its reasonable critical properties, 
its low toxicity and its chemical inertness. It is an excellent choice for non-polar organic 
compounds. However, it has a severe limitation in that its polarity is often too low to 
obtain efficient extractions, either because the analytes lack sufficient solubility or the 
extractant has poor ability to displace the analytes from the active matrix sites. As most of 
the work on SFE has used analytes spiked on inert supports, it has been assumed that CO2 
is the ideal leacher. However, in authentic samples, the matrix-analyte interactions 
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dramatically reduce the extraction efficiency which further reduces as the polarity of the 
analytes increases. There are however ways of getting round this problem as summarised 
24 in Figure 1.5 
SFs other 
Change paraimters of than ' Use of polar 
SRC02 I modifiers 
Use of ion-pair SMTEGIES 
foram fonmdon 
Esterification and Organometallics 
analogous reactions formation. 
Figure 1.5: Strategies for Facilitating SFE of Polar and Ionic Compounds 
The simplest of these strategies to apply, when SF-CO2 at its most polar is ineffectual, 
would be to use an alternative supercritical fluid. However, in practice, many difficulties 
are encountered when using polar fluids (e. g. ammonia tends to dissolve pump seals and 
water has impractical critical parameters (Tc = 374 °C, pe = 227 atm)). As a result of this, 
the extraction of polar analytes is usually carried out with the addition of polarity 
modifiers. 
The combination of modifier and high temperature has been shown by Yang et a125 to be 
highly effective in the extraction of polar analytes. The modifier can either be added 
directly to the sample in the extraction cell or mixed with the CO2. In general, the latter is 
more effective since the modifier is continuously passed through the sample. However, as 
will be seen later, the addition of the modifier directly to the sample also has its 
advantages. 
Although methanol is the most widely used modifier in SFE, a variety of organic 
compounds have been used including alcohols, propylene carbonate, 2-methoxyethanol and 
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methylene chloride. 26 The selection of modifiers and their concentration has been largely 
empirical as very little analyte solubility data exists for modified SFs. In addition, the 
competitive interactions between the modified SF and the target analytes with the sorptive 
sites on the matrix are poorly understood. Janssen et a127 have evaluated methods of 
estimating critical properties and densities of mixed fluids. 
The use of modifiers in SFE was first reported by Zhuze28 Probably the best known 
extraction using SFE is that of caffeine from coffee and tea. 9 Although caffeine is 
extremely soluble in COZ, it cannot be extracted from coffee and tea leaves using CO2 
alone. The addition of a small amount of water to the CO2 allows almost complete 
extraction thus, emphasising the importance of the use of modifiers. 
1.2.2 ANALYTES 
The choice of analyte is not a free variable, but is predetermined by the sample. Analysts 
are interested in qualitative presence and quantitative amounts of a small number of the 
compounds present in the sample. By adjusting the solubilizing power of CO2 in SFE, we 
can selectively reduce the number of compounds extracted 30 This is done by adjusting the 
temperature and/or pressure or by the addition of a modifier. 
For samples in e. g. blood, serum and plasma, the non-polar nature of SF-CO2 allows easy 
extraction of non-polar drugs e. g. nitroglycerine from water, salts, proteins, carbohydrates, 
peptides, amino acids and other interfering compounds in a biological matrix. In general, 
drugs of abuse are polar in nature and thus, the addition of a polar modifier to SF-CO2 is 
essential to the extraction process. 31 
1.2.3 MATRICES 
SFE exhibits its best advantage when extracting analytes from solids or semi-solids as 
opposed to liquids, fluids and gases. 0 The primary limitation in extracting from a liquid or 
fluid sample matrix is the design of the extraction cell. The matrix is held within the 
extraction cell by porous frits, similar to those used for the end frits in HPLC columns. 
These frits hold small particles inside the column and allow fluids to pass through, thus 
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attempts to pass SF-CO2 through a liquid will result in the liquid matrix passing through 
the frits. Successful SFE of liquids requires the liquid being mixed with a solid material 
e. g. diatomaceous earth so that the sample is no longer free flowing. 
1.2.4 CHOICE OF EXTRACTING FLUID 
A good solvent for extraction should: 21 
" Be selective: as the objective is to separate the analyte from a matrix, the solvent should 
be able to dissolve the desired analyte better than the other constituents of the matrix 
" Have a high capacity for the analyte: this helps minimise the volume and time required 
to extract quantities suitable for analysis 
" Be stable and unreactive to the solute and matrix under the conditions of the extraction 
" Not be corrosive to the equipment 
" Be relatively inexpensive 
" Be non-toxic 
From an extraction point of view, the important properties of supercritical fluids include 
the diffusion coefficient, the density and the viscosity. Faster diffusion leads to more 
efficient separations than liquids facilitate. The viscosity of a supercritical fluid falls 
between that of a gas and a liquid, which facilitates pumping and fluid flow. Enhanced 
passage of the solvent into the interstices of the matrix occurs as a result of low viscosity 
and the absence of surface tension. 
1.2.5 SELECTIVITY IN EXTRACTIONS 
The extraction of analytes from adsorbing matrices involves three basic steps: 32 
1. Removal of compounds from the matrix surface. 
2. Solvation of analytes in the fluid. 
3. Mass transport of solubilized molecules to the bulk of the fluid to allow removal from 
the extraction vessel. 
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To optimise analytical SFE, it is necessary to define a rate determining step (RDS). Due to 
the chemical differences of each molecule and matrix, the analyte-matrix interactions are 
unique for each sample. Conditions have to be selected to emphasise the differences 
between any interferences present and the target analyte in order to achieve effective 
extraction. 
Step three is least likely to introduce selectivity. The primary driving force here is 
molecular diffusion within the solid matrix and the rate is defined by the diffusion 
coefficient. 33 This is inversely proportional to the square root of the molecular weight of 
the solute at constant density of the fluid, therefore if this was the RDS, separation would 
only occur between species of substantially different weights. 34 These differences can be 
emphasised by adjusting the porosity of the extraction matrix. 35 However, in most cases 
the interferents do not differ substantially from the analytes in weight. 
Step two has been extensively investigated. 36.37 To ensure dissolution of the analyte in the 
fluid, the cohesive energy (i. e. the energy which holds the structure of a substance together) 
must be overcome by the interaction of the molecules with the fluid. When this is the case 
the solubility properties of the solutes are defined by the solubility parameter (8). 38 
lo. s [D(Hv - RT) 
0.5 
M 
where: AE = energy of vaporisation V= molar volume 
D= density OH = heat of vaporisation 
R= Gas constant (8.314 J K'' mol"1) T= temperature 
M= molecular weight of solute or fluid 
This same value of S can however be calculated for a SF more conveniently by using 
Giddings equation as described in section 1.1.1.2. 
As the solubility of analytes in a fluid is related to the difference between their solubility 
parameters, the more similar the solubility parameters are, the greater the solubility. It is 
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therefore feasible to design experiments where the analyte is soluble in the fluid, but the 
interferents are not. This is only possible if the analyte and the interferents have different 
solubility parameters. 
The most promising separations are achieved by the presence of an additional phase in the 
system. A distribution constant K, can be defined, which is related to the differences in the 
solubility properties of the two phases. 39 There must be a substantial difference between 
the distribution constants and the solubility parameters corresponding to the analyte and 
interferences to ensure complete separation based on a low efficiency system such as a 
loosely packed extraction column. 
In addition to determining a single type of analyte, the selectivity of SFE can be exploited 
by controlling the temperature and pressure, to perform a sequential extraction of various 
classes of analytes, providing they are of suitably different polarities. At a constant 
temperature, the extraction of non-polar analytes is favoured at low pressures, while the 
extraction of polar analytes requires increased pressure. Most extractions use a low 
temperature of the order of 50 °C and increasing pressure is used to extract increasingly 
more polar target analytes to obviate the risks to thermolabile compounds. However, 
Langenfeld et a14° demonstrated that the influence of temperature is paramount to the 
efficiency of the extraction of polar compounds in environmental matrices. 
Step one makes use of solid surface adsorbants. Separation occurs due to partitioning 
differences caused by different interactions between the target analyte and interactions with 
the surface. Interactions between the surface and the analyte can be in the form of weak 
adsorption through dispersive interactions, but can also involve sharing of electrons 
between the adsorbent and the analyte (chemisorption) 41 Interactions with a surface, are 
much more specific than with a liquid. Small differences in geometry, basicity or acidity of 
the molecules can differentiate between individual molecules. This means that molecules 
with similar solubility properties which differ in chemical or steric properties can be 
separated. 
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The other advantage is that the elution process can be designed to be selective since it 
proceeds through the formation of the activation complex. Figure 1.6 shows the energy 
requirements for the desorption process of an analyte from a solid surface. If partitioning is 
involved, with a liquid as the stationary phase, equilibrium is established immediately 
according to the partition coefficient (neglecting adsorption/desorption kinetics at the 
interface). If the process involved is desorption from a solid surface it is kinetically limited 








Analyte in fluid 
Reaction coordinate 
Figure 1.6: Free Energy v Reaction Coordinate Indicating Enerey Requirements for 
Desorption of Chemisorbed Species31 
The thermal energy easily overcomes the low energy barriers associated with weakly 
adsorbed species. However, strongly adsorbed species require that the activation energy 
(Ea) be reduced by selective interaction of solvent molecules with the matrix-solute 
complex in order to break the bonds. Instead of the solubility parameter of the eluting 
solvent being the most important parameter, its chemical/structural properties have more of 
an effect. It should be noted that it may be easier to remove the interferents first, leaving 
the analyte of interest on the extraction surface until harsher conditions are applied. 
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1.2.6 PARTICLE SIZE 
Another factor effecting extraction recoveries is the particle size of the extracting media. 
Diffusion from the sample matrix is very important. It has been shown that the percentage 
recovery increases from 78% to 99% by halving the particle size. 21 An alternative way to 
increase the recovery would be to increase the extraction time by a factor of four. As one 
of the main advantages of SFE is its reduced time, this is extremely impractical. 
1.2.7 EXTRACTION METHODOLOGY 
SFE can be carried out in either a dynamic or a static mode. 8 However, most SFE methods 
are in the dynamic mode where the SF is passed continuously through the extraction cell. 
Pressure is controlled via a flow restrictor which maintains supercritical conditions inside 
the extraction vessel, but allows depressurisation into a collection device. Static SFE is 
carried out by pressurising the extraction vessel and extracting the sample without an 
outflow of the SF. After a pre-defined time, a valve is opened which allows the extracted 
analytes to be swept out into the collection device. It is here that the advantage of adding 
the modifier directly to the extraction vessel is important. A fixed amount of modifier can 
be added to the matrix and then the extraction vessel pressurised using only CO2. 
An advantage of dynamic SFE is that fresh SF is constantly passed over the surface of the 
matrix containing the analytes. However, this method uses more fluid than static SFE 
which is particularly important when the sample volumes are large. 
1.2.8 OFF-LINE SFE VERSUS ON-LINE SFE 
Off-line SFE is inherently simpler than on-line SFE, as only the extraction step needs to be 
optimised and the extract can be analysed by any appropriate method. 8 On-line SFE 
requires optimisation of both the SFE and the chromatographic conditions and unlike with 
off-line SFE, the sample extract is not available for subsequent analyses. The principle 
advantages of on-line SFE are, the elimination of sample handling between the extraction 
and chromatographic analysis and the potential to achieve maximum sensitivity by 
quantitatively transferring the extracted analytes into the chromatographic system. 
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1.2.8.1 OFF-LINE SFE 
Off-line SFE has been extensively studied as a sample preparation technique for 
chromatographic analysis. 8 The analytes are most often collected in a few millilitres of a 
liquid solvent and analysis is carried out as it would be in a conventional liquid solvent 
extraction. It is adaptable to sample sizes ranging from milligrams to several grams and is 
equally applicable to the recovery of trace analytes or complex mixtures. 2 One important 
concern with off-line SFE is the efficacy of the analyte trapping/collection method as 
discussed in section 1.2.9. 
1.2.8.2 ON-LINE SFE 
The combination of SFE with a chromatographic technique is a logical extension of the 
process. 8 The variable solvating power of a SF provides the mechanism for the selective 
extraction of the components of interest from the sample matrix. It also provides the basis 
for an automated method where the sample preparation and final analysis can be 
instrumentally linked. On-line SFE is particularly attractive for small sample sizes and/or 
trace analysis. 
1.2.9 SFE-COUPLED TECHNIQUES 
A variety of techniques have been used for both on and off line analysis with SFE. 22,43 The 
most common of these is GC8 with both packed and capillary columns. Other methods 
which have been used include TLC44, HPLC45, SFC 46 Selection of the best technique for 
coupling is based on the nature of the analytes e. g. if the analytes have sufficient vapour 
pressure, GC is a good choice due to high resolution per unit time and the possibility for 
the use of many types of detector. 
1.2.9.1 TRAPPING TECHNIQUES FOR SFE- COUPLED TECHNIQUES 
For good results with chromatographic coupling, it is essential to trap and focus the 
analytes before chromatography commences. If this step was omitted, the resulting 
chromatogram would be a collection of flat broad peaks. The trapping methods used must 
be capable of quantitatively collecting all the analytes at relatively high flow rates. 
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Trapping can be external or on-column. External trapping can be done using either a cold 
trap or a sorbent resin. The extract is depressurised onto the trap and once the SFE has 
finished, the trap is heated and the analytes swept onto the chromatographic column. This 
method is preferable to on-column trapping as the fluid does not have to be vented and 
hence, there is no risk of contaminating the column or detector. However, if the primary 
objective is quantitation, on-column trapping is far superior. The use of an external 
cryogenic trap is particularly useful with SFE-GC where a FID is used. Modifiers e. g. 
MeOH, cause detector problems and since the trapping can be made selective, the MeOH 
can be removed prior to injection onto the column. 
1.2.9.2 SFE-TLC 
SFE-TLC provides a rapid and simple insight into the performance of an extraction. The 
strength in this technique is that the extract is deposited directly onto the TLC plate and 
therefore, detection is a static process. 47 Both one and two dimensional chromatography 
can be carried out. 
There are several limitations with this technique including difficult quantitation and low 
resolution compared to SFE coupled with HPLC, GC or SFC. There is also the possibility 
that the high pressures involved in the SFE can cause problems with the TLC support 
material. 
1.2.9.3 SFE-HPLC 
Various off-line applications of SFE-HPLC have been reported e. g. investigating the 
effects of different extraction parameters on the amount of caffeine extracted from roast 
coffee beans. 48 Off-line SFE-HPLC can be carried out using a closed loop system with 
recycling and a trap column. The analytes are washed from the trap column, collected and 
injected into the HPLC system. 
On-line SFE-HPLC was first reported by Unger and Roumeliots in 1983 49 Their system 
consisted of two high pressure sample injection valves connected in series. The first of 
these valves acted as a switch valve to the loop and controlled the pressure over the 
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column. Two short microbore columns were placed between the valves to absorb the 
analytes and act as a sample loop for the second valve which served as an injector for the 
HPLC column. 
1.2.9.4 SFE-GC 
Most of the work on coupled SFE techniques concentrates on SFE-GC, although SFE-SFC 
is becoming more widespread. Examples of off-line SFE-GC include the analysis of 
polyaromatic hydrocarbons (PAH's) and polychlorinated biphenols (PCB's) which are well 
documented in the literature. 2 As samples for GC analysis tend to be volatile, the method 
by which the analytes are trapped is very important. Various trapping methods have been 
tried including solvent traps and sorbent traps (e. g. XAD-2, polyurethane foam and 
Tenax), so 
On-line SFE-GC was first carried out by Hawthorne and Miller51 when they successfully 
analysed automobile-exhaust organics. Since then, the number of applications reported on 
this technique has increased dramatically. 
There are several possible modes of action for SFE-GC, such as quantitative extraction of 
analytes from a matrix, quantitative extraction and concentration of trace analytes and 
selective extraction at various solvating powers. The supercritical extract can either be 
directly pressurised inside a conventional split/splitless injection port or on the column 
itself. The best sensitivity is achieved where the sample is small since all the extracted 
analytes go directly onto the column. If the sample is large, the split mode can be used. 
1.2.9.5 SFE-SFC 
An obvious advantage of SFE is that it is an ideal way to introduce a sample into an SFC 
system. The injection solvent is the same as the mobile phase and therefore, the criteria for 
successful coupling of different techniques are fulfilled. An additional advantage that the 
technique has over SFE-HPLC/GC is that it is highly unlikely that sample components 
which are insoluble in the mobile phase will be introduced into the column. 
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There are many ways of combining SFE with SFC. Conventional packed columns, 
capillary columns and packed capillary columns have all been successfully used. 2 
Directly coupled SFE-SFC with packed columns was introduced in 1985 by Sugiyama et 
a152 for the analysis of powdered coffee beans. No sample pretreatment was required. The 
system was set up with an injector valve containing an extract trap loop after the extraction 
column and another valve prior to the SFC column, which remained closed during the 
extraction step. Once extraction was complete, the valve prior to the column was opened 
and the contents of the extract trap loop flushed onto the column. The use of valve 
switching is very common in SFE-SFC and is well documented 53 
SFE with capillary SFC has also been widely investigated. Gmur et al54 investigated the 
optimisation of important instrumental parameters for the analysis of natural products. On- 
line SFE-capillary SFC had also been coupled with off-line FTIR for the separation and 
identification of PAH's in coal pitch. In this case the samples were collected on a bromide 
ss disc after the SFC. 
The use of packed capillary columns is advantageous as it provides higher loading 
capabilities and shorter analysis times than capillary columns. However, capillary columns 
give lower pressure drops, lower flow rates and higher efficiencies than packed column 
SFC. 
1.2.10 TRAPPING TECHNIQUES IN SFE 
Three different trapping techniques are commonly used in off-line SFE for the collection of 
analytes. 
" Liquid collection 
" Dry deposition onto a solid surface 
" Solid phase sorption 
All three systems have their advantages and disadvantages with respect to choice of 
restrictor type, maximum flow rate and compatibility with various types of SF's, modifiers 
and analytes. 56 
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One of the main problems in SFE, is the limitation in the decompression speed after the 
extraction due to difficulties in collecting the extracted analytes with good efficiency. In 
most systems, the maximum flow through the restrictor is in the range of 0.5-2.0 mLmin-' 
which is equivalent to a flow after the restrictor of 500-1000 mLmiri' of gas. Since it is 
desirable to minimise the extraction time, a maximum flow of 0.5-2.0 mLmin-' of SF leads 
to limitations in the size of the extraction vessel and thus limitations in the detection 
limits. 
1.2.10.1 LIQUJI) (, OLLECTION 
Liquid collection is the simplest method for collecting analytes from an SFE system. The 
restrictor is simply placed into a vial containing solvent as indicated in Figure 1.7. The 
analyte is trapped in the solvent while the decompressed SF vents to the atmosphere. The 
solvent used must be compatible with the analytes and with any modifier which is required 
for the extraction. A broad range of solvents have been used for SFE including methanol, 
methylene chloride, chloroform, acetone and hexane. 57 Due to the cooling associated with 
the decompression of C02, it is possible for the trapping solvent to freeze and for small 
pieces of ice to clog the restrictor tip. For this reason, the restrictor is often heated or the 
collection solvent maintained at a constant temperature. However the advantage of this 
cooling is that it prevents evaporation of the collection solvent which would occur due to 
the high gas flows. 8 
From CO2 pump 
Rheodyne 
Extraction Cell 




Figure 1.7: Diagram of Liquid Collection Set-up 
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1.2.10.2 DRY DEPOSITION 
Here, the surface of a solid is used as a support to collect the analytes of interest. The 
surface may be cooled cryogenically using liquid nitrogen or carbon dioxide or simply by 
the expansion of the SF at the flow outlet. Typical solid surfaces which have been used are 
glass vials, stainless steel beads and glass beads. Once trapped, the analytes are washed 
from the surface and collected for further analysis. With this method, faster flow rates (up 
to 4 mLmin 1) may be used however, an additional washing step is required which is not 
necessary with liquid trapping. 
1.2.10.3 SOLID PHASE SORPTION 
This is often a chromatographic packing material which traps by two mechanisms. The 
trap is cryogenically cooled again either by an external source or by the expanding SF and 
the analytes are absorbed onto the packing material. The analytes can then be washed from 
the packing material using a suitable solvent. As with dry deposition, flow rates up to 4 
mL min' can be used, again an additional wash step is required. 
1.2.11 APPLICATIONS OF SFE 
The applications of SFE, some of which have been mentioned in the course of this report, 
are very varied. In general the applications of SFE have been developed as faster, less 
solvent-intensive alternatives to traditional extraction schemes. Some of the categories of 
compounds have been analysed by SFE are summarised in Table 1.3. 
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Table 1.3: Examples of Uses of SFE 
Explosives and propellants Nitroglycerin 
Trinitrotoluene 
Di ro 1 hthalate 
Polar compounds Phenols 
Pol h drox benzoic acids 
Flavours and fragrances Red and black pepper 
Citrus oils 
Fossil fuels PAH's 
Coal and petroleum itches 
Environmental samples Sediments/soils/sands 
Chlorinated materials 
Pesticides and herbicides 4-nitro phenol 
Natural products Dairy produce 
Fats and oils Triglycerides 
So abean oil 




Drugs of abuse 
1.2.11.1 SFE OFDRucs 
Of the applications mentioned, the one of most relevance to this report is drugs. Several 
methods exist in the literature for the supercritical analysis of drugs but these are mainly 
concerned with chromatography. 58,59,60 
The SFE of alkaloids has been reviewed extensively in particular caffeine and nicotine, 
both of which are of great interest for health and consumer reasons. 61 The extraction of 
chemotherapeutic pyrrolizidine alkaloid from plant substrates has been described by 
Schaeffer et al62 Pyrrolizidine alkaloids are known to be anti-tumour active and more 
recently have become of interest as anti-cancer agents. They occur naturally in several 
plant species and are often difficult to extract and isolate without degradation or the use of 
toxic solvents. Another group of therapeutic drugs which have been reviewed are 
xenobiotics. Nam et a163 applied SFE to various xenobiotics in biological tissues and 
fluids and achieved good recoveries of all but the polar solutes when CO2 was used alone. 
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Methods also exist in literature for the subcritical extraction of morphinic alkaloids in 
urine64, the supercritical fluid extraction of budesonide from blood plasma65 and 
benzodiazepines from solid dosage forms66 and more recently the extraction of drugs of 
abuse (morphine, cocaine) from drug addict hair. 67 As these drugs are mentioned later in 
this report, these papers will be reviewed where relevant. 
In general, despite these examples, the extraction of pharmaceutical drugs and drugs of 
abuse using supercritical fluids is not well documented. 
1.3 INSTRUMENTATION IN SFE 
1.3.1 INTRODUCTION 
Inherently SFE is a simple process. The SF is delivered by a pumping system through a 
thermostated high pressure vessel, containing the sample of interest, and a flow restrictor to 
an appropriate analyte collection device. Due to this, the instrumentation for SFE has 
required little development since it was first introduced. Commercial systems are available 
which have addressed issues like automation, multiple extensions, flow restrictor plugging, 
analyte collection and interfacing. 
A schematic representation of the instrumentation required for SFE is given in Figure I. S. 
It consists of three basic sections. The first of these is a pumping system similar to that 
used in HPLC, the second is an extraction vessel which houses the matrices from which the 
analytes have to be extracted and the third is a pressure regulator. 
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Figure 1.8: Schematic Representation of the Main Components of a SF System 
Two other important components of the SF system are the collection device, used to trap 
the extracted analytes and a flow restrictor at the end of the outlet tubing which helps 
prevent complete depressurisation of the SF in the outlet tubing. A detector, generally UV, 
can also be used to monitor the extraction effluent. 
1.3.2 SFE Pumps 
The pumps used for SFE are derived from HPLC pumps, often with little or no 
modification. One useful adaptation is to cool the head of the CO2 pump so that the CO2 
is in its liquid form and is thus highly compressed. '" It is important to properly insulate the 
CO2 pump cooling system to prevent excessive air moisture condensation and loss of 
cooling efficiency. Cut-to-fit polystyrene foam can be used with expanded polystyrene 
hoses for the cooling system tubing. 
When high flow rates are being used, reciprocating pumps are preferred. As well as 
having the advantage of delivering unlimited volumes within a continuous flow, they can 
easily incorporate a gradient system. When syringe pumps are being used it is found that 
they take a long time to fill their cylinder if only the CO, vapour pressure displaces the liquid 
Pressure Regulator 
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into the pump. Thus, they can only be used with very low flow rates (pLmin 1 c. f. mLmin 1 
for reciprocating pumps). The problem of filling the syringe barrel can be reduced by the 
addition of helium to the CO2 cylinder (padded cylinders). The addition of He to the 
cylinder can enhance the gas head pressure to 110-175 bar. One advantage of using syringe 
pumps at low flow rates is that they provide pulseless flow. However, in most SFE 
applications reciprocating pumps are used. 
1.3.3 CARBON DIOXIDE 
The C02, which is usually the main extraction fluid, is provided as a liquid-gas mixture. 
For analytical SFE, PT10 cylinders containing 7.2 kg of CO2 are used. Regardless of the 
grade of the CO2 used, it is essential that a full length dip tube is installed in the cylinder as 
it is the liquid CO2 which is required for pumping. At room temperature CO2 has a 
substantial vapour pressure which helps displace the liquid to the pump. 
1.3.4 MODERS 
Organic modifiers can be introduced into the eluent in a number of ways. Cylinders doped 
with MeOH, 2-propanol and other solvents are commercially available. Alternatively, 
various mixtures of modifiers in CO2 can be made by mixing the components together in a 
syringe pump or by having a two pump system and using on-line mixing which allows 
gradient eluent compositions. 
1.3.5 EXTRACTION VESSEL 
The high pressure sample vessels initially used for SFE were made using empty HPLC 
columns. Subsequently, vessels designed specifically for SFE have been introduced. 
Unlike HPLC, where only the inlet fitting is under pressure, the extraction column outlet 
fitting is also under pressure and must withstand the maximum operating pressure in 
general at least 4500 psi. 
Conveniently, HPLC fittings can be used for SFE systems, but great care must be taken 
regarding the pressure resistance of such components. When a gas is compressed to a high 
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pressure, at a few hundred kg cm'3, a considerable amount of energy is stored that could be 
explosively released if the vessel is damaged, compared with liquids, where only a little 
energy is stored due to their lower compressibility. 
Saito et a169 calculated that a typical HPLC column with an internal diameter (i. d. ) of 4.6 
mm and an outer diameter (o. d. ) of 1/4" (6.35 mm) has sufficient mechanical strength for 
the maximum operating pressure of 4500 psi. Furton and Rein70'71 studied the effect of 
extraction vessel dimensions for the SFE of PAH's. They found that, the observed 
efficiencies for the largest PAH studied were increased by more than a factor of 2 by 
increasing the vessel diameter : length from 1: 20 to 1: 1. The results indicate that for longer 
cells inductive effects may be important but as the diameter : length ratio increases, 
diffusion controlled mechanisms dominate the extractability of PAH's. 
Ong et a172 designed an extraction cell for use with either liquid or solid samples which 
yielded an extraction efficiency of 98% for cholesterol spiked equine blood/serum. 
Another approach for liquid samples is to absorb the liquid onto a solid material prior to 
extraction. Hopper and King73 reported the use of calcified diatomaceous earth to increase 
the permeability of the sample to the SF extracting solvent, and absorb H2O from the 
sample. 
1.3.6 THE BACK PRESSURE REGULATOR 
The device which characterises SF instrumentation is the back-pressure regulator (BPR). 
The BPR, pressurises the system and is where the main pressure drop of the system 
abruptly occurs. There are two different types of BPR currently used in SFE and SFC. 
1. Simple restrictor 
2. Mechanical or electronic feedback regulator 
A simple restrictor is a capillary tube with an appropriate length for the required back- 
pressure and flowrate. This type of restrictor is used most commonly with open-tubular 
capillary SFC. It is easy to assemble and has a small dead volume. However, in order to 
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change the back-pressure, it is necessary to alter the flowrate as the back-pressure is 
produced only by flow resistance. 
A mechanical/electrical feedback regulator is a complex device consisting of a pressure 
sensitive mechanism and a needle valve. The regulator can control back pressure 
irrespective of the mass flowrate of the fluid. Therefore, these BPR's are more convenient 
to use than simple restrictors for the precise examination of extraction yield versus pressure 
in SFE and other parameters which require measurement under the same mass flowrate. 
However, conventional BPRs have a high dead volume and thus, must be placed in line in 
the system post-detector. 
An ideal BPR should have a low dead volume (<10 µl), high precision, pressure control 
independent of mass flowrate and an external reference signal for pressure/density 
programming. Saito et a174 have developed a new style BPR based on a totally different 
operational system to that conventionally used. Flow resistance is created by changing the 
gap size between a needle valve and a valve seat. The system is based on high speed 
switching of the fluid flow by periodically opening and closing the flow path, and is used 
in conjunction with a pressure transducer and control circuitry for the regulation of back- 
pressure. 
1.3.7 DETECTION IN SFE 
Various types of detector have been used for SFE and SFC including ultra-violet (UV), 
diode array (DAD), flame ionisation (FID), mass spectrometry (MS) and Fourier transform 
infra-red (FTIR). Although the detector is an integral part of a SFC system its use in SFE 
is advantageous as the extraction process can be monitored. 
The most widely used type of detector in SFE is UV. With SFs and UV detectors, some 
noise is inherent due to density related changes in the highly compressible SF. However, 
this is counteracted by the fact that SF-CO2 is transparent even at 190 nm, which is the 
short wavelength cut-off of most variable wavelength detectors. Thus, even compounds 
which are thought to have little or no UV absorbance, e. g. lipids, can be detected by UV at 
wavelengths of <200 nm. This advantage of SF-CO2 is revoked by the addition of 
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modifiers to the SF system which generally have cut-off wavelengths >200 nm e. g. 
methanol -+ 205 nm, ethyl acetate -+ 255 nm, diethylether -º 205 nm 
Although fixed wavelength UV detectors have been the detector of choice for analytical 
SFE, photodiode array detectors have also been used. By using multiwavelength 
photodiode array detectors, it is possible to monitor the UV spectra of an analyte as a 
function of extraction time. 
To utilise any type of UV detector with a SF, it must be equipped with a high pressure flow 
cell which can withstand pressure of at least 4500 psi. Metal gaskets of lead or 24 ct. gold 
with sapphire windows are generally suited for the construction of high pressure flow cells. 
However, the UV cut-off wavelength of sapphire is =220 nm which sacrifices the excellent 
transparency of SF-CO2. Although the tensile strength of quartz is several times lower than 
that of sapphire and thus the window must be substantially thicker, it is a good material for 
use when monitoring below 220 nm. 
1.3.8 FLOW THROUGH THE SYSTEM 
The CO2 remains liquid throughout the pumping and compression zones and passes 
through small diameter metal tubing as it approaches the column (SFC) or extraction cell 
(SFE). A preheated injection valve before the column or extraction cell is useful so that 
supercritical conditions are applied immediately to the analyte matrix. The flow then 
passes through the column/extraction cell at a rate and temperature determined during 
method development. The mathematical product of the time period and flow rate yields a 
net volume of CO2 analogous to partition coefficients and total retention volumes in other 
types of extraction and chromatography. Next, the SF containing the extracted analyte 
flows through additional capillary tubing (via the detector) until it reaches the restriction 
zone at the BPR. After leaving the extraction vessel, the fluid can return to liquid state. At 
this point retaining supercritical conditions for analyte solubility is unnecessary. Lower 
temperatures increase the density which in turn causes an increase in intrinsic saturation 
solubility. At the restrictor zone, the temperature usually increases significantly. Between 
the pump and the outlet of the restrictor the pressure is deliberately increased to a very high 
level. As the fluid passes out of the restrictor the conditions are no longer supercritical. 
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The pressure is lowered to 1 bar in a short period of time over a short linear distance. 
Joule-Thomson type cooling occurs which is compensated by heating the restrictor zone to 
avoid plugging and too rapid precipitation of the analytes, CO2 or any other material 
present. 
Finally the analyte either goes to waste or is collected for further analysis. There are three 
main types of collection device as described in section 1.2.8. All three methods are 
dependent on flow restriction. There is a risk of plugging due to co-extracted or extraneous 
materials due to the sudden decrease in pressure at the flow outlet. This can be prevented 
by the use of a post-extraction solvent flush. 
1.4 SETTING UP OF INSTRUMENTATION 
A home-made SFE system was favoured over a commercial one, as many of the 
components were already available. A schematic representation of the instrumentation 
used for this study is shown in Figure 1.9. The system consisted of the following 
components. 
9 PT 10 CO2 cylinder fitted with a full length dip-tube (7.2 kg of C02) 
" Two Gilson 1OSC pumps programmed via Gilson 715 software 
"A Gilson 811B dynamic mixer 
"A Gilson 805S manometric module 
"A 7125 Rheodyne fitted with a 100 [il injection loop 
"A Pye Series 104 GC oven 
"A Kratos Spectraflow 757 UV detector 
"A Rheodyne 7037 back-pressure regulator 
Chapter One: Introduction to Supercritical Fluids 
co 
2 
Figure 1.9: Instrumentation Used for SFI 
Page32 
The original PTFE (polytetrafluoroethylene) check valves in the C02-IOSC pumphead 
were replaced with PVDF (polyvinyldifluoride) check valves as these are more resistant to 
extremes of heat and cold. This pumphead was chilled using a SFC3 refrigeration unit. 
The second pumphead was used with the PTFE check valves and was used to pump 
modifier. 
The pressure at the pump end of the system (i. e. before the extraction cell) was measured 
by the Gilson 805S manometric module and monitored on the Gilson 715 software 
package. The software controller allows programming of up to four pumps. The CO2 and 
modifier were premixed by the Gilson 811 B dynamic mixer. An HPLC 7125 Rheodyne 
valve fitted with a 100 µl injection loop was used to apply the samples to the extraction 
vessel and this was placed in line between the dynamic mixer and the extraction cell which 
was housed within the GC oven. Ideally the Rheodyne should be placed inside the oven so 
that supercritical conditions are applied directly to the matrix containing the analytes, but 
with the initial set up used, this was not mechanically feasible. 
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The extraction vessels were originally prepared from empty HPLC columns which had the 
stationary phase removed. The dimensions of these columns were 4.6 mm i. d. (0.25" o. d. ) 
10 cm length and they were made of stainless steel. 
The UV detector was next in line and was used to monitor the extractions. The original 
flow cell was replaced with a high pressure flow cell which although larger than the 
original and thus liable to produce more noise, provided better sensitivity and was capable 
of withstanding the high pressure required for SFE. A mechanical BPR was placed 
downflow of the detector which could be opened and closed manually with the use of a 
spanner to maintain the required pressure. The BPR had a gauge attached to it in order to 
monitor the pressure at this end of the system. 
An additional HPLC column (4.6 mm i. d. x 10 cm) loosely packed with Lichoprep 60 was 
placed in the system between the CO2 cylinder and the CO2 pumphead. This was to 
prevent deposits from the CO2 cylinder contaminating the system. 
It is essential that the CO2 cylinder is not allowed to be pumped dry as gaseous CO2 will 
harm the check valves in the pumphead. For this reason in order to monitor the amount of 
liquid CO2 remaining in the cylinder, it was placed on a set of bathroom scales. 
The system which is described above was used for preliminary method development. 
Throughout the course of this study several modifications were made to the system 
however, these will be discussed where relevant in the following chapters. 
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Chapter Two Benzodiazepines paw 
2. BENZODIAZEPINES 
2.1 INTRODUCTION 
Benzodiazepines were accidentally discovered in 1955 by Dr. Leo Sternbach in the 
Hoffman LaRoche laboratories. 75 Initially, it was thought that the newly discovered drug 
belonged to the quinazoline-N-oxide group of compounds. However, further investigation 
showed effects very different to those of the quinazolines. On administration, the new drug 
was found to have calming effects, produce muscle relaxation and prevent convulsions. 
Evaluation of the chemical structure of the drug showed it to be a benzodiazepine and it 
was given the name chlordiazepoxide. Chlordiazepoxide is now marketed under the name 
Librium® and is prescribed for the treatment of anxiety. 
2.2 PRESCRIPTION 
Since the development of chlordiazepoxide, hundreds of benzodiazepines have been 
synthesised and at present 16 are available by prescription in the United Kingdom. 76'77 
These 16 drugs along with some of their proprietary names are shown in Table 2.1. 
The benzodiazepines are used primarily in the treatment of anxiety. However, some are 
used as sleeping aids, some as antiepileptics and three are used as premedications. 
2.3 CHEMICAL STRUCTURE 
After the discovery of chlordiazepoxide, to determine which aspects of its chemical 
structure were related to its pharmacological effects, several other benzodiazepines were 
synthesised. Most were found to have effects similar to chlordiazepoxide however, one 
was found to be much more potent. This drug was given the name diazepam and was 
marketed as Valium®. 
The basic structure of benzodiazepines is detailed in Figure 2.1 and the 10 of the prescribed 
benzodiazepines with this basic structure are indicated in Table 2.2. 









Figure 2.1: Basic Structure of 14-Benzodiazepines 
Table 2.1: Currently Prescribed Benzodia epz ines 
Name Pro rieta Name(s) Treatment Action 
Alprazolam Xanax® anxiolytic PA 
Bromazepam Lexotan® anxiolytic IA 
Chlordiazepoxide Librium®, Tro ium® anxiolytic PA 
Clobazam NA anxiolytic, anti-epileptic PA 
Clonazepam Rivotril® anti-epileptic - 
Clorazepate Tranxene® anxiolytic PA 
Diazepam Valium®, Valclair , 
Diazemuls®, Heminevrin ® 
anxiolytic, anti-epileptic, 
skeletal muscle relaxant, 
premed 
PA 
Flunitrazepam Roh pnolo hypnotic IA 
Flurazepam Dalmane® hypnotic PA 
Loprazolam. NA hypnotic IA 
Lorazepam Ativar® anxiolytic, anti-epileptic, 
premed 
IA 
Lormetazepam NA hypnotic IA 
Midazolam H novel® light sedative (IV) - 
Nitrazepam Mogadon®, Remnos®, 
Unisomnia® 
hypnotic PA 
Oxazepam NA anxiolytic IA 
Temazepam Normison® hypnotic, premed IA 
PA Prolonged action, IA Intermediate action, 
The activity of benzodiazepines arises from the substituent on the 7-position of the 1,4- 
benzodiazepine structure. 8 This is generally a chloride or a nitro group (R4). Substitution 
of chloride or fluoride on the ortho position of the 5-phenyl ring (R2) usually decreases the 
half life and almost always increases the potency. Another developmental approach was to 
synthesise new 1,4-benzodiazepines which were extensively metabolised to 
desmethyldiazepam i. e. pro-drugs. Synthesis of the newest benzodiazepines has involved 
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annelation of the 1,2-diazepine position -with a triazo (alprazolam) or an imidazo ring 
(midazolam). 
Table 2.2: Structural Groups of Classic Benzodiazepines 
Benzodiazepine R1 R2 R1 R4 
Clonazepam H Cl H NO2 
Clorazepate H H COOH Cl 
Desmeth ldiaze am* H H H Cl 
Diazepam CH3 H H Cl 
Flunitrazepam CH3 F H NO2 
Flurazepam C6H14N F H Cl 
Lorazepam H Cl OH Cl 
Lormetazolam CH3 Cl OH Cl 
Nitrazepam H H H NO2 
Oxazepam H H OH Cl 
Temazepam CH3 H OH Cl 
* metabolite of diazepam 
2.4 PHARMACOLOGY 




" Muscle relaxant 
The predominance or potency of these effects differs from drug to drug and therefore, the 
use of a specific benzodiazepine for a particular ailment depends on the acceptability of the 
other properties as side effects, e. g. in sufficient dosage, all benzodiazepines act as 
sedatives. 
Research on the benzodiazepines shows that these drugs attach to specific receptors named 
the benzodiazepine receptors. All benzodiazepines shown to be capable of reducing 
anxiety are also capable of binding to the receptors. The more effective the anxiety relief 
the tighter the binding is found to be. Other drugs which are capable of reducing anxiety 
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e. g. meprobamate, barbiturates and alcohol do not bind to these receptors and hence it 
seems that the receptors are specific to benzodiazepines. 
Scientists believe that the body itself may produce compounds which act on the 
benzodiazepine receptors and are thus working on isolating and identifying a natural 
anxiety-reducing compound. 9 
2.5 METABOLISM 
The metabolism of benzodiazepines is largely predictable. Classic benzodiazepines are 
metabolised by N-demethylation (N-methyl hydroxylation followed by hydrolysis) and by 
hydroxylation in the 3-position of the diazepine ring. This is known as phase I metabolism 
and is followed by conjugation with glucuronic acid (phase II metabolism). Other 
metabolic reactions do occur but these are minimal. In most cases, activity is maintained 
after N-demethylation (e. g. diazepam desmethyldiazepam). After the hydroxylation 
step, the metabolites are rapidly conjugated and therefore do not accumulate in the blood. 
This means that e. g. oxazepam, the hydroxylation metabolite of diazepam, rarely achieves 
significant concentrations in the plasma after the administration of diazepam. Figure 2.2 
indicates the metabolic routes of several benzodiazepines. 
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Figure 2.2: Metabolic Route of Benzodiazepines79 
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2.6 PHARMACOKINETICS 
Benzodiazepines exhibit a two compartment pharmacokinetic model. 9 Central 
compartment redistribution is rapid with a second phase redistribution to adipose and 
peripheral tissue. With single dose administration, the redistribution phase determines the 
duration of action for each benzodiazepine, with lipid solubility being an important 
variable. Highly lipophilic benzodiazepines tend to be redistributed quicker than less 
lipophilic ones. With multiple dosing, once the adipose sites are saturated, the drug is not 
redistributed so quickly. Accumulation of the drug may occur for the more lipid soluble 
drugs which are extensively metabolised. Due to the possibility of active metabolites, and 
the large redistribution of benzodiazepines with high lipid solubility, the characterisation of 
benzodiazepines according to the elimination half life of the parent drug is not a reliable 
indication of the duration, onset or clinical effects of the drug. A better indicator of the 
therapeutic effect of benzodiazepines is the time which benzodiazepines exist at or above 
their therapeutic concentration at the intended receptor site. 
Some of the pharmacokinetic data for the prescription benzodiazepines is given in Table 
2.3. 
Table 2.3: Pharmacokinetic Data for Benzodiazepines80 
Drug tuu2 (hr) VD 
(Lk "1) 
CL 





Al razolam 6-20(12) 1 1 / 70 
Bromaze am 8-19(12) 0.9 / / 40-70 
Chlordiazepoxide 5-30(15) 0.3-0.6 0.5 P: S 33 90-97 
Clobazam 10-58(25) 1 0.5 / 85 
Clonazepam 18-45 2-4 1 / 85 
Clorazepate 2 0.5-2.5 0.1-0.3 P: WB 1.1 97 
Diazepam 20-100(48) 0.5-2.5 0.3-0.5 P: WB 1.8 98-99 
Desmethyldiazepa 25-200(40- 
100) 
0.5-2.5 0.1-0.3 P: WB 1.7 97 
Flunitrazepam 10-70(25) 4 2 P: WB 0.75 78 
Flurazepam 2-3 97 
Loprazolam 4-11(7) / / 
Lormetazolam 10 5 4 / 90 
Lorazepam 2 0.5-2.0 2-8(5) / 95 
Midazolam 9-24(14) 1-2 1 / 90 
Nitrazepam 18-38(28) 2-3 1 / 85-88 
Oxazepam 4-25(8) 0.5-2.0 1-2 P: WB 0.9 95 
Temaze am 3-38(10) 1 1-2 P: WB 1.9 97 
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t112 = elimination half life from blood (bracketed numbers = mean) 
P: S; Plasma : Saliva 
P: WB; Plasma : Whole Blood 
2.7 PHARMACODYNAMICS 
Pharmacodynamically, a reverse loop hysterisis has been seen with some benzodiazepines. 
This means that while benzodiazepine concentrations remain constant or increase, the 
impairment of mental functioning improves over the time course of a few hours. It is 
unclear why this happens, but it is thought that receptor kinetics and adaption are more 
important in determining the pharmacodynamic effects of the benzodiazepines. $' 
2.8 LEGAL STATUS 
Benzodiazepines are prescription only medicines. They were inserted into the Misuse of 
Drugs Act in 1985 and are controlled under Class C which makes them illegal to supply. 
However, it is legal to possess them in the medicinal form without a prescription. 
2.9 ANALYSIS OF BENZODIAZEPINES 
Reviewing the previous literature on the analysis of benzodiazepines shows an increase in 
the reporting of SPE compared to LLE and HPLC and GC/MS compared to GC/FID and 
GC/ECD. In his handbook on benzodiazepines, Schütz reviewed the extraction 
methodology of the late 1970's and early 1980's. 82 Of 21 reviews, only 3 use HPLC as the 
method of choice for analysis and only one reference was made to the use of MS as a 
detector. 
The most recent literature has been concerned with the GC/MS analysis of benzodiazepines 
with derivatisation. In 1996, Valentine et a! 94 compared the use of HPLC versus GC/MS 
for the quantitation of urinary benzodiazepines. They conclude by stating that both 
methods can be used for the determination of benzodiazepines. However, HPLC offers 
some advantages including reduced analysis time and better determination of some of the 
benzodiazepines e. g. chlordiazepoxide. Table 2.4 summarises some of the more recent 
literature detailing the type of extraction and analysis. 
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19911, GC/MS/MS SPE Q 10 ml Urine 
19911, GC/NPD, 
HPLC 
LLE S/Q 1 ml Serum 
19911, FPIA, 
HPLC 
LLE S/Q 1 ml Serum 
1994 86 / IA S / Urine 
198987 GC/MS SPE 2 ml Urine 
1992 HPLC SPE 1 ml Blood 
1994 89 HPLC LLE I ml Blood 
199690 HPLC SPE Q 1 ml Serum/ 
Plasma 
19959, HPLC LLE S/Q 1 ml Blood/SC/ 
Liver 
1995 92 GC/MS LLE 1 ml Urine 
1997 93 HPLC SPE Q lg/2 ml Tissue/ 
Blood 
1996 94 GC/MS, 
HPLC 
LLE Q 3 ml, 
1 ml 
Urine 
SC: stomach contents. 
2.10 SUPERCRITICAL FLUID ANALYSIS OF BENZODIAZEPINES 
As with most drugs of abuse there is a severe lack of literature available on the SFE of 
benzodiazepines. To date only one other group appear to have investigated the extraction 
of benzodiazepines using SF's. Lawrence et al used SFE to extract benzodiazepines from 
95 their solid dosage forms. Their method used CO2 with 2% MeOH as a modifier, a 
temperature of 65 °C and 100 atmospheres pressure with an extraction time of 15 minutes 
(5 minutes static, 10 minutes dynamic). The drugs analysed represented parent drugs and 
metabolites (e. g. oxazepam was readily extracted). In addition, by using GCIMS, no 
matrix components or contaminants were found to be extracted. 
2.11 CURRENT METHODOLOGY 
The methodology used at present in the routine toxicology laboratory consists of SPE 
followed by HPLC with UV detection. The SPE method is detailed in section 2.11.1 and 
was used as a comparison method for SFE. The HPLC method used is described in 
Section 2.12.1.1. 
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2.11.1 SPE OF BENZODIAZEPINES 
A 10 ml Plastipak syringe was plugged with a small amount of glass wool and 3/4 filled 
with dichloromethane (DCM) washed Extrelut® (diatomaceous earth). Three types of vials 
were prepared as follows: 
1) Standard vial containing: 100 µl of standard mix (temazepam, triazolam, 
chlordiazepoxide, desmethyldiazepam and diazepam, all 3-5 mg/100 ml), 100 ml of 
prazepam (3 mg / 100 ml), 0.9 ml blank blood, 250 µl 5% NH3 and phosphate buffer 
(pH 7.4). 
2) Blank vial containing: 100 µl of prazepam (3 mg/100 ml), 1 ml blank blood, 250 µ15% 
NH3 and 1 ml of phosphate buffer. 
3) Sample vial containing: 100 µl of prazepam (3 mg/100 ml), 1 ml sample blood, 250 µl 
5% NH3 and 1 ml of phosphate buffer. 
For each vial, an Extrelut® column was prepared and a labelled 8 ml vial placed under each 
column. 250 µl of 5% NH3 were pipetted onto the top of each column and the vortexed 
contents of each vial pipetted onto the appropriate column. This was allowed to sit for 5 
minutes before elution with diethylether under gravity. Approximately 7 ml were eluted 
and then evaporated to dryness under a stream of N2. The dried residue was reconstituted 
in 180 µl of HPLC mobile phase. 
The phosphate buffer added to the vials was prepared as follows: 
A= 13.6 g of KH2PO4 / 500 ml H2O 
B =4 g of NaOH / 500 m1 H2O 
450 ml of A and 355 ml of B were mixed and the pH adjusted to pH 7.4 using either A or 
B. 
2.12 HPLC OF BENZODIAZEPINES 
2.12.1 SEr-UP OF HPLC 
2.12.1.1 EXPERIMENTAL 
A Gilson HPLC system was tested to ensure that the analytical results produced for the 
separation of benzodiazepines were comparable to those produced in the routine 
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laboratory. The system consisted of a Gilson 305,5SC pump, a Gilson 805 manometric 
module, and a Gilson 115 UV detector controlled via Gilson 715 software. The mobile 
phase (0.01M Na2HPO4 : MeOH (30 : 70 (v/v)) was prepared as follows and allowed to 
equilibrate in the HPLC system for 30 minutes before recycling. 
1.78 g of Na2HPO4.2H20 (m. wt. 177.99) was dissolved in 1L of distilled water (dH2O). 
120 ml of this was added to 280 ml of MeOH and degassed with helium for 10 minutes at 
room temperature. 
The flowrate for the separation was 1.0 ml min'' which gives a pressure of approximately 
2500 psi through a 25 cm x 4.6 mm i. d. Hypersil ODS column. Injections were controlled 
via a 7125 Rheodyne fitted with a 20 µL loop. For the detection of benzodiazepines, the 
wavelength used was 254 nm. 
Solutions of the eleven benzodiazepines listed in table 2.5 which had been prepared for the 
routine laboratory were analysed by HPLC. A1 ml aliquot of each standard was pipetted 
into a vial, evaporated to dryness under N2 at 60 °C and reconstituted in 1 ml of HPLC 
mobile phase. By reconstituting the standards in mobile phase, the solvent front and peak 
distortions are minimised. A 20 tl injection of each solution was made into the HPLC and 
the chromatograms recorded on a Asea Brown Boveri (ABB) SE 120 chart recorder. 
2.12.1.2 RESULTS AND DISCUSSION 
The retention times and capacity factors obtained from the chromatograms of the eleven 
benzodiazepines, including the five routinely screened for (marked * in Table 2.5), with 
prazepam as an internal standard are shown in Table 2.5. 
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Table 2.5: Retention Times of Selected Benzodiazepines. 
Drug Retention time (R. T. ) 
(minutes) 
Capacity Factor (k') 
Clonaze am 4.4 0.96 
Nitrazepam 4.7,6.9) 1.19 (2.21) 
Clobazam 5.2 1.31 
Lo razolam 5.6 1.49 
Lorazepam 6.0, (9.9) 1.22 (2.67 
Triazolam * 5.7 1.11 
Oxazepam 6.4 1.37 
Temaze am * 6.8 1.52 
Chlordiaze oxide * 7.1, (8.3) 1.63 (2.07) 
Desmeth ldiaze am * 7.7 1.85 
Diazepam * 8.7 2.22 
Praze am 14.3 4.30 
Each of the benzodiazepines chromatographed had separate retention times and capacity 
factors. However, for several of the drugs, the retention times and capacity factors were 
close e. g. loprazolam (5.6 min) and triazolam (5.7 min) and thus, it would be desirable to 
have a separate method in order to verify which drug was being detected in an unknown 
sample. 
It was essential that great care was taken while preparing the mobile phase. The elution of 
benzodiazepines is extremely sensitive to the addition of excess methanol to the system. 
Inaccuracies of as little as 5 ml in a litre of mobile phase was found to cause co-elution of 
some of the more commonly encountered drugs e. g. temazepam and chlordiazepoxide. 
2.12.2 DETERMINATION OF RETENTION TIME OF CHLORDIAZEPOXIDE, NITRAZEPAM AND 
LORAZEPAM 
2.12.2.1 EXPERIMENTAL, RESULTS AND DISCUSSION 
As can be seen in Table 2.5, the injections of chlordiazepoxide, nitrazepam and lorazepam, 
gave two peaks. Fresh standards of these drugs were prepared in methanol and these gave 
only one peak per drug (the retention time which is not in brackets). Of the three, 
chlordiazepoxide is the only one of relevance to this study, as nitrazepam and its 
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metabolites are chromatographed by a separate method and lorazepam is only analysed for 
in cases where the subject is known to have used the drug. 
2.12.3 CHLORDIAZEPOXIDE STABILITY 
The degradation peak of chlordiazepoxide elutes between desmethyldiazepam and 
diazepam and for the normal standard mix used (triazolam, chlordiazepoxide, temazepam, 
diazepam, desmethyldiazepam) does not affect the chromatography to any great extent so 
long as the optimal methanol volume is not exceeded. Chlordiazepoxide abuse at the time 
of this initial study was extremely rare and on the occasions where positives were 
observed, a fresh standard was prepared for quantitation purposes. However, the situation 
in 1997 has changed with reference to benzodiazepines and with the withdrawal of 
temazepam from the market, more chlordiazepoxide is found in case samples. 




Figure 2.3: Structure of Chlordia epoxide 
2.12.3.1 EXPERIMENTAL 
A short study was carried out to see how quickly the chlordiazepoxide decomposed. A 
standard mix containing all five of the standards used in the laboratory was prepared by 
pipetting 5 ml of each drug standard (5 mg/100ml) into a vial, evaporating to dryness under 
N2 at 60 °C and reconstituting in 5 ml of MeOH. For injection onto the HPLC, aliquots of 
Chapter Two Benzodiazepines Page45 
this standard mix were pipetted into a vial, evaporated to dryness and reconstituted in the 
appropriate volume of mobile phase. 
In addition, a fresh chlordiazepoxide standard was prepared by dissolving a5 mg Librium 
tablet into 100 ml of methanol in a volumetric flask. The study was carried out over one 
week to determine how quickly the degradation peak appeared. 
2.12.3.2 RESULTS AND DISCUSSION 
The relative peak heights of the five standards to prazepam were calculated from the traces 
obtained from HPLC injections on day one and day eight and are shown in Table 2.6. 
Table 2.6: Chlordiazepoxide Stability Study 






Triazolam 5.3 1.26 1.07 
Temaze am 6.3 1.46 0.91 
Chlordiaze oxide 6.7 1.14 0.20 
Desmeth ldiaze am 7.4 1.56 1.30 
Im uric 7.8 0 0.74 
Diaze pam 8.1 1.20 1.13 
Praze am 13.4 1.00 1.00 
Although none of the relative peak heights from days one and eight have remained 
constant, the one which has shown the most marked decrease is chlordiazepoxide. Over 
the eight days, an impurity peak has appeared which elutes between desmethyldiazepam 
and diazepam. By injecting each of the drugs on their own, it was confirmed that this peak 
was due to the chlordiazepoxide as each of the other drugs produced only one peak none of 
which corresponded to the impurity peak. 
For the chlordiazepoxide on its own, initially (t=0 hours), only one peak was observed. At 
the end of the first day (t=2 hours) an additional peak was observed at 7.8 minutes with a 
height of 0.6 cm. After 18 hours the peak height had increased to 2.1 cm and after 4 days 
the peak height was 8.5 cm corresponding to a 1417% increase from t=2 hours. These 
results are shown graphically in Figure 2.4. 
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Figure 2.4: Increase in Height of ' Chlordia epoxide Impurity Peak with Time 
As chlordiazepoxide rapidly degrades, it is essential that if a case sample is positive, a new 
chlordiazepoxide standard is prepared prior to quantification. It should be noted that the 
relative height of the impurity peak to chlordiazepoxide could not be calculated as in order 
to measure the height of the impurity peak, the sensitivity of the detector had to be 
increased and thus, the chlordiazepoxide peak was off scale on the chart recorder. 
The HPLC chart recorder traces of the chlordiazepoxide and its impurity on days one and 
four are shown in Figure 2.5. 
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Figure 2.5. Chromatograms of Chlordiazepoxide Peaks on Days One and Four 
2.12.4 IDENTITY OF CHLORDIAZEPOXIDE IMPURITY PEAK 
2.12.4.1 EXPERIMENTAL 
A fresh standard of chlordiazepoxide in MeOH was prepared (1 mg/5 ml). This was 
injected into HPLC and GC/MS immediately after preparation. Each day after, further 
injections were made on both instruments and the impurity peak monitored. The solution 
was made concentrated so that the impurity peaks mass spectrum could be obtained for 
quantification. Several small impurity peaks were observed in the chlordiazepoxide mass 
chromatogram. Only one of these was found to increase in area with time. After 28 days 
at room temperature, the impurity peak was larger than the chlordiazepoxide peak. 
The mass spectrum obtained for the impurity peak was investigated in order to attempt to 
identify the impurity. The mass spectrum obtained is shown in Figure 2.6. 
Time (minutes) 
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Figure 2.6: Mass Spectrum of Chlordiazepoxide Impurity 
As it was not possible to determine the structure of the impurity from this information, an 
additional study was carried out. Approximately 0.5 mg of chlordiazepoxide was dissolved 
in H2O, MeOH, EtOH and deuterated MeOH (D3OD). Again the solutions were injected 
on day one and consecutive days thereafter, until the impurity peak mass spectrum could be 
ascertained. 
The mass chromatograms for the chlordiazepoxide in H2O and EtOH showed no impurity 
peak after 10 days. The chromatograms for chlordiazepoxide in MeOH and CD3OD 
showed a peak at the same retention time that had been observed for the experiment 
previously carried out in MeOH. The mass spectra of these impurity peaks are shown in 
Figure 2.7, the mass spectrum for chlordiazepoxide is also given for comparison. 
From these spectra alone, it was not possible to identify the impurity. It can be 
hypothesised that in some way the MeOH (CD3OD) is adding into the chlordiazepoxide 
structure (from the m/z 313 in the MeOH which becomes m/z 317 in CD3OD) possibly at 
the imino amide part of the diazepine ring. 
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Figure 2.7: Mass Spectra of CDP Impurity in MeOH and D30D 
2.12.5 RETENTION TIME REPRODUCIBILITY 
2.12.5.1 EXPERIMENTAL 
The remainder of this study was carried out using only the five benzodiazepines routinely 
screened for as highlighted in Table 2.5. Three to five injections of each of the standards 
were made in order to check the retention time reproducibility of the HPLC system for an 
equilibrated mobile phase (MP1). An injection of each standard was also made using a 
freshly prepared mobile phase (MP2) to ensure reproducibility in the mobile--phase 
preparation. The second mobile phase was equilibrated in the system overnight. 
2.12.5.2 RESULTS AND DISCUSSION 
The retention time reproducibility results are reported in Table 2.7, where xi and x2 are the 
mean retention times for mobile phases 1 and 1+2 respectively. The relative standard 
deviation (RSD) for each set of means was computed using a calculator. 
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Table 2.7: Infection Time Reproducibility 
Sample MP1 MP2 xl X2 RSD1* RSD2 
Triaz 5.3, 5.3, 5.2, 5.2, 5.3 5.2 5.3 5.3 1.04% 1.04% 
Temaz 6.4, 6.3, 6.3 6.2 6.3 6.3 0.91% 1.29% 
CDP 6.8, 6.8, 6.7, 6.7, 6.7 6.6 6.7 6.7 0.81% 1.12% 
DMD 7.4, 7.4, 7.4, 7.4, 7.4 7.3 7.4 7.4 0.00% 0.55% 
Diaz 8.1, 8.2, 8.1, 8.1, 8.1 8.2 8.1 8.1 0.55% 0.63% 
Praz 13.6, 13.4,13.4 13.4 13.5 13.5 0.86% 0.74% 
*For calculation of RSD see Appendix 11. 
From these results it is apparent that the reproducibility of the system is sufficient for use 
both on a daily basis and a weekly basis which requires changing of the HPLC mobile 
phase. There is little variation seen in the retention times of the peaks and the RSD values 
are low (all less than 1.3%). 
2.13 SET UP OF SFE SYSTEM. 
2.13.1 INrrrAL SET-up 
The initial SFE set-up is described in Section 1.4. A start-up check list was devised as 
indicated below: 
" Switch on the chiller unit, the detector and the GC oven 
9 Prime the modifier pump with the CO2 cylinder closed 
" Once the chiller is cold, check the system for leaks with CO2 (Do not pump CO2 until 
the chiller is cold) 
" Once the oven is at the correct temperature, switch on the pumps and the mixer 
" Adjust the pressure using the back-pressure regulator 
" Place the extraction cell into the oven 
" Put the analyte collection device in-line (in this case a6 ml hypovial containing -2 ml 
of MeOH) 
" Start the run using the Gilson 306 software 
" Inject the matrix containing the analytes to be extracted into the rheodyne 
9 Switch the rheodyne valve from load to inject and remove the syringe 
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After extraction: 
" Switch the rheodyne valve from inject to load 
" Remove the collection vial 
" Evaporate the MeOH to dryness 
" Reconstitute the residue in HPLC mobile phase 
" Inject the sample onto HPLC 
At the end of the day: 
" Stop the flow. 
" Remove and clean the extraction vessel. 
" Isolate the two halves of the system by switching the rheodyne to the middle position 
and letting the pressure drop on the oven side. 
" Unplug the chiller unit. 
" Switch off the mixer, the oven and the detector. 
" Turn off the CO2. 
2.13.1.1 EXPERIMENTAL 
In order to check that the system had no mechanical or electronic faults and that there were 
no leaks, an ODS Hypersil (25 cm x 4.6 mm i. d., 5µ particle size) HPLC column was 
inserted into the GC oven. A 100 t1 injection of a mixed solution of the five 
benzodiazepine standards was made under the following conditions: 
1%-25% MeOH in CO2 over fifteen minutes, hold for two minutes, back to 1% MeOH 
over one minute at 60 °C and 0.5 ml min''. 
2.13.1.2 RESULTS AND DISCUSSION 
All six peaks were found to elute within the first few minutes and the peak shapes were 
very poor. However, on injecting blank MeOH, no peaks were observed other than a slight 
solvent front indicating that the system was functioning and improvement of the 
chromatography could be achieved with simple method development. 
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However, the purpose of this study was SFE and thus, as the system was functioning, an 
extraction vessel was prepared. An empty HPLC column (10 cm x 4.6 mm i. d. ) was half 
filled with DCM washed Extrelut°. 200 µl of the benzodiazepine standard mixture was 
loaded into this and the column inserted into the oven which was set at 60 °C. At the flow 
outlet, a hypovial containing MeOH was attached, ensuring that the end was immersed in 
the MeOH. The vial was sealed using a butyl rubber septa and a disposable needle was 















Figure 2.8: Collection Device for SFE 
Initially I% MeOH was pumped through at I ml min-', however, as the pressure increased, 
the flow had to be decreased to 0.5 ml min-1. The percent of MeOH was increased stepwise 
to 25% over three minutes. Next, the ODS column was reinserted in place of the 
extraction vessel, and the extract injected. All previously detected peaks were found to 
elute. 
These two experiments indicated that the SF system was functioning properly and thus was 
suitable for use for the SFE of benzodiazepines. 
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2.14 METHOD DEVELOPMENT: SFE OF BENZODIAZEPINES 
Several benzodiazepines were investigated by SFE, namely triazolam, temazepam, 
diazepam, desmethyldiazepam, chlordiazepoxide and prazepam. These were initially 
extracted from methanol standards by loading 200 µl of the mixed drug standard onto 
DCM washed Extrelut®. The Extrelut® was chosen as an extraction media as this is the 
same as that used in the routine SPE method. 
2.14.1 SFE OF TRIAZOLAM 
2.14.1.1 EXPERIMENTAL 
As opposed to extracting all five benzodiazepines at once, it was decided to investigate one 
drug and then apply the developed conditions to all five. Triazolam was the first 
benzodiazepine to be investigated. The initial conditions used were 5% diethyl ether, 1500 
psi, 0.5 ml min 1 and 70 °C. Again, diethyl ether was chosen as a modifier as it is used 
in 
the SPE of benzodiazepines. Using these conditions, two fractions were collected, one 
from 0-5 minutes and the other from 5-10 minutes. 
The extracts were collected into MeOH at the flow outlet, evaporated to dryness under N2 
at 65 °C and reconstituted in 100 µl of HPLC mobile phase. 
A second extraction of triazolam was carried out using the same conditions except that the 
pressure was increased by closing the pressure regulator to a pressure of 3000 psi. For this 
extraction, the extract fractions were collected from 0-8 minutes and 8-15 minutes. 
2.14.1.2 RESULTS AND DISCUSSION 
HPLC of the first extraction fractions showed several peaks at the solvent front and one 
peak at 4.6 minutes. This peak was masking two other peaks at 4.2 minutes and 5.1 
minutes. On injection of a standard solution of triazolam this was found to have a 
retention time of 5.4 minutes, thus no triazolam had been extracted. On HPLC of the 
second extraction extracts, the 0-8 minutes extract showed a peak at 5.3 minutes 
corresponding to triazolam. The recovery, as calculated by comparing the PH of the 
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extracted standard to that of an unextracted standard at the same concentration, for this 
part of the extraction was very low (<5%). The 8-15 minutes extract had no corresponding 
peaks. 
2.14.2 SFE OF TEMAZEPAM 
The number of toxicology cases in the period 1992-1996, which were positive for 
benzodiazepines was investigated and yielded the bar chart shown in Figure 2.9. No 
triazolam positive cases were found in this time period. In addition to this, it was found 
that the most commonly encountered benzodiazepine in toxicology samples in the period 
leading up to this study in 1994 was temazepam. For this reason it was decided to use 
temazepam instead of triazolam as a starting drug. 
Temazepam 
  Diazepam 
  Desmethyl diazepam 
  Chlordiazepoxide 
Q Nitrazepam 
Figure 2.9: Ben: odia: epine Cases 1992-1996 
2.14.2.1 EXPERIMENI AL 
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The second set of conditions used for triazolam (i. e. 3000 psi, 5% diethyl ether, 0.5 ml 
min-', 70 °C) were used for the extraction of temazepam. The pressure was difficult to 
control and fluctuated throughout the extraction. For this reason all pressures quoted 
1992 1993 1994 1995 1996 
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development are an average of the initial and final pressures. All extractions were run for 
fifteen minutes unless otherwise stated. 
2.14.2.2 RESULTS AND DISCUSSION 
At an average pressure (pa) of 2502 psi, temperature at 70 °C and 0.5 ml min 1, only a very 
small amount of temazepam was extracted (<I%). At the same temperature and pressure 
but with 15% diethyl ether, the recovery was still less than 5%. The modifier was changed 
from diethyl ether to methanol and this time the peak height of the extracted temazepam 
increased from 2.9 cm to 20.8 cm which corresponded to an approximate recovery of 
100%. 
2.14.3 SFE OF THE STANDARD MIX + INTERNAL STANDARD 
2.14.3.1 EXPERIMENTAL 
As the 15% MeOH, 70 °C, 0.5 ml min' extraction conditions appeared to work for 
temazepam, a mix of the standards and the internal standard was extracted at 15%, 10% 
and 5% MeOH. The pressure was = 3000 psi, the flowrate 0.5 ml miri d, and the 
temperature 60 °C in all cases. Only the 15% and 10% extractions could be directly 
compared as the 5% run was carried out using a different standard mix. 
2.14.3.2 RESULTS AND DISCUSSION 
The results obtained for the SFE of the five standard benzodiazepines with prazepam as the 
internal standard at varying percents of MeOH are shown in Table 2.8. The retention times 
(R. T. ) are in minutes and the peak heights (P. H. ) in cm. 
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Table 2.8: Comparison of Extractions at Various % MeOH 
Drug 15% MeO H 10 % MeO H 5% McO H 
R. T. P. H. PHR R. T. P. H. PHR R. T. P. H. PHR 
Triaz 5.4 2.3 3.3 5.4 4.6 2.1 5.4 6.75 1.2 
Temaz 6.4 2.5 3.6 6.4 4.4 2.0 6.4 5.1 0.9 
CDP 6.8 0.9 1.3 6.9 1.8 0.8 6.9 1.8 0.3 
DMD 7.5 1.2 1.7 7.5 4.8 2.2 7.4 7.6 1.4 
Diaz 8.4 0.9 1.3 8.3 2.6 1.2 8.3 6.6 1.2 
Praz 14.1 0.7 1.0 14.1 2.2 1.0 14.1 5.5 1.0 
A blank extraction of MeOH was made to see if there was any carry over of the 
benzodiazepines within the system. Traces of all the benzodiazepines were observed by 
HPLC. A second blank extraction was carried out this time using diethyl ether. Again 
peaks were observed by HPLC. Finally, another MeOH blank was extracted. This time, 
no peaks were observed by HPLC. The carry over peaks indicate that either the extraction 
time is not long enough, that the conditions are not ideal for 100% recovery, that the drugs 
have an affinity for the stainless steel tubing or that there is a "cold-spot" in the SFE 
system. 
From the results in Table 2.8, it appears that as the % modifier is reduced, the peak heights 
of the drugs extracted increases. The extraction at 10% was repeated. However on 
injection onto HPLC at the previous sensitivity of 0.05, all peaks were off scale. It was 
noted that the GC oven had been switched off and therefore, the extraction mixture was not 
supercritical. As a result of this, the effects of temperature on the extraction were 
investigated. 
2.14.4 TEMPERATURE EnEcrs. 
2.14.4.1 EXPERIMENTAL 
A series of extractions were carried out on the standard mix at ambient, 40 °C and 60 °C. 
The flow was set to 0.5 ml mini 1 with MeOH as the modifier at 10%. A new extraction 
column was put in place. The pressure for the ambient extraction was - 4500 psi which 
was too high and thus the pressure was decreased by opening the regulator until a pressure 
of = 3500 psi was obtained for the other extractions. To ensure that there was no carryover 
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between extractions, blank diethyl ether was injected between each extraction. No carry 
over peaks were observed. 
2.14.4.2 RESULTS AND DISCUSSION 
The % recoveries calculated for the extraction of the five benzodiazepines at various 
temperatures on a peak height basis are shown in Table 2.9. 
Table 2.9: Recoveries for Standard Benzodiazepines at Various Temperatures 
Drug Unextracted Ambien t 40 °C 60 °C 
P. H. PHR P. H. %Rec PHR P. H. %Rec PHR P. H. %Rec PHR 
Triaz 12.3 1.07 14.4 117 1.5 9.5 77 1.51 1.6 13 1.6 
Temaz 10.4 0.90 8.9 86 0.93 6.3 61 1.00 1.0 9.6 1.0 
CDP 2.3 0.20 2.1 91 0.22 1.4 61 0.22 0.2 43 0.2 
DMD 14.4 1.25 13.3 92 1.39 9.2 64 1.46 1.5 10 1.5 
Diaz 13.0 1.13 10.9 84 1.14 8.0 62 1.27 1.2 9.2 1.2 
Praz 11.5 1.0 9.6 83 1.0 6.3 55 1.0 1.0 8.7 1.0 
It can be seen that as the temperature increases the % recovery decreases, but at low 
temperatures, the system is not operating in the supercritical mode. The benzodiazepines 
seem to be remaining absorbed on the Extrelut® at the higher temperatures. 
The temperature in the SFE system was set to 50 °C and the extractions run at 10,15 and 
20% MeOH. The pressure and flow rate were left at- 3500 psi and 0.5 ml min 1. These 
conditions did not improve the extraction efficiency and it was thought that at the higher 
percents of MeOH that the system was again not supercritical. 
2.14.5 CRITICAL TEMPERATURE OF CO2 AND MEOH MIXTURES 
As an estimation of the critical temperature at various % modifiers, a straight line graph 
can be plotted from T,, for CO2 to Tc for modifier. Using the X-axis for % modifier from 
0-100%, with the critical temperatures of the two components on the y-axes, the T, of the 
mixture can be approximated. In practice, due to forces mentioned in section 1.1.2 of the 
SF introduction, these temperatures may not be supercritical and thus a temperature of 5- 
10 °C higher is suggested as a good starting point for method development. 
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The graph in Figure 2.10 shows the approximate critical temperatures for CO2 and MeOH 
mixtures. So for example at 30% MeOH in C02, the approximate critical temperature 









Figure 2.10: Approximation of the Critical Temperature ofMeOH in Supercritical CO2 
2.14.6 CONTINUATION OF TEMAZEPAM METHOD DEVELOPMENT 
Instead of trying to further continue this line of method development with all five 
benzodiazepines plus the internal standard, it was decided to once more investigate 
temazepam on its own. The conditions developed should extract the other 
benzodiazepines due to their similar structures. 
2.14.6.1 ExP EwTAL 
The initial conditions used for the temazepam extraction were: 
" Flow rate: 0.5 ml min 1 
9% modifier: 20% MeOH 
" Temperature: 70 °C 
0 20 40 60 80 100 
% MeOH 
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" p;: 4017 
" Pf: 4075 
" Pa: 4046 
The extraction was recorded and the profile indicated that the drug is extracting between 3 
and 12 minutes as indicated in Figure 2.11. 
Injection of unextracted temazepam onto the HPLC produced a peak height of 10.2 cm. 
Using the SFE conditions described, a peak height of 3.2 cm was obtained, corresponding 
to a recovery of 31 %. 
Figure 2.11: Extraction Profile of Tema epam 
2.14.7 OPTIMISATION OF TEMAZEPANj EXTRACTION. 
Optimisation of SFE can be achieved in three ways: 96 
---- ý. ýý JLV. VV tz. VV 14.00 
TEMAZ1.001\DAT001. DTI Channel A 
Temazepam. 
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" Altering the modifier /% modifier 
" Altering the temperature 
" Altering the pressure 
2.14.8 EFFECT OF ALTERING THE % MODIFIER. 
2.14.8.1 EXPERIMENTAL 
The percent of MeOH used for the extraction of temazepam was varied 
from 10-50% 
whilst maintaining the pressure at -4000 psi and the temperature at 
70 °C. The extractions 
were carried out as described previously. 
2.14.8.2 RESULTS AND DISCUSSION 
The average pressures are indicated in Table 2.10 with the results obtained for the 
extraction of temazepam at various percent of MeOH. 
Table 2.10: Variation in % Recovery with Increasing % Modifier 
% modifier % recovery P (psi) 
10 9.8 3894 
20 18 4126 
30 26 3828 
40 59.4 3640 
50 96 3718 
As the % modifier is increased, the % recovery increases but again the conditions will not 
be supercritical (Tc at 50% MeOH - 135 °C). 
2.14.9 REPRODUCIBILITY OF EXTRACTION USING MEOH (40%) AS THE MODIFIER 
2.14.9.1 EXPERIMENTAL 
Three extractions were carried out at 40% with all other parameters kept constant. The 
collected extracts were injected in duplicate ensuring that the 25 µl loop on the HPLC 
system was overfilled. 
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2.14.9.2 RESULTSAND DISCUSSION 
The results for the reproducibility test are shown in Table 2.11. 
Table 2.11: Extraction Reproducibility 
Injection El E2 E; 
1 8.297% 7.588%) 15.1>100%) 
2 10.4 (>100%) 11.2 (>100%) 15.9 (>100%) 
The extraction at 40% showed poor reproducibility by HPLC, both intra- and inter- 
extraction and therefore, a peak height injection reproducibility test was carried out on the 
HPLC. 
2.14.10 HPLC SYSTEM REPRODUCIBILITY 
2.14.10.1 EXPERIMENTAL 
The temazepam standard in MeOH was injected five times onto the HPLC at a sensitivity 
of 0.5. The peak heights obtained were measured manually. 
2.14.10.2 RESULTS AND DISCUSSION 
The peak heights obtained for the five injections of temazepam were: 
8.4 cm, 8.8 cm, 8.4 cm, 9.8 cm, 8.4 cm. 
These heights give a mean peak height of 8.76 and a RSD of 6.9%. It would appear that 
the 9.8 cm value is an outlier, however, more injections would be required in order to 
verify this. In practice only a maximum of three injections can be made per extraction due 
to the reconstitution volume and so the reproducibility of the HPLC system is unacceptable 
for this work. 
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2.14.11 TEMAZEPAM EXTRACTION FROM WHOLE BLOOD 
2.14.11.1 EXPERIMENTAL 
Despite the conditions at 70 °C and 40% MeOH being non-supercritical, these were 
yielding reasonably high recoveries and thus were used in an attempt to extract temazepam 
from a spiked blood standard. 
A1 ml aliquot of 38.4 pg ml'1 temazepam standard in methanol was evaporated to dryness 
under nitrogen, reconstituted in 1 ml of blank blood and sonicated for three minutes. A 
fresh extraction vessel was inserted into the GC oven and the system was set for 0.5 ml 
min"', 40% MeOH and 70 °C. A 100 µl injection of the blood standard was made followed 
by an injection of 100 tl of distilled water (dH2O). The rheodyne was then switched back 
to the load position and flushed through with dH2O until it ran clear and after one minute a 
further injection of 100 µl dH2O was made in an attempt to spread the blood over the 
Extrelut® in the column. 
The initial pressure was 3840 psi and the final pressure was 4640 psi. A second blood 
extraction was attempted. This time, a pressure drop of - 1000 psi was seen across the 
system. On removing the column, the pressure drop was found to be due to the injected 
blood forming a clot in the extraction vessel, thus the injections of dH2O were not 
spreading the blood, over the contents of the extraction vessel. In addition, the collection 
solvent turned pale brown in colour which was possibly due to the water carrying blood 
through to the collection vial. Two further extractions were carried out and the extraction 
vessel changed between each one to prevent blocking. 
2.14.11.2 RESULTS AND DISCUSSION 
Results for the first extraction and the two further extractions were obtained by HPLC and 
are reported in Table 2.12. The peak height of the unextracted temazepam was 10.9 cm. 
Chapter Two Benzodiazepines Page63 
Table 2.12: Reproducibility for 3 Standard Blood Extractions 
Extraction Recovery (Peak heig ht (cm)) 
Injection Ext. 1 Ext. 2 Ext. 3 
1 53.2%* (5.8) 86.2% (9.4) >100% (11.2) 
2 99% (10.8) 80.7% (8.8) >100% (13.4) 
3 94.5 (10.3) 81.7 (8.9) >100 (15.8) 
* HPLC mobile phase not settled down, therefore, peak late. 
In addition to the temazepam peak, the blood extract traces were showing a large impurity 
peak at approximately 14 minutes. This will probably co-elute with the internal standard 
(prazepam) once it is introduced to the system. An extraction of blank blood was carried 
out and the impurity peak was still present. One of the components of blood which could 
be responsible for the peak was cholesterol and thus, an injection of a cholesterol standard 
in mobile phase was made in order to determine if it had the same retention time. No 
peaks were observed after 20 minutes. An alternative possibility for the peak is the 
anticoagulants and preservatives added to blank blood at the hospital. As a solution of the 
hospital additives was not available, to determine if the peak was due to this, a post- 
mortem sample, which contained no additives and was known to be negative for 
benzodiazepines, was extracted. No corresponding peak at 14 minutes was observed and 
the MeOH collection solution showed no breakthrough blood. 
The extraction of temazepam from spiked hospital blood did however yield good 
recoveries using the conditions described. It was decided to continue method development 
by altering the modifier to determine if the extraction could be made more effective using a 
different modifier. 
2.14.12 EFFECT OF ALTERING THE TYPE OF MODIFIER 
As stated previously, the conditions with 40% MeOH are not supercritical. In order to 
make the conditions supercritical it was decided to use a different modifier, namely ethyl 
acetate (EtAc). 
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2.14.12.1 EXPERIMENTAL 
The following conditions were set-up and both standards from MeOH and blood extracted. 
" Flow rate: 0.5 ml miri I 
" Pressure: = 3000 psi 
" Temperature: 70 °C 
" Modifier: 10% EtAc 
2.14.12.2 RESULTS AND DISCUSSION FOR 70 °C 
For both MeOH and blood standards, recoveries of >80% were achieved. In addition, the 
peak at 14 minutes was no longer observed and the solvent front was markedly cleaner, 
indicating better selectivity. In order to decrease the harshness of the conditions, the 
temperature was decreased to 50 °C with 10% EtAc as, at this temperature, the conditions 
are still supercritical. In addition, in order to decrease the extraction time, the flow rate 
was increased to 1.0 ml mini 1. 
2.14.12.3 RESULTS AND DISCUSSION FOR 50 °C 
At 10% EtAc, 50 °C, 1 ml min' (p = 2762 psi) the extraction recovery was only 9.6%. 
The EtAc was increased to 15% and the extraction was repeated (p = 3462 psi). This time, 
the % recovery was 82.4%. 
2.14.13 EFFECT OF TEMPERATURE WITH ETAC (15%) AS THE MODIFIER 
2.14.13.1 EXPERIMENTAL 
The percent of EtAc was set to 15% and the effect of altering the temperature monitored 
whilst keeping the pressure constant. 
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2.14.13.2 RESULTS AND DISCUSSION 
At 60 °C, 15% EtAc (p = 2974 psi) the recovery was 100% but by increasing the 
temperature further, the recovery dropped to 37% at 70 °C, 20% at 75 °C and 27% at 80 
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Figure 2.12: % Recovery Vs Temperature for Tema: epam at 15% FtAc 
The approximate critical temperature plot for EtAc in CO2 is shown in Figure 2.13. 
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Figure 2.13: ('rilicul "Temperature Graph for CO, - EtAc Mixtures 
The critical temperature for 15% EtAc in CO2 is approximately 64 °C, therefore an 
additional extraction was attempted at 65 °C, 15% EtAc, 3500 psi and 0.5 ml min-' for 20 
minutes. 
The extraction at these conditions was attempted several times without success. The % 
modifier and flowrate were increased as problems were encountered in maintaining the 
pressure in the system. The head pressure of the CO2 cylinder was found to have dropped 
from Az700 psi to ; 500 psi. This decrease in head pressure was enough to prevent 
sufficient pressurisation of the system, and it was thought that gaseous CO2 was being 
pumped and thus a new cylinder was placed in the system. 
Future cylinders were checked once the head pressure had dropped by X150 psi to 
determine if they required replacing. This method was found to be more effective than 
weighing the cylinders, and thus use of the scales mentioned in Chapter 1 was 
discontinued. 
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2.14.14 ALTERATION OF EXTRACTION CELL LENGTH 
With the new cylinder in place, an extraction was carried out at 5% EtAc, 65 °C and 2 ml 
min"' as these were the last conditions tried on the previous cylinder. The recovery was 
100%. Until this point, the extractions were carried out in a 10 cm long extraction vessel. 
The same conditions were tried using a5 cm long extraction vessel and again the recovery 
was 100%. 
2.14.15 CONFIRMATION OF ETAC (5%) AS THE MODIFIER OF CHOICE 
2.14.15.1 EXPERIMENTAL 
The % EtAc was further decreased to 1% to determine if the solvent in the system could be 
further reduced without decreasing the recovery of temazepam. The extraction at 5% was 
also repeated three times using a freshly prepared temazepam blood standard (4.42 mg/L) 
to check the reproducibility of the conditions. 
2.14.15.2 RESULTS AND DISCUSSION 
It was found that by decreasing the % EtAc further to 1% reduced the recovery to - 20%. 
For the triplicate extraction of temazepam at 5%, the recoveries were 96%, 98% and 100% 
thus, the reproducibility of the extraction was suitable. 
2.14.16 ADDITION OF OTHER BENZODIAZEPINES TO THE SYSTEM 
2.14.16.1 EXPERIMENTAL 
Using the same extraction conditions, diazepam and desmethyldiazepam were extracted on 
their own, however, the recoveries were very low. The standard mixture was then 
extracted to determine the effect of the other benzodiazepines on the extraction of 
temazepam. 
2.14.16.2 RESULTS AND DISCUSSION 
The results for one extraction of the standard mix are shown in Table 2.13. 
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Table 2.13: Effect of other Benzodiazepines on Temazepam 
Unextracted Extracted 
Drug R. T. P. H. R. T. P. H. Recovery. 
Triaz 5.7 16 5.7 11 69% 
Temaz 6.8 11.7 6.8 11.6 99% 
CDP 7.1 1.8 7.1 1.6 89% 
DMD 7.8 16.9 7.8 20.2 120% 
Diaz 8.8 14.9 8.8 17.2 115% 
It should be noted that the extraction conditions also yielded 100% temazepam at a flow of 
1.0 mlmin'1 however, by using a flowrate of 2.0 ml min I the extraction time is reduced. 
With the exception of triazolam, the recovery levels of all the drugs are acceptable. 
2.14.17 Ericr of PREssuRE 
In order to investigate the effect of pressure on the extraction, it was decided to introduce 
the internal standard (prazepam) to the extractions. For the optimum conditions, it is 
essential that both the drug of interest and the internal standard are extracted to the same 
extent so the best conditions need not be those that give the highest recoveries of 
temazepam. 
2.14.17.1 EXPERIMENTAL 
1 ml of prazepam and 1 ml of temazepam were pipetted into a vial, evaporated to dryness 
under nitrogen and reconstituted in 1 ml of MeOH. 100 µl aliquots of this solution were 
extracted. The extraction was carried out five times at different pressures. 
2.14.17.2 RESULTS AND DISCUSSION 
The following table (2.14) indicates the results obtained for the extraction of temazepam 
and prazepam at various pressures. 
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Mean Pressure (psi) P. H. Temaz PHR %Rec. Temaz 
1536 8.4 1.68 74% 
2016 6.2 2.48 55% 
2362 4.5 2.00 40% 
3096 7.7 2.33 68% 
3675 5.3 2.52 47% 
The unextracted PHR was 2.06. A graph of pressure versus recovery was plotted Figure 
2.14) and from this the pressure for the extractions was chosen as 3000 psi as the rate of 
change of PHR with pressure is less pronounced at this pressure and the recovery is 
relatively high. 
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Figure 2.14: Variation of »HR with Pressure 
Peak height ratio v's pressure 
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2.14.18 VARIATION OF PRESSURE WITHIN THE SFE SYSTEM 
2.14.18.1 EXPERIMENTAL 
As the pressure appears to have such a pronounced effect on both the PHR and the % 
recovery of temazepam and prazepam, a study on the variation of a set pressure of 3000 psi 
for 20 minutes was carried out. 
2.14.18.2 RESULTS AND DISCUSSION 
The variation in pressure of the SFE system at a set pressure of 3000 psi is shown in Table 
2.15. 
Table 2.15: Variation of Pressure set at 3000 psi 
Time (min) Pressure (psi) Time (min) Pressure (psi) 
0 2944 11 2770 
1 2688 12 2900 
2 2494 13 2770 
3 2248 14 3495 
4 2436 15 3118 
5 2436 16 3205 
6 1508 17 3683 
7 1523 18 3248 
8 1639 19 3321 
9 1392 20 3625 
10 1639 
0-10 2129 (RSD=26%) 11-20 3053 (RSD=19.5%) 
As can be seen from these results there is very little pressure control in the system. As the 
CO2 did not require changing, this variation was thought to be due to the check valves in 
the CO2 pump which were changed and the experiment repeated. The repeated pressure 
results are given in Table 2.16. 
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Table 2.16: Variation of Pressure Set at 3000 psi with New Check Valves 
Time (min) Pressure (psi) Time (min) Pressure (psi) 
0 2987 11 3045 
1 2625 12 3089 
2 2436 13 3002 
3 2306 14 3132 
4 2813 15 3045 
5 2944 16 3045 
6 3016 17 3060 
7 2944 18 3045 
8 2944 19 3074 
9 2987 20 3161 
10 3060 
0-10 2824 (RSD = 9%) 11-20 3070 (RSD = 1.5%) 
The mean pressure for the twenty minutes was 2941 with a RSD of 7.5%. But, if five 
minutes re-equilibration time is allowed for, the mean pressure is 3043 psi with a RSD of 
2.0% which is acceptable. 
2.14.19 REPEAT OF EXTRACTION AT 3000 PSI 
2.14.19.1 EXPERIMENTAL 
The extraction at 3000 psi was repeated in order to redetermine the PHR and recoveries of 
temazepam and prazepam at this pressure. 
2.14.19.2 RESULTS AND DISCUSSION 
The results for the repeat extraction at 3000 psi are shown in Table 2.17. 
Table 2.17: Repeat of Extraction at 3000 psi 
Temaz Praz PHR 
Unextracted 11.3 5.5 2.055 
Extracted 9.9 (88%) 5.2 (95%) 1.904 
It can be seen that these results agree well with those obtained during the optimum pressure 
study and thus it was decided to use a pressure of 3000 psi for future extractions. 
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2.14.20 EFFECT OF TEMPERATURE 
2.14.20.1 EXPERIMENTAL 
A temperature study at 3000 psi, 5% EtAc and 2 ml min 1 was carried out. Three 
extractions were made at each temperature and the initial and final pressures were noted. 
Previous studies have indicated that a temperature around 60 °C should be ideal and thus 
the temperature was varied around this value. It should be noted that precise control of the 
temperature gauge on the GC oven controller was difficult so the exact temperature 
measurements were made by placing a thermometer into the oven. - 
2.14.20.2 RESULTS AND DISCUSSION 
The results for the temperature study on temazepam and prazepam are shown in Table 
2.18. For the runs at 62 °C, the EtAc was not pumping efficiently which explains the 
relatively low recoveries at this temperature. This was found to be due to faulty modifier 
pump check valves which were subsequently changed. 
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Table 2.18: Temperature Study flor Tema 










PHR Mean (SD) Pressure (psi) 
55 °C 1 . 947 
139 129 121 121 2.232 2.133 3169 
90 (61) 90 (31) 2.098 0.087) 3067 
160 151 2.070 2890 
60 °C 1 . 991 
73 103 76 99 1.929 2.047 3133 
123 (26) 117 (21) 2.092 (0.103) 3205 
112 105 2.120 3212 
62 °C 2.152 
41 37 44 41 2.022 2.332 3365 
56 (21) 68 (29) 1.775 (0.762) 3179 
14 10 3.200 3125 
64 °C 1.991 
90 106 92 103 1.951 2.042 3227 
114 (14) 110 (96) 2.066 (0.082) 3154 
114 107 2.109 3104 
66 °C 2.055 
72 107 73 105 2.025 2.043 3314 
178 (61) 174 (60) 2.000 (0.055) 3053 
71 69 2.105 2920 
2.14.21 EFFECT OF COLLECTION SOLVENT AND CONTINUATION OF TEMPERATURE STUDY 
2.14.21.1 EXPERIMENTAL 
It has been suggested in literature that MeOH is a poor collection solvent and that 
chloroform should give better recoveries. 97 For the rest of the temperature survey, the 
extracts were collected in both MeOH and CHC13 so that the recoveries for each could be 
compared. 
2.14.21.2 RESULTS AND DISCUSSION 
The results for the extraction of temazepam and prazepam using chloroform and methanol 
as collection solvent at varying temperatures are shown in Tables 2.18a and 2.18b. 
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Table 2.18a: Temperature Study Using Chloroform as a Collection Solvent 
Temazepam 
Recovery 
Prazepam Recovery Peak Height Ratio Pressure 
64 °C 2.087 
121 99 2.549 2.323 3118 
73 133 (67) 69 122 (68) 2.225 (0.20) 3140 
206 198 2.196 3089 
65 °C* 2.743 
132 135 135 139 2.680 2.67 3003 
137 142 2.650 3089 
66 °C 1.815 
123 109 2.042 1.947 3161 
141 118(25) 128 110 (18) 2.000 (0.13) 3220 
92 93 1.800 3170 
70 °C 2.0 87 
17 15 2.467 3154 
Table 2.18b: Temperature Study Using Methanol as a Collection Solvent 
Temazepam 
Recovery 
Prazepam Recovery Peak Height Ratio Pressure 
64 °C 2.087 
111 107 2.173 2.210 3261 
95 78(45) 95 75(45) 2.082 (0.15) 3118 
27 23 2.375 3111 
65 °C* 2.7 43 
101 104 119 110 2.341 2.644 3067 
107 100 2.946 3060 
66 °C 1.815 
127 118 1.915 3082 
91 109 (20) 93 103 (12) 1.780 1.895 3183 
92 93 1.800 (0.13) 3169 
126 109 2.085 3214 
70 °C 2. 087 
2.3 2.9 2.000 3075 
* For the run at 65 °C a more concentrated solution was injected (25 mg/L c. f. 5 mg/L) to 
see if a smaller injection volume would improve the reproducibility. 
Although the intra-temperature results were not very reproducible, as seen from Figure 
2.15, the optimum temperature with least variance is around 65 °C. With the temperature 
gauge on the GC oven programmer set to 65 °C, the temperature reading on a thermometer 
placed in the oven was found to be 64 °C which is satisfactory. 









Peak height ratio v's temperature 
Figure 2.15: Variation of PHR with Temperature 
2.14.22 EXTRACTION OF TEMAZEPAM AND PRAZEPAM FROM BLOOD 
2.14.22.1 EXPERIMENTAL 
Standards of temazepam and prazepam were prepared in blood, however post-restrictor 
blocking became problematic, possibly due to Joule-Thomson cooling of extracted water 
in the outlet tubing. A column containing dried silica was placed in-line before the 
extraction vessel in order to trap the water. An extraction of temazepam and prazepam in 
methanol was carried out in order to see whether or not the silica affected the extraction. 
This was followed by an injection of MeOH. 
2.14.22.2 R ,, SIIL7SANI) I)I. SCUSSION 
The results for the effect of a silica drying column on the extraction of temazepam and 
prazepam are shown in Table 2.19. 
54 59 64 69 
Temperature (oC) 
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Table 2.19: Effect of Silica on Temazepam MeOH Standard Extraction 
Area Temaz (%Rec) Area Praz (%Rec) PHR 
Unextracted 23.5 10.5 2.238 
Extracted 11.1 (47%) 7.1(68%) 1.563 
MeOH flush 9.4 (40%) 5.7 (54%) 1.647 
Total Extracted 20.5 (87%) 12.8 (122%) 1.602 
An extraction of the spiked blood standard was also carried out, but no peaks were 
observed. The low recoveries obtained for the MeOH standards indicate that the silica may 
be retaining the drugs and that a post extraction flush might be necessary for high 
recoveries. With post-extraction drying, the recoveries dropped again (MeOH extraction, 
Temaz 3.2 cm (14%), Praz 4.6 cm (44%), PHR = 0.696). A blank blood extraction after 
this eluted 1.45 cm (6%) temazepam and 0.5 cm (5%) prazepam (PHR = 2.900). The 
spiked blood standard was extracted again but only trace amounts were recovered. 
2.14.23 ALTERNATIVE METHOD OF PREVENTING RESTRICTOR PLUGGING 
2.14.23.1 EXPERIMENTAL 
As an alternative to using a silica column to dry the extracts, the outlet tubing was coiled 
inside the oven and the remaining tubing which was outside the oven lagged. Again at this 
point, the CO2 head pressure was dropping and thus the cylinder was replaced. 
Several injections of temazepam and prazepam MeOH and blood standards were made into 
the SFE system. 
2.14.23.2 RESULTS AND DISCUSSION 
From MeOH the recoveries were 24% and 60% for temazepam and prazepam respectively 
however, the blood extract showed recoveries of >100% for both drugs and a subsequent 
MeOH flush was negative indicating that the blood extract had removed the remaining 
temazepam and prazepam from the MeOH extraction. It was not possible to calculate the 
recoveries for the blood extract, as the concentrations were different to those of the MeOH 
standards. 
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2.14.24 PREPARATION OF STANDARD TEMAZEPAM AND PRAZEPAM 
2.14.24.1 EXPERIMENTAL 
Fresh standards in MeOH and blood were prepared keeping the concentrations constant as 
follows. 4 ml of temazepam (5.16 mg / 100 ml) and 4 ml of prazepam (4.50 mg / 100 ml) 
were pipetted into two vials and evaporated to dryness under N2 at 60 °C. To the residue, 5 
ml of MeOH or 5 ml of blood was added and the vial sonicated for three minutes in an 
ultrasonic bath. The concentrations of these standards were 41.3 mg/L temazepam and 
36.0 mg/L prazepam. The unextracted MeOH standard gave peak heights of 13.7 cm and 
7.2 cm for temazepam and prazepam respectively and a PHR of 1.903. 
2.14.25 COMPARISON OF SFE AND SPE FOR TEMAZEPAM AND PRAZEPAM 
2.14.25.1 EXPERIMENTAL 
A SPE was carried out on the blood standard for comparison with SFE. The method used 
was as described in Section 2.11.1 however, only 100 t1 of the blood standard was 
extracted for a direct comparison with SFE. 
2.14.25.2 RESULTS AND DISCUSSION 
The results obtained by SPE were temazepam 13.3 cm (97%) and prazepam 6.6 cm (92%), 
PHR 2.015. The SFE of the same blood standard gave 5.2 cm (38%) temazepam and 8.75 
(122%) prazepam, PHR 0.594 with a MeOH flush yielding 0.75 cm (5%) temazepam and 
0.4 cm (6%) prazepam indicating that the extraction set-up was still not robust. 
2.14.26 PROCEDURE FOR DRYING OF BLOOD SAMPLES 
Due to the many problems which were being encountered with the "wetness" of the blood 
samples, a literature search on the problem of water in SFE systems was carried out with 
suggestions found on removing the water prior to extraction by freeze drying followed by 
SPE98 and cryogenic trapping 99 Alternatively, a modifier could be selected with 
sufficiently strong antifreeze properties to counteract the Joule-Thomson cooling effect. 10° 
The most feasible of these, which would cause least disruption to the system, would be the 
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addition of antifreeze either as or in the modifier. However, as the extraction conditions 
used are mild and provide high recoveries, an alternative sample loading method was 
investigated. 
Instead of injecting the samples via the rheodyne loop onto the Extreluto in the extraction 
vessel (i. e. the extraction vessel was in the position of an HPLC column), the plumbing of 
the system was altered and the extraction vessel was placed over the loop position of the 
rheodyne. This has the following advantages: 
" The extraction vessel can be changed without disturbing the equilibrium of the 
supercritical fluid 
" Reduction in blockages in loop and connective tubing 
" Reduced chance of contamination from sample to sample as the system will operate in a 
one vessel per extraction mode 
9 Reduce time, as a post extraction flush will not be required 
Initial runs with this system gave poor recoveries, possibly as the drugs needed to be 
extracted twice, as the original vessel was still in line. The original extraction vessel was 
removed and replaced with a dead volume connector. 
The first blood extraction with this system gave good recoveries (100%) with a PHR of 
1.804 (c. f. 1.652) however, pressure fluctuations were still problematic throughout the 
course of the extraction. It was decided to dry the blood samples on the Extrelut® prior to 
insertion into the extraction vessel. Although this step is time consuming and allows for an 
increased chance of sample loss, the importance of these factors is counteracted by the 
following three points: 
" Reduction in blockages (increased up-time) 
" Multiple samples can be prepared and dried overnight 
" Prazepam is added to the samples and thus any loss of sample is compensated for 
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The components for the initial extraction were weighed in order to monitor the sample loss. 
0.19 g of Extrelut® and 0.10 g were weighed onto the boat and dried. 0.22 g of this were 
transferred to the column. Therefore, without taking into account losses due to drying of 
the sample, the recoveries should be 76%. The recoveries obtained were 95% for 
temazepam and 80% for prazepam giving a PHR of 2.051 (c. f. 1.729 for the standard). 
Taking into account the variability seen for the unextracted standards and errors which 
might occur in sample preparation of both the unextracted standards and the blood 
standards, this method was chosen for use on authentic forensic samples, validation 
pending. 
2.14.27 EFFECT OF ALTERING THE SUPPORT MEDIUM 
2.14.27.1 EXPERIMENTAL 
In addition to changing the temperature, pressure and % modifier in the extraction, the 
other variable which was investigated was the effect of the support medium. Until now all 
method development was carried out using Extrelut®. Two other support mediums, 
namely C18 and HCX were investigated for the extraction of all 6 benzodiazepines. 
2.14.2Z2 RESULTS AND DISCUSSION 
From Extrelut® all 6 benzodiazepines were extracted however, the other two support 
mediums were less successful. Using C18, triazolam, temazepam, chlordiazepoxide, 
desmethyldiazepam and diazepam extracted but the recoveries were very low and the 
prazepam did not extract. Using the HCX support medium, none of the benzodiazepines 
extracted. For this reason the support medium was kept as Extrelut®. 
2.14.28 CONCLUSIONS FROM METHOD DEVELOPMENT 
The final conditions developed for the extraction of temazepam and prazepam are as 
follows: 
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" Flow Rate: 2.0 mlmin 1 
"% EtAc: 5% 
" Temperature : 65 °C 
" Pressure: 3000 psi 
" Run Time: 5 minutes 
" Support Medium: Extrelut® 
The SFE system was set to equilibrate at the above conditions and samples prepared as 
follows. A 100 µl aliquot of the sample to be analysed was loaded onto Extrelut® in a 
weighing boat and mixed thoroughly. This was allowed to dry at room temperature until a 
friable consistency was achieved and then loaded into an extraction vessel. The extraction 
vessel was placed into the equilibrated SFE system and the extraction commenced by 
switching the Rheodyne valve from load to inject, allowing the flow of supercritical fluid 
to pass through the extraction vessel. A Hypovial® containing MeOH placed at the flow 
outlet, trapped the extracted analytes. 
2.15 METHOD VALIDATION FOR TEMAZEPAM 
2.15.1 HIGH CONCENTRATION CALIBRATION CURVES 
2.15.1.1 EXPERIMENTAL 
The first part of the validation was carried out by producing high concentration calibration 
graphs for: 
1) MeOH standards straight onto HPLC (Table 2.20) 
2) MeOH extracted standards (Table 2.21) 
3) Blood extracted standards (Table 2.22) 
The range of concentrations was from 0-51.6 mg/L. For the unextracted standards, 100 µl 
of temazepam was evaporated to dryness and reconstituted in 100 µl of mobile phase and 
for the extractions, either 100 µl of MeOH standard or blood standard were extracted and 
the collected extract evaporated to dryness and reconstituted in 100 µl of mobile phase. 
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2.15.1.2 RESULTS AND DISCUSSION 
The peak heights of temazepam obtained for the calibration are shown in Tables 2.20,2.21 
and 2.22. The % recoveries were calculated by comparing the extracted PH's to the 
extracted PH for the relevant concentration. The equation for each of the best fit lines is 
given as y= Bx + A. 
Table 2.20: Unextracted Standards 







r2 = 0.995 
A=-0.469' 
B= 0.332 
Table 2.21: MeOH Extracted Standards (average of 3) 










Table 2.22: Blood Extracted Standards (1 infection one) 






51.60 11.65 (68%) 
r2 = 0.919 
A=2.800 
B= 0.163 
At this point, the concentrations of the standards used were much higher than those seen 
from therapeutic and even overdose levels of benzodiazepines in case samples. It can be 
seen that in addition to the poorer correlation seen for the blood extracted standards the 
concentration range appears to have overloaded the range for extraction (i. e. a longer 
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extraction time would have to be used in order to extract this amount of temazepam). This 
is also the case for the 51.6 mg/L MeOH extraction. 
In terms of the gradients (B) of the curves produced, it can be seen that as the matrix 
effects increase (i. e. MeOH to blood) compared with the unextracted standards, a decrease 
in the gradient is seen. 
The injection reproducibility of the HPLC system was checked again. Ten injections of the 
51.6 µg ml" standard were made and the peak heights were found to range from 16.9 cm to 
18.3 cm (mean 17.4 cm, RSD 2.86%). A 20 µl loop was used and 50 µl was injected each 
time. This was compared to five 25-30 µl injections; range 16.0-18.5 cm, mean 17.2 cm, 
RSD 5.23%. Thus, the injection reproducibility could also contribute to the results 
obtained as the blood extraction results were based on only one injection. 
2.15.2 EXTRACTIONS WITH INTERNAL STANDARD 
2.15.2.1 EXPERIMENTAL 
The MeOH unextracted and extracted calibrations were repeated this time including 
prazepam to compensate for the injection reproducibility. 0.5 ml of each standard dilution 
plus 0.5 ml prazepam was analysed in each case (N. B. prazepam on its own extracts 
100%). 
2.15.2.2 RES ULTS AND DISCUSSION 
The results for the extractions with prazepam and temazepam are shown in Table 2.23. 
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Table 2.23: Extraction with Temazeyam and Prazepam 
[Temaz] PHR Ext. PHR Unext. %Rec. 
Temaz 
%Rec. Praz % Error 
0 0 0 na na na 
5.16 0.633 0.313 76 38 +103 
10.32 0.900 0.775 58 50 +11 
12.9 1.077 0.923 39 33 +17 
20.64 1.714 1.56 40 36 +10 
25.80 1.78 2.20 42 52 -19 





Again at the higher concentrations, a loss of temazepam is apparent and the gradient is less 
than that of the unextracted standards. 
2.15.3 LINEARITY OF EXTRACTION ABOVE THE THERAPEUTIC CONCENTRATION 
2.15.3.1 EXPERIMENTAL 
A fresh standard of temazepam was prepared by weighing 1.28 mg of temazepam standard 
into a 100 ml volumetric flask and making up to the mark with MeOH to give a 
concentration of 12.8 mgL'I This was sequentially diluted to give calibration solutions of 
0,1.28,2.56,3.84,6.40,12.8 mgL"I of temazepam with 11.24 mgL"1 of prazepam in each. 
Each standard type was extracted by SPE and SFE for comparison. 
2.15.3.2 RESULTS AND DISCUSSION 
The unextracted standard calibration was carried out in duplicate in order to check the 
reproducibility. The results are shown in Tables 2.24 and 2.25. 
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Table 2.24: Unextracted MeOH Standards 1 







Table 2.25: Unextracted MeOH Standards 2 













From these results it can be seen that a reproducible calibration graph can be easily 
constructed over this concentration range. 
Using the system as described previously with the chart recorder, calibrations for MeOH 
SFE standards and blood SPE standards were constructed as shown in Tables 2.26 and 
2.27. 
Table 2.26: Extracted MeOH 1- SFE 







r2 = 0.995 
A=0.038 
B=0.156 
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Table 2.27: Extracted Blood 1- SPE 







r2 = 0.998 
A= -0.044 
B=0.203 
At this point there were no other graphs to compare these to, however, the correlation 
coefficients are high and in the case of the MeOH SFE extracts, the gradient is similar to 
that of the unextracted standards. 
2.15.4 CONTINUATION OF CALIBRATION wim SYSTEM CONTROLLER 
2.15.4.1 EXPERIMENTAL 
At this point, the system controller was modified so that the traces could be directly 
compared using the Gilson software. This also reduces the human error from manually 
measured peak heights. Injections of the unextracted MeOH standards and extracted blood 
and MeOH, SFE and SPE extracts were continued using the new set-up. 
2.15.4.2 RESULTS AND DISCUSSION 
The unextracted MeOH standard calibration was repeated. As can be seen from the results 
in Tables 2.28,2.29,2.30,2.31 and 2.32 a slightly different gradient is calculated using the 
system controller peak areas as opposed to manually measured peak heights. 
Table 2.28: Unextracted MeOH Using Gilson Software I (n=3) 
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During the course of the SFE extractions it was noted that the PTFE check valves in the 
modifier pump were allowing flow back of CO2 into the solvent reservoir. These were 
replaced and left overnight, however, the same problem was noted the next morning. In 
order to check whether it was the combination of PTFE and EtAc, PVDE check valves 
were inserted into the modifier pump. These did not hold the flow at all. A fresh batch of 
PTFE check valves were inserted which worked well, and thus the problem was attributed 
to a faulty batch of check valves. As the CO2 had been leaking throughout the night, a new 
cylinder was placed in the system. 
Table 2.29: Extracted MeOH - SFE (3 extractions, 3 infection each n=9) 







r2 = 0.991 
A=0.015 
B=0.121 
Table 2.30: Extracted Blood - SFE (2 extractions 3 infections each n=6) 







r2 = 0.827 
A=0.220 
B=0.086 
Table 2.31: Extracted MeOH - SPE (1 extraction, 3 infections n=3) 










Chapter Two Benzodiazepines Page87 
Table 2.32: Extracted Blood SPE (2 extractions. 3 infections n 







r2 = 0.981 
A= -0.065 
B=0.078 
From these tables it can be seen that good correlation exists over the range 1.28-12.80 
mg/L temazepam for the various extractions. 
2.15.5 INTRA- AND INTER-DAY REPRODUCIBILITY 
2.15.5.1 EXPERIMENTAL 
To check the reproducibility of the temazepam extraction throughout the course of one day 
and from day to day, sequences of extractions of the same standard were extracted on days 
one and two. This experiment was also used to ensure that there was no carry over of the 
benzodiazepines in the system. 5 extractions of temazepam and prazepam were carried out 
on day one, and 6 on day two with blank extractions in between to ensure no carryover. 
The temperature in the oven was found to be 62 °C instead of 64 °C as previously noted 
using the thermometer in the oven. 
2.15.5.2 RESULTS AND DISCUSSION 
The results for the extractions on day one are shown in Table 2.33. 
Table 2.33: Extraction of Temazenam and Prazepam " Day I 
Extraction Area Temaz Area Praz PAR 
1 6102 9590 0.636 
2 5005 9477 0.528 
3 35583 57505 0.619 
4 31208 63479 0.492 
5 57152 113041 0.506 
Unext. 501961 602912 0.833 
X=0.556 
RSD: 12% 
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NB: The sensitivity of the HPLC was turned up for the injections of extracts 3,4 and 5 and 
the unextracted standard. 
The results for the extractions on day two are shown in Table 2.34. 
Table 2.34: Temazepam and Prazepam Extraction; Day 2 
Extract Area Temaz Area Praz PAR 
1 108258 140896 0.768 
2 79817 123005 0.649 
3 32316 51446 0.628 
4 117640 190665 0.617 
5 44081 61156 0.721 
6 22548 39166 0.576 
Unext. 501961 602912 0.833 
x: 0.660 
RSD: 11% 
The mean PAR over the two days was 0.613 with a RSD of 13.9%. Thus the variation 
from day to day is no greater than that seen within the same day. 
Due to the slight variation in PAR observed between extractions, for any authentic samples 
extracted, the standard will have to be run in triplicate at least. 
2.15.6 ALTERATION OF OUTLET RESTRICTION 
2.15.6.1 EXPERIMENTAL 
Problems were being encountered due to blockages caused by precipitation of material 
within the flow outlet tubing. This was causing a reduction in the recoveries at the 
previously optimised conditions and was thought to be due to insufficient restriction being 
provided. In order to amend this, the pressure in the system was set to 1500 psi and the 
end of the outlet tubing crimped until an increase in pressure was observed. With this in 
place, extractions were carried out at 10% EtAc, 5% EtAc and then 10% EtAc again. 
2.15.6.2 RESULTS AND DISCUSSION 
The results for the extractions at 5 and 10% EtAc are shown in Table 2.35. 
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Table 2.35: Temazepam Extractions With Crimped Outlet 
% EtAc Area Temaz (% Rec) Area Praz (% Rec) PAR 
10/1 85455 (21) 251453 (51) 0.340 
5 136636 (33) 305927 (61) 0.447 
10/2 183388 (44) 333325 (67) 0.550 
Unext. 414021 497680 0.832 
The recoveries were still quite low, so to ensure that the drugs were not binding to matter 
which had adhered to the inside of the tubing, all of the tubing in the system was replaced. 
Due to the recent problems with the system, the extraction conditions for benzodiazepines 
were modified slightly to 10% EtAc, 65 °C, 2.0 ml min" and 3000 psi. Despite the fact 
that the use of 10% EtAc decreases the selectivity of the extraction slightly, it was found to 
be better for the extraction of authentic forensic samples perhaps due to the increased 
matrix effects as compared to spiked blood samples. 
2.15.7 VITREOUS HUMOR 
2.15.7.1 DEFINITION 
In addition to analysing blood samples, this study was also involved with the extraction of 
drugs from post-mortem vitreous humor samples. The vitreous humor is defined as a clear, 
avascular, gelatinous body which comprises two thirds of the volume and weight of the eye 
and fills the space bound by the lens, retina and optic disc. 101 It consists of approximately 
99% water with the remaining components including collagen and hyaluronic acid which 
give it its specific physical character. 
The gel like form of the vitreous is due to a loose mass of long chain collagen molecules 
capable of binding up to 200 times their own weight in water. The hyaluronic acid 
molecules are very large, loose bundles capable of binding up to 60 times their own weight 
in water. Combined with the collagen element, they account for the physical 
characteristics of normal vitreous. 
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The use of vitreous humor as an alternative to post-mortem blood is of particular 
importance when the body has undergone considerable decomposition or burning. 102 In 
comparison to post-mortem blood, which is often putrefied, vitreous humor is a relatively 
simple matrix as highlighted in Table 2.36. It is also much less susceptible to post-mortem 
changes. The transport of drugs across the blood / vitreous humor barrier is limited by the 
lipid solubility of the drug and its charge at physiological pH. '°3 





Water (20-70%) Water (98.0-99.7%) 
Lysate Glucose 
Clots - denatured & bacterial Hyaluronic acid 
Denatured protein Simple anions & cations 






Most studies concerning the analysis of vitreous humor have been concerned with time- 
since-death determinations 104 and it is only in the last decade that interest has been placed 
on the use of vitreous humor for the determination of drug levels. 
Some of the drugs which have been investigated in vitreous humor include morphine, 105 
flurazepam, 106 methadone, 107 and cocaine. 102 The methodology usually involves a solid 
phase extraction followed by the appropriate analysis technique. 
2.15.8.1 VITREOUS HUMOR ANALYSIS FOR BENZODIAZEPINES 
In terms of this study, the 10% EtAc extractions were found to give slightly better 
recoveries from authentic forensic samples than the 5% EtAc. The method development 
for vitreous humor is taken as being the same as the McOH standard method development. 
The reasons for this are twofold: 
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" No blank vitreous humor was available for direct comparison 
" The matrix used to mimic vitreous humor was water, however as the samples are dried 
prior to extraction, the addition of water to the Extrelut® should make little difference to 
the matrix to be extracted. 
2.15.9 EXTRACTIONS WITH ETAC (10%) AS THE MODIFIER 
2.15.9.1 EXPERIMENTAL 
A combination of various standards was extracted using 10% EtAc to ensure that the 
system was functioning and that the 10% EtAc produced high recoveries. The standards 
analysed are detailed below. 
Extraction 1: Triazolam 
Extraction 2: Temazepam 
Extraction 3: Chlordiazepoxide 
Extraction 4: Diazepam 
Extraction 5: Desmethyldiazepam 
Extraction 6: Triazolam + Temazepam 
Extraction 7: Temazepam + Diazepam 
Extraction 8: Temazepam + Desmethyldiazepam 
Extraction 9: Triazolam + Temazepam + Desmethyldiazepam + Diazepam 
Extraction 10: All 5 standards 
2.15.9.2 RESULTS AND DISCUSSION 
The results are shown in Table 2.37 on page 92. 
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From Table 2.36 it can be seen that the extractions work well with good recoveries 
and thus the 10% EtAc was used for all future analyses. 
2.16 METHOD VALIDATION FOR ALL FIVE STANDARDS 
2.16.1 LINEARITY OF DIAZEPAM, DESMETHYLDIAZEPAM, CHLORDIAZEPOXIDE AND 
TRIAZOLAM METHANOL STANDARDS 
2.16.1.1 EXPERIMENTAL 
The linearity for diazepam, desmethyldiazepam, chlordiazepoxide and triazolam from 
methanol standards was calculated. Each of the results is an average of three 
extractions and three injections (n=9). The results obtained are shown in Tables 2.38, 
2.3 9,2.40 and 2.41. 
2.16.1.2 RESULTS AND DISCUSSION 
Table 2.38: Linearity for Diazepam; Methanol Standards 












0 0 376610 0 0 126320 0 
0.55 74593 174663 0.427 r2: 0.997 18454 55613 0.332 r2: 0.988 
1.10 111750 134850 0.829 A: 0.128 37460 63283 0.592 A: -0.098 1.66 151680 137650 1.102 B: 0.594 59210 65235 0.908 B: 0.662 
2.21 232840 160620 1.450 72608 51827 1.401 
2.76 269600 153270 1.759 189560 107760 1.759 













0 0 374379 0 0 308326 0 
0.42 91825 386670 0.237 r2: 0.999 99775 368763 0 271 r2: 0 989 
0.85 175928 384498 0.458 A: 0.007 167417 273455 . 0 612 . A: 0 053 
1.27 275638 399624 0.690 B: 0.537 147918 161554 . 0 916 . B: 0 630 
1.70 338065 370187 0.913 241397 215479 . 1 120- . 
2.12 424846 368959 1.551 532755 392761 . 1.356 
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Table 2.40: Linearity for Chlordiazepoxide: Methanol Standards' 












0 0 309210 0 0 197976 0 
0.84 20760 299681 0.069 r2: 0.980 39487 329021 0.120 r2: 0.989 
1.68 41073 315776 0.130 A: -0.044 69464 317427 0.219 A: 0.042 
2.52 70073 300417 0.233 B: 0.112 109292 353057 0.310 B: 0.101 
3.36 95808 310848 0.308 159054 441691 0.360 
4.20 135004 299282 0.451 142440 300824 0.473 













0 0 418840 0 0 89123 0 
0.71 33598 435380 0.077 r2: 0.936 15887 227390 0.077 r2: 0.985 
1.42 25112 172230 0.146 A: 0.034 30040 219200 0.137 A: 0.010 
2.12 38077 151910 0.251 B: 0.083 52818 265555 0.199 B: 0.089 
2.83 44259 163100 0.271 33474 138440 0.242 
3.54 58552 189810 0.308 36381 107300 0.339 
From these it can be seen that the linearity over the range studied is good and the 
gradients of both the unextracted and extracted standard curves are in good agreement 
for all drugs. 
2.16.2 LINEARITY OF DIAZEPAM AND DESMETHYLDIAZEPAm BLOOD STANDARDS 
2.16.2.1 EXPERIMENTAL 
For blood standards only diazepam and desmethyldiazepam were extracted as these 
and temazepam were the only benzodiazepines quantitated in the authentic blood 
samples as discussed in chapter 6. 
2.16.2.2 RESULTS AND DISCUSSION 
The PAR's obtained for three extractions and three injections of diazepam and 
desmethyldiazepam blood standards are shown in table 2.42. 
Chapter Two: Benzodiazepines Page95 
Table 2.42: Linearity for Diazepam and Desmethyldiazepam: Blood Standards 
E Diazepam n Desmeth ldiaze am 
Conch 
(m ) 





0 0 0 0 0 0 
0.55 0.427 0.180 r2: 0.919 0.42 0.237 0.380 r2: 0.881 
1.38 0.852 0.430 A: -0.190 1.06 0.549 0.517 A: 0.231 
2.21 1.450 0.771 B: 0.508 1.70 0.913 0.606 B: 0.279 
L 2.76 0.759 1.364 2.12 1.151 0.903 
Although the correlations are poorer for the blood standards than the MeOH 
standards, the gradients are still in good agreement. 
2.16.3 PREPARATION OF FRESH STANDARDS AND CALCULATION OF LIMITS OF 
DETECTION 
2.16.3.1 EXPERIMENTAL 
Fresh standard benzodiazepines were prepared at the following concentrations: 
Temazepam: 3.44 mg/100 m1 
Diazepam: 3.17 mg/100 ml 
Desmethyldiazepam: 3.09 mg/100 ml 
Prazepam: 2.52 mg/100 ml 
The limit of detection was calculated for temazepam, diazepam and 
desmethyldiazepam using these standards by sequentially diluting the stock standards. 
2.16.3.2 RESULTS AND DISCUSSION 
The limit of detection results obtained are shown in Table 2.43. 
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Table 2.43: Linearity for Limit of Detection .1 
Temaze am DMD Diazepam 
Soli m /L PAR m PAR mg/Ll PAR AUFS 
1P 4.3 0.204 3.96 0.352 3.86 0.418 0.05 
2P 2.15 0.099 r2: 0.996 1.98 0.178 r2: 0.993 1.93 0.203 r2: 0.999 0.05 
3P 1.08 0.054 A: 0.002 0.99 0.104 A: 0.012 0.97 0.101 A: 0.003 0.05 
4P 0.54 0.035 B: 0.046 0.50 0.067 B: 0.086 0.48 0.062 B: 0.107 0.05 
5P 0.27 0.010 0.25 0.018 0.24 0.029 0.01 
6P* 0.14 0.012 0.13 0.036 0.12 0.023 0.002 
*The prazepam peak in 6P overloaded the detector and thus the PAR for these values 
was not taken into account for the linearity. 
New standard dilutions were prepared using a more dilute prazepam standard. This 
time the concentrations of each drug were quoted in absolute nanogram values 
injected into the HPLC system as this way the limits of detection can be more easily 
converted for different extraction volumes. The results are shown in Table 2.44. 
Table 2.44: Linearity for Limit of Detection :2 
T emaze am DMD Diazepam 
Sol' ng PAR ng PAR ng PAR 
1 688 12.169 634 11.319 618 13.316 
2 344 7.470 r2: 0.989 317 6.996 r2: 0.987 309 7.825 r2: 0.993 
3 68.8 1.265 A: 0.174 63.4 1.038 A: 0.117 61.8 1.232 A: 0.08 
4 34.4 0.733 B: 0.018 31.7 0.578 B: 0.018 30.9 0.669 B: 0.02 
5 6.88 0.121 6.34 0.169 6.18 0.125 
6 3.44 0.094 3.17 0.063 3.09 0.080 
The last solution (6) was diluted further as the limit of detection had not been reached, 
to yield the following nanogram values and PAR's for each drug: 
Table 2.45: Linearity for Limit of Detection. - 3 
Temazepam DMD Diaze am 
Sol' ng PAR ng PAR ng PAR 
6a 3.44 0.087 3.17 0.076 3.09 0.084 
6b 2.29 0.051 2.11 0.038 2.06 0.062 
6c 1.72 0.043 1.59 -ve 1.55 0.049 
6d 0.86 -ve 0.79 -ve 0.78 -ve 
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From this the limit of detection was taken as being 1.72 ng for temazepam, 2.11 ng for 
desmethyldiazepam and 1.55 ng for diazepam. In all cases, the drugs could still be 
distinguished clearly from the baseline noise. 
2.17 CONCLUSIONS 
It has been found that supercritical fluid extraction can be used successfully for the 
extraction of benzodiazepine drugs from a variety of matrices loaded onto Extrelut®. 
This method which was developed and consequently used for the extraction of 
Forensic blood and vitreous humor samples (see Chapter 6), is described below. 
Samples were prepared by loading the 100 µl of sample blood or vitreous humor onto 
approximately 19 g of Extrelut®. To this, 100 µl of internal standard was added, 
mixed and allowed to dry. Once dry, the Extrelut® was transferred to an extraction 
cell which was sealed and placed into the SEE oven at 65 °C. The SEE system which 
was equilibrated at a flow of 2 ml mini' and a pressure of 3000 psi was then switched 
to extract and the extracted analytes collected for 10 minutes into MeOH at the flow 
outlet. 
The methodology was found to be reproducible and provide high recoveries of 
temazepam, desmethyldiazepam and diazepam (80-100%), the three most commonly 
encountered benzodiazepines in forensic specimens in the West of Scotland over the 
studied period. In addition, the method was found to be comparable to the currently 
employed SPE method but was less solvent intensive (2 ml of EtAc used per 
extraction c. f. -15 ml of diethylether for SPE). 
1Lm Sh4espeare; Othello 
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3. OPIATES 
3.1 INTRODUCTION 
The opiates are a group of drugs derived from the opium poppy (papaver somniferum). tos 
Their use as analgesics dates back as early as the 7th century B. C. with reference to the 
juice of the poppy in the Assyrian medical tablets. 109 By the 16th century opium was well 
established in Western European medicine and many of the physicians of the time stated 
that they could not practice medicine without it. At the beginning of the 19th century, the 
use of opium was still thought to be central to medicine however, its widespread use 
became restricted in 1868 when the first Pharmacy Act became law. In addition, after 
World War One, Britain implemented an international agreement to prohibit non-medical 
use of opiates due to the large number of post-war addicts. 
Natural opiates which are found in the opium poppy include morphine and codeine, both of 
which are effective as painkillers. Diamorphine (heroin) was first synthesised from 
morphine in 1874110 and in its pure form is a white fluffy powder which is more than twice 
as potent as morphine. It was initially thought to be a safe means of curing morphine 
addiction and its potential for abuse was largely ignored. A number of other synthetic 
opiates have been manufactured as pain-killers including pethidine, dipipanone and 
methadone, the latter of which will be discussed more fully in Chapter 4. 
In order to monitor the size of the national heroin problem, a Home Office Notification 
System was set up in 1968. In 1993, the number of registered addicts was 27,976. 
However, as this is based on those users who register their addiction with their GP, this 
number is an under-estimation and the number of actual opiate addicts is believed to be 
greater than 125,000. 
3.2 PRESCRIPTION 
Opiates are generally prescribed as painkillers, however, they also have medical uses as 
cough suppressants and anti-diahorrea agents. Table 3.1 lists the opiates commonly 
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prescribed along with their proprietary names and uses. In the U. K., morphine is the 
favoured opiate by most doctors for the treatment of severe pain. 
ll t, t t2 Table 3.1: Prescription Opiates 
Name Proprietary Name(s) Treatment 
Alfentanil Ra ifen® Pain 
Buprenorphine Tem esic® Pain, premed. 
Codeine Diarrest®, Co- 
Codamol® 
Anti-diarrhoea, pain 




Diamorphine - Pain (IV), cough 
Dihydrocodeine DF118 Forte® Pain 
Diphenoxylate Lomotil®, Tro er en® Anti-diarrhoea 
Dipipanone Diconal® Pain 
Fentanyl Duro esic® Pain 
Loperamide Imodium°, 
Lo era en® 
Anti-diarrhoea 
Meptazinol - Pain 
Methadone Ph se tone® Pain, cough 
Morphine MST Continus®, 
Kaolin®, Oramorph 
SR®, Sevredol® 
Pain, cough, dyspnoea 
Nalbuphine Nubain® Pain, premed. 
Oxycodone - Pain 
Pa averetum - Pain 
Pethidine Pamer an® Pain 
Phenazocine Na hen® Pain 




Tramadol. Zydol SR® Pain 
3.3 CHEMICAL STRUCTURE 
The three opiates which are of interest to this study are diamorphine (3,6-o- 
diacetylmorphine), 6-monoacetylmorphine (6-MAM) and morphine ((5aR, 5S, 7aR, 8R, 9cS)- 
4a, 5,7a, 8,9,9c-hexahydro-12-methyl-8,9c-iminoethanophenanthro[4,5-bcd]furan-3,5-diol). 
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Methadone, which is also an opiate is discussed in Chapter 4. All three of the drugs which 
will be discussed here have the same basic chemical structure, which differs only in the Rl 
and R2 groups as indicated in Figure 3.1 and Table 3.2. 
2 
Figure 3.1: Structure of opiates 
Table 3.2: R1 and Rz Groups for Opiates of Interest 
Drug R, R2 
Diamorphine COCH3 COCH3 
6MAM H COCH3 
Morphine H H 
3.4 PHARMACOLOGY 
Opiates appear to share some of the properties and mimic the action of some groups of the 
body's naturally occurring chemicals called peptides and in particular the endorphins, 
enkephalins and dynorphins. Binding studies have indicated that there may be as many as 
eight types of opiate receptors which in addition may all have sub-type receptors. 113 
Opiates directly cause a large number of actions: 
" Effects on the central nervous system 
" Effects on the peripheral nervous system 
" Induced histamine release-related effects 
9 Effects for which there is no identified and/or proven causal effect 
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The main pharmaceutical uses of opiates are due to their effects on the CNS. These 
include pain relief and cough reflex depression as well as some of the less desired side 
effects including nausea, vomiting, and respiratory depression which is the main cause of 
opiate related deaths. 
Pain relief with opiates occurs through a number of pain reducing mechanisms and altered 
perception of painful stimuli. Opiates do not alter the sensitivity of the nerve endings to 
pain, but instead, interfere with the transmission of signals via the nervous system to the 
brain by four mechanisms: 
9 Decreasing the conduction along the nerves running between the nerve endings and the 
spine 
" Preventing production of chemicals which allow signals to pass between the nerves and 
the spinal cord 
0 Stimulating production of serotonin (5HT) and noradrenaline which significantly 
reduces the pain signals reaching the brain 
9 Mimicking the action of endorphins at their receptor sites 
The side effect which is responsible for the national opiate addiction problem is euphoria. 
Although the mechanism by which opiates produce a sense of euphoria is not yet agreed, it 
is thought to be partly via action on part of the brain called the locus cerulus, which is 
known to have a high concentration of opioid receptors. 114 
3.5 METABOLISM 
Diamorphine is the active ingredient of Heroin. Post-administration, it is readily absorbed 
and rapidly hydrolysed to 6-MAM in blood, then more slowly metabolised to morphine 
which is the major active metabolite. Normorphine is also formed to a lesser extent. All 
metabolites may be conjugated with glucuronic acid to form the glucuronide derivatives. 
Morphine itself undergoes considerable first pass metabolism and is widely distributed to 
the kidneys, liver, lungs and spleen. It does not however accumulate in the tissues. Figure 
3.2 shows the major metabolic pathway of diamorphine. 
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Morphine Glucuronides 
I 
HO HO HO 
OOý........ ... O 
N-CH3 N-CH3 


















Due to the short half lives of diamorphine and 6MAM, there is a lack of pharmacokinetic 
data on these drugs. The information available from Clarkes Identification of Drugs' 15 is 
summarised in Table 3.3. As can be seen other than the half lives of diamorphine, and 
6MAM, no pharmacokinetic data was available and the volume of distribution (VD), 
clearance (Cl) and protein binding quoted for these drugs refer to morphine. 
Table 3.3: Pharmacokinetic Data for Opiates 




Diamorphine -3 min - - - 
6-MAM -30 min - - - 
Morphine 2-3 hr 3-5 15-20 20-30% 
Chapter Three: Opiates Page103 
Diamorphine is difficult to detect in plasma due to its rapid hydrolysis to 6MAM. An 
intravenous dose of 4-5 mg declines to a blood concentration of 0.01 mg/L within 10 
minutes. Therapeutic morphine plasma concentrations are usually in the range 0.01-0.07 
mg/L. The estimated LD50 for diamorphine in man is 200 mg however, addicts can tolerate 
up to 10 times this amount and fatalities have been known after only 10 mg. 
3.7 LEGAL STATUS 
Opium is one of the few drugs in the Misuse of Drugs Act which in its raw form, is not 
authorised for medicinal use and can only be supplied, possessed or administered in 
accordance with a Home Office Licence. It is also an offence to frequent a place used for 
smoking opium, to posses utensils used for smoking and preparing opium or to allow 
premises to be used for smoking or preparing opium. 
Dextromoramide, dipipanone, fentanyl, heroin, methadone, morphine, opium and pethidine 
are all Class A drugs. Codeine and dihydrocodeine are Class B drugs unless prepared for 
injection in which case they are Class A drugs. Dextropropoxyphene and buprenorphine 
are Class C drugs. Dilute mixtures of codeine, morphine or opium used for the treatment 
of coughs or diarrhoea are available over the counter from pharmacies. 
3.8 ANALYSIS OF MORPHINE 
In reviewing the available literature on morphine analysis it was found that the tissue of 
choice for analysis was plasma. Here morphine is present in unconjugated form and there 
is little else in the matrix likely to interfere with the isolation of the drug, although up to 
30% plasma protein binding is reported. However, plasma is seldom available in most 
postmortem cases and the tissue most commonly supplied is haemolysed, often putrefied, 
blood. 
Direct analysis of body fluids and tissues is impractical and usually some form of cleanup 
or pre-concentration is required before chromatographic methods can be applied. RIA can 
be performed on unprepared samples but a simple extraction into MeOH is usually carried 
Chapter Three: Opiates Page 104 
out to eliminate matrix interference and increase sensitivity. Methods which have been 
used for the preparation of samples to be analysed for morphine include: 
1. Protein precipitation, ultrafiltration and centrifugation (Curry, 1969)116 
2. Liquid/liquid extraction (Jones et al, 1985117 - urine: GC/MS; Basett, 1980118 - plasma: 
GC-ECD; Todd et al, 1982119 plasma/CSF: LC-EC; White, 1979120 - blood: LC-EC) 
3. SPE (Mule, 1974121 urine: GC, Moore et al, 1984122 - plasma: LC-ED; Fritschi et al, 
1985123 urine: GC/MS/SIM; Derko et al, 124 - urine: LC-UV) 
In terms of the analysis of opiates, the method of choice has to be GC/MS due to its 
sensitivity and selectivity via the use of SIM. The use of GC/MS for opiates is well 
documented and recently a simultaneous method for the determination of acetylcodeine, 
monoacetylmorphine and other opiates in urine was reported by O'Neal and Poklis. 125 
Other popular methods for the analysis of opiates are summarised in Table 3.4. 









126 1972 HPLC-UV n/n n/n n/n No 
198717. HPLC-ED n/n Serum n/n n/n 
1984 GC/MS n/n n/n n/n Yes 
1991 GC 
- n/n Blood/ Bile n/n Yes 





130 1994 GC/MS SPE Urine 0.5 ml Yes 
1994 131 
- 
GC-FID n/n Blood stains n/a No 
199737 GC/MS SPE Saliva/ 
Blood/ Serum 
n/n Yes 
1995 133 Review various various various - 
1995 HPLC SPE Serum 200 1 No 
3.9 SFE ANALYSIS OF MORPHINE 
The super/sub critical analysis of opiates has been reported by several authors. 135,136 Janicot 
et a1135 used CO2 with an amine polar modifier for the successful separation of opium 
alkaloids from poppy straw extracts and Edder et al'36 reported the use of SF-CO2 with a 
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polar modifier for the extraction of opiates from biological matrices. Indeed this second 
method was used as a starting point for the SFE of morphine as described in section 3.13. 
3.10 STATUS OF CASES 
Figure 3.3 shows the number of toxicology cases in which morphine was found over the 
time period 1992 to 1997. It should be noted that this number will include therapeutically 










Figure 3.3: Morphine Related Deaths 
It can be seen from this figure that over the period 1992 to 1995, there was a sharp 
increase in the number of morphine fatalities whereas from 1995-1997, the morphine 
related deaths appear to be declining in number. One explanation for this is the 
introduction of the methadone maintenance programmes. This will be discussed in more 
detail in the next chapter. 
3.11 CURRENT METHODOLOGY 
At the time of this work the method of extraction employed in the routine laboratory made 
use of solid phase extraction as described below. 
1992 1993 1994 1995 1996 1997 
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Samples and blanks were prepared by pipetting 1 ml of O. 1M ammonia buffer, 1 ml of 
sample or blank blood and 50 µl of d3-morphine (1µg/ml) into a vial. In the case of 
standards, 50 µl of morphine (1µg/ml) was also added. Two extraction columns were 
required for each extraction. The first was prepared by plugging a small amount of glass 
wool into a 10 ml plastic syringe and filling to the 10 ml mark with EtOH / MeOH washed 
Extrelut®. The other extraction columns were Bond Elut SCX. In each case the extraction 
columns were labelled with the appropriate sample number. 
The contents of the sample, standard and blank vials were pipetted onto the corresponding 
Extrelut® column and allowed to stand for 10 minutes. The Extrelut® columns were then 
washed with 5 ml of hexane and put to one side. The SCX columns were placed on the 
vac-elut system and conditioned with 2 ml of methanol, followed by 2 ml of water and 
finally 1 ml of ethyl acetate : isopropanol (9: 1 v/v). The Extrelut® columns were then 
placed on top of the SCX columns via an adapter and eluted using 12 ml of EtAc: IPA (9: 1 
v/v) under a vacuum of approximately 5 psi. The Extrelut® columns were then discarded 
and the SCX columns washed using 5 ml of MeOH : ACN (l: lv/v). Labelled tubes were 
placed under the appropriate columns on the vac-elut system and 2 ml of 10% ammonia in 
MeOH : ACN (1: 1 v/v) was passed through and collected. The collected extracts were 
transferred into small vials and evaporated to dryness under nitrogen. 50µ1 of BSTFA (1% 
TMCS) were added to each vial which was then sealed and heated at 90 °C for 15 minutes. 
For GC-MS analysis, 1 µl of the derivatised extract was injected. 
3.12 GC/MS METHODOLOGY 
The GC/MS for both morphine and methadone (chapter 4) was carried out using a Fisons 
GC 8000 series gas chromatograph with a MD 800 mass spectrometer. The GC was fitted 
with a HP! capillary column (30 mx0.25 mm x 0.25 µm film thickness). 
For the analysis of morphine and 6MAM, the temperature programme was as follows: 
Initial Temperature: 100 °C 
Final Temperature: 300 °C 
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Temperature Ramp: 10 °C/min 
Final hold Time: 5 minutes 
Injector Temperature: 225 °C 
The detector was run in the selected ion monitoring mode (SIR) and the mass to charge 
ratios (m/z) detected were 414 and 429 for morphine and 432 for d3-morphine. The 
6MAM was investigated at a later stage and the m/z which were used are discussed in 
section 3.14. 
It should be noted that morphine peaks at m/z : 414 and m/z : 429 are only defined as being 
positive when the m/z ratio of 414/429 is between 0.4 and 0.85. The value obtained is 
usually close to 0.5, however alterations in the tuning of the instrument give some 
variation. 
3.13 EXPERIMENTAL 
Initially, a literature review on previous methodology was carried out. Several papers were 
noted to use CO2 as an extractant for the quantitation of opiates as previously 
mentioned. 136,137 The first of these to be reviewed was the subcritical extraction method for 
morphine, published by Edder et a1.29 This method makes use of a ternary phase extractant 
which at the low temperatures used will be sub-critical and not supercritical. The 
conditions used for the extraction were as follows: 
" Support medium: C18 silica 
" Extraction phase: C02: MeOH : Et3N (90: 8.5 : 1.5 (v/v)) 
" Pressure: 25 MPa (3625 psi) 
" Temperature: 40 °C 
" Time: 30 minutes 
" Flowrate: 0.5 ml miri 1 
Chapter Three: Opiates Page 108 
3.13.1 SUB-CRITICAL Rum EXTRACTION OF MORPHINE 
3.13.1.1 EXPERIMENTAL 
Four extractions of morphine and d3-morphine in MeOH were carried out using a variety of 
C18 supports. In each case, 100 µl of morphine and d3-morphine (10 mg/L) were pipetted 
onto a C18 support and allowed to dry at room temperature. In addition to the MeOH 
extracts, an additional extraction (1/1) was carried out using a blood spiked standard (10 
mg/L). Again 100 µl of the standard containing morphine and d3-morphine were loaded 
onto the C18 support. 
In their paper, Edder et a1136 suggest that a small amount of water added to the extraction 
vessel may aid the extraction and thus 10. tl of dH2O was added to two of the four MeOH 
extracts. A further two blood standard extractions (2/1,2/2)were carried out the following 
day, this time, one (2/2) had 10 µl of dH2O added. 
The actual conditions used were slightly modified from the original conditions used by 
Edder et a1136 as follows: 
" Extraction phase: CO2 : MeOH : Et3N (90: 8.5: 1.5 (v/v)) 
" Pressure: 3500 psi 
" Temperature: 45 °C 
" Time: 30 minutes 
" Flowrate: 1.0 ml min" 
3.13.1.2 RESULTS AND DISCUSSION 
The extraction support phase was varied as only limited amounts of C18 from any one 
supplier was available. The phases used are detailed below. 
MeOH Extraction 1: Shandon 5µ ODS 
MeOH Extraction 2: As for Extraction 1 (10 µl dH2O added) 
MeOH Extraction 3: Spherisorb C18 
MeOH Extraction 4: Glass Appliances 5µ ODS 
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Blood Extractions: Hypersil ODS 
The results obtained for the four MeOH extractions are shown in Table 3.5. Area based % 
recoveries were calculated for each of the monitored ions. 
Table 3.5: Morphine MeOH Extractions : Modification of method by Edder et al 






m/z ratio m/z ratio 
414/429 429/432 
Area Unext. 64431052 84183768 47162980 0.560 1.307 
Ext. 1 77 70 67 0.536 1.178 
Ext. 2 180 147 145 0.553 1.064 
Ext. 3 31 27 27 0.552 1.145 
Ext. 4 42 30 30 0.570 0.926 
The results obtained for the blood extractions on days one and two are shown in Table 3.6. 












Ext. 1/1 176 172 151 0.529 1.243 
Area Unext. 64431052 84183768 47162980 0.560 1.307 
Day Two 
Ext. 2/1 348 314 400 0.576 1.077 
Ext. 2/2 618 619 707 0.518 1.193 
Area Unext. 37501364 44641888 20241124 0.453 1.190 
Although in both cases (blood and MeOH) the % area recoveries vary widely from 
extraction to extraction, good comparison with the unextracted standard in terms of the 
429/432 ratio is observed. Some of the variation in the areas can be attributed to the 
derivatisation procedure as highlighted in section 3.13.7. 
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3.13.2 EXTRACTION AT VARIOUS VOLUMES OF MORPHINE/D3-MORPHINE 
3.13.2.1 EXPERIMENTAL 
The same conditions which were applied in section 3.13.1, were used for the extraction at 
various volumes of morphine and d3-morphine from 0 to 1.0 ml. Both extracted and 
unextracted MeOH standards were run through the GCIMS. 
3.13.2.2 RESULTSANDDISCUSSION 
The results obtained for the subcritical extraction of various volumes of morphine and d3- 
morphine are shown in Table 3.7. 
The volumes of standard used cover a range from 1.1 to 11.0 mg/L of morphine 
hydrochloride. The case samples which have been received for analysis by SPE to date are 
in the concentration range 0.03 to 1.1 mg/L by SPE followed by GC/MS, thus a ten-fold 
dilution of these samples will have to be carried out in order to check the linearity over this 
range. 
Table 3.7: Subcritical Extraction at Various Volumes of Morphine and dr-Morphine 
Unextracted m/z ratio Extracted m/z ratio Apparent 
Vol. (ml) 429/432 414/429 429/432 414/429 Concn 
0 0.0033 13.89 0.0044 10.42 -ve 
0.1 0.9298 0.582 1.1176 0.574 1.32 
0.2 1.0457 0.597 1.2016 0.570 1.26 
0.3 1.0337 0.628 1.1390 0.575 1.21 
0.4 1.0116 0.632 1.1340 0.577 1.23 
0.5 1.0578 0.602 Extract solidified 
0.75 1.0576 0.795 1.0475 0.551 1.19 







As the volumes of morphine and d3-morphine being analysed were the same, the m/z 
429: 432 ratio should remain constant. From the results obtained in this and the previous 
sections, it is noticeable that the 429/432 m/z ratio of morphine for unextracted standards 
varies from 0.93 to 1.44 on a day to day basis. For this reason it is essential that where 
possible, an unextracted standard is run on the same day as the extracted standards. 
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3.13.3 LINEARrrx of MoR HiNE ExTRACn0N 
3.13.3.1 EXPERIMENTAL 
An 11 mg/L morphine hydrochloride standard solution was diluted 1: 10 to give a stock 
concentration of 1.1 mg/L. In real samples, the morphine being analysed will not be as the 
hydrochloride, therefore the concentrations were adjusted for morphine only, to give a 
stock solution concentration of 0.98 mg/L. Aliquots of this solution were pipetted into a 
vial with 200 µl of d3-morphine, blown to dryness under a stream of nitrogen, reconstituted 
in 50 µl of BSTFA (1% TMCS) and derivatised for 15 minutes at 90 °C. The same 
volumes of morphine and d3-morphine were also extracted by pipetting the appropriate 
volumes of morphine and d3-morphine onto C18, drying, extracting and derivatising as 
detailed above. The derivatised samples were then injected onto the GGMS. 
3.13.3.2 RESULTS AND DISCUSSION 
The results for various concentration of morphine at constant d3-morphine concentration 
are shown in Table 3.8. 
Table 3.8: Morphine Linearity over the range 0.049 to 0.98 mQ/L 
Unextracted m/z ratio Extracted m/z ratio 
Vol. (1) Concn 429/432 414/429 429/432 414/429 
0 0 0 0 0 0 
50 0.049 0.256 0.702 0.224 0.681 
100 0.098 0.553 0.581 0.475 0.589 
200 0.196 1.144 0.535 0.957 0.632 
300 0.294 1.698 0.519 1.567 0.559 
400 0.392 2.310 0.513 2.354 0.521 
500 0.490 2.754 0.504 2.962 0.498 
600 0.588 3.216 0.504 3.186 0.558 
700 0.686 3.620 0.501 3.589 0.603 
800 0.784 4.036 0.501 3.964 0.540 
900 0.882 4.590 0.497 4.479 0.503 
1000 0.980 4.932 0.498 4.877 0.536 
For the unextracted standards: r2: 0.995, A: 0.165, B: 5.0 19. 
For the extracted standards: r2: 0.987, A: 0.110, B: 5.041. 
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The morphine m/z 414 and mlz 429 peaks for the 0.049 mg/L standard were still easily 









Figure 3.4: Mass Chromatogram of 0.049 mg/L Morphine 
3.13.4 SUPERCRITICAL FLUm EXTRACTION METHOD 
3.13.4.1 EXPERIMENTAL 
An additional method for the supercritical fluid extraction of morphine was investigated. 137 
This method was designed for the extraction of hair samples but it was attempted in a 
modified form for the extraction of morphine from MeOH and blood standards. ' The 
original method uses the following conditions: 
" Temperature: 100 °C 
Flowrate: 2.0 ml min" 
" Pressure: 25 Mpa (3625 psi) 




Chapter Three: Opiates Page 113 
The conditions were maintained with the exception of the modifier which was kept as the 
MeOH : Et3N used in the initial extraction method by Edder et al. 136 
Fresh standards of morphine and d3-morphine were prepared in methanol as follows: 
Morphine: 1.35 mg of morphine hydrochloride was weighed into a 100 ml volumetric 
flask and made up to the mark with methanol. As the morphine is as the hydrochloride, the 
actual concentration of morphine -* 1.20 mg/100 ml 
d3-morphine: 1.01 mg of d3-morphine were weighed into a volumetric flask and prepared 
as above. 
For d3-morphine the absolute concentration does not have to be calculated. It is only 
important that the concentration is approximately the same as the morphine concentrations 
being investigated and that it is kept constant for all samples and standards. 
An extraction calibration curve with these standards diluted 1: 10 was carried out. 1000 tL 
of d3-morphine was added for each extraction. 
3.13.4.2 RESULTS AND DISCUSSION 
The results for the calibration using the new extracted standards are shown in Table 3.9 and 
Figure 3.5. 









0 .0 4.5* 10" 10.31 
100 0.12 0.202 0.879 
200 0.24 0.387 0.826 
300 0.36 0.550 0.838 
400 0.48 0.879 0.681 
500 0.60 0.957 0.806 
750 0.90 1.337 0.819 
















0 0.2 0.4 0.6 0.8 1 1.2 1.4 
Concentration Morphine (mg/L) 
Figure 3.5: Linearity of Morphine over the Runge 0.12-1.20 mg 1, 
The new standards yielded a better correlation coefficient for the extraction. The gradients 
of the two calibrations could not be directly compared as the amount of internal standard 
added was different (1000 µl c .f 
200 µl). In order to check that the two sets of standards 
were however providing reproducible results, the PAR's were plotted against each other as 




.. v.. ý I1.. J Z 
New Standards (PAR) 
Figure 3.6: Comparison of Old and New Morphine Standards 
7F 
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As the concentrations were different for the two sets of standards, the points for the old 
standard were calculated using the equation of the best fit line (y=5.019x+0.165). For the 
two sets of standards, the coefficient of correlation was calculated as 0.989 and the 
equation of the line was y=3.465x-0.045, indicating that similar results would be obtained 
using either standard. 
3.13.5 LINEARrry of MORPHINE EXTRACTION 
3.13.5.1 EXPERIMENTAL 
The linearity test with the new standards was repeated, this time reducing the concentration 
to 0.012 mg/L morphine for MeOH and blood standards. Each set of MeOH standards was 
injected into both GC/MS's to ensure that both instruments were producing the same 
results. 
3.13.5.2 RESULTS AND DISCUSSION 
The results obtained for the MeOH extractions on both GC/MS's and for the blood 
standards are shown in Table 3.10. 
Table 3.10: Linearity After One Hundred-Fold Dilution of Standards 
GC/MS A: MeOH GC/MS B: MeOH Blood 
Conc" 429/432 414/429 429/432 414/429 429/432 414/429 
0 0 0 0 0 0 0 
0.012 no 429 no 429 no morphine 
0.018 no 429 no 429 no morphine 
0.024 no 429 0.027 0.886 no morphine 
0.06 0.054 1.506 0.040 0.792 no morphine 
0.12 0.097 1.687 0.075 0.750 no mo hine 
0.18 0.201 1.190 0.224 0.682 0.213 0.623 
0.24 0.183 1.040 0.183 0.691 0.363 0.578 
0.60 0.351 1.202 0.423 0.571 0.745 0.643 
1.20 0.777 1.103 1.042 0.518 1.362 0.518 
Although the detection limit for the method appears quite high it should be noted that the 
extractions are based on only 100 µI of blood or MeOH being extracted instead of the 1 ml 
Chapter Three: Opiates Pagel 16 
used in SPE. Thus, if for example 500 tl were extracted, the detection limit should be 
decreased by a factor of five. 
From the results in Table 3.10 it is apparent that the results from the two GC/MS's are not 
comparable. For GC/MS A, the r2 value was 0.983 with a gradient of 0.604 and for 
GC/MS B, the r2 value was 0.981 with a gradient of 0.839. In addition, the LOD using 
GC/MS B is 0.024 compared to 0.06 using GC/MS A for MeOH standards. 
In theory, all method development should be carried out using the same GCIMS, however 
this was not always possible. The linearity (indicated by r)and limits of detection are 
however, good enough for use with the samples involved in this study. 
3.13.6 COMPAusON of SFE AND SPE 
3.13.6.1 EXPERIMENTAL 
A comparison between SFE and SPE was made to check that the same results were 
achieved for the extraction of blood using the two methods. 
A stock blood standard was prepared by pipetting 5 ml of 1.2 mg/L morphine and 5 ml of 
the 1: 10 diluted d3-morphine internal standard into a vial and evaporating to dryness under 
a stream of nitrogen. Once dry, 5 ml of blank blood was pipetted into the vial and 
sonicated at room temperature for three minutes. Three extractions were carried out for 
each method (SFE and SPE) using the methods previously described. The same 
concentration was extracted in each case and an unextracted standard in MeOH also 
injected for comparison. 
3.13.6.2 RESULTS AND DISCUSSION 
The results shown in Table 3.11 are averages of three injections for each of the triplicate 
extracts. 
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Table 3.11: Comparison of SFE and SPE for the Extraction of Morphine from Whole 
Blood 
m/z ratio 429/432 m/z ratio 414/429 
Unext. Std. 1.186 0.549 
SFE 1 1.124 0.555 
SFE 2 1.152 0.554 
SFE 3 1.136 0.554 
SPE 1 1.292 0.561 
SPE 2 1.242 0.549 
SPE 3 1.121 0.535 
SFE + unextracted: x=1.150±0.03, RSD=2.34% 





Both methods were found to produce similar results with SFE yielding slightly better 
reproducibility. 
3.13.7 EFFEcr OF DEtrvATTSATION TIME 
3.13.7.1 EXPERIMENTAL 
The effect of derivatisation time on the areas of morphine and d3-morphine was 
investigated. An unextracted standard was prepared by pipetting 100 µl of both morphine 
and d3-morphine into a vial, evaporating to dryness and adding 50 µ1 of BSTFA (1% 
TMCS). After 15 minutes of derivatisation at 90 °C, an injection of the standard was made 
onto the GC/MS. The same standard was reinjected after a total derivatisation time of 1 
hour. 
3.13.7.2 RESULTS AND DISCUSSION 
The results for the effect of derivatisation on the peak areas of morphine and d3-morphine 
are shown in Table 3.12. The last row shows the relative % increase in peak area obtained 
by increasing the derivatisation time from 15 minutes to 1 hour. 
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Table 3.12: Effect of Derivatisation Time 




15 min. 2696164 3090318 1607642 1.146 0.520 
1 hour 84656264 100363992 58051708 1.186 0.578 
lhr/15min 3140% 3248% 3610% 
Although the 414/429 and 429/432 m/z ratios are the same for the two derivatisation times, 
and thus would yield the same analytical results, an increase of greater than 3000 % is seen 
simply by leaving the standards derivatising for 1 hour as opposed to the stated 15 minutes. 
In practice this is not always practical as it is time consuming and in some cases, the 
samples were found to dry in the vials and thus, had to be reconstituted before injection. 
This step incurs a decrease in the recovery of the samples. 
3.13.8 CONCLUSIONS ON METHOD To USE 
As both of the methods investigated yielded good results for the extraction of both MeOH 
standards and blood standards, it was decided to use the supercritical method as opposed to 
the subcritical method. The final conditions used for the extraction are detailed below: 
Extractant Fluid: C02: MeOH: Et3N (90: 8.5: 1.5) 
Pressure: 3500 psi 
Temperature: 100 °C 
Support Medium: EtOH: MeOH washed Extrelut® 
Flow Rate: 2.0 ml min' 
Extraction Time: 20-30 minutes 
Collection Solvent: MeOH 
3.14 INTRODUCTION OF 6MAM INTO THE SFE 
As the purpose of this study was to investigate heroin related deaths, it was decided to look 
at one of the more confirmatory metabolites of diamorphine namely, 6- 
monoacetylmorphine (6MAM), as a means of determining if the death was heroin or 
morphine related. 
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A concentrated solution of 6MAM was prepared by pipetting 5 ml of a 13.3 mg/L solution 
of 6MAM in MeOH into a vial, evaporating to dryness under N2 and reconstituting in 50 µl 
of BSTFA (1 % TMCS). This solution was then derivatised for 15 minutes at 90 °C and 
run full scan on the GC/MS using the morphine GC parameters to determine the best peaks 
to look for. The mass spectrum of the 6MAM peak is shown in Figure 3.6 and from this 
the ions m/z 340 and m/z 400 were initially chosen. 
 




73 /400 Y. FS 43 287 
342 ?5i34 
253 { 343 1.819 4 r-2161 
M/z 100 200 300 400 
Figure 3.6: Mass Spectrum of BSTFA Derivatised 6-Monoacetylmorphine 
3.14.1 DETERMINATION OF M/z 340/400 RATIO FOR VERIFICATION PURPOSES 
3.14.1.1 EXPERIMENTAL 
A set of standards at varying concentrations of 6MAM from 0.67-2.66 mg/L were run 
through the GUMS in order to determine the ratio of 340: 400 for confirmation of positive 
6MAM. d3-morphine was included as an internal standard in order to plot a calibration 
curve for the concentrations investigated. 
3.14.1.2 RESULTS AND DISCUSSION 
The results obtained are shown in table 3.13. 
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Table 3.13: Calculation of 340/400 for 6MAM 
Vol. (1) m/z ratio 400/432 m/z ratio 340/400 
0 0 0 
50 0.135 2.34 
100 0.371 2.32 
150 0.513 2.28 
200 0.686 2.10 




This experiment was also carried out for extracted standards. However, the samples had to 
be left in the refrigerator for one week while routine maintenance was carried out on the 
GC/MS and on analysis, morphine peaks were observed. A second batch of 6MAM 
standards were extracted to ensure that: 
1) The 6MAM was not breaking down to morphine during the extraction 
2) The 6MAM was not effecting the extraction of morphine 
3.14.2 STABu. rrY OF 6MAM IN THE SFE SYSTEM AND ITS EFFECT ON MORPHINE 
3.14.2.1 EXPERIMENTAL 
Two sets of standards were prepared as previously described. The first had the various 
concentrations of 6MAM and 100 µl of d3-morphine and the second was as above but also 
had 100 µL of morphine added to each sample. 
3.14.2.2 RESULTS AND DISCUSSION 
The results for the extractions are shown in Table 3.14. 
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0 0 0 - 
0.67 Sample dried in vial 
1.33 2.860 0.148 0 - 
2.00 2.757 0.340 0 - 
2.66 2.792 0.629 0 - 
With Morphine 
0 - - 0.896 0.555 
0.67 2.735 0.169 0.925 0.560 
1.33 2.729 0.224 0.990 0.548 
2.00 2.699 0.672 0.934 0.553 
2.66 2.453 0.996 0.837 0.562 
For the three points obtained for the 6-MAM without morphine: r2: 0.986, A: -0.349, B: 
0.361 
For the extractions with morphine: r2: 0.932, A: -0.220, B: 0.441 
The presence of 6MAM does not appear to effect the extraction of morphine. In addition, 
no morphine was observed for the 6MAM and d3-morphine extractions and thus, the 
extraction conditions are not causing the 6MAM to degrade to morphine. 
3.14.3 INVESTIGATION OF MORPHINE GLUCURONIDE 
In addition to investigating the 6MAM it was also decided to see whether or not the 
morphine glucuronide was being broken down to morphine during the SFE process. This 
degradation could result in artificially high results obtained by SFE compared to the SPE 
method which does not break down the glucuronide. 
3.14.3.1 EXPERIMENTAL 
A 200 µl aliquot of a 7.65 mg/L morphine glucuronide sample prepared in water, was 
loaded onto Extrelut® and extracted. The extract was dried under nitrogen, derivatised and 
injected onto the GC/MS. 
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3.14.3.2 RESULTS AND DISCUSSION 
Peaks for both morphine and d3-morphine were observed. As no d3-morphine had been 
added to the standard at any stage it was assumed that either the glucuronide standard was 
contaminated or the system was contaminated as had been observed previously for the 
benzodiazepines. The outlet tubing of the system was changed. The replacement tubing 
had a narrower internal diameter and thus provided additional restriction at the flow outlet. 
A second standard of morphine glucuronide from a fresh bottle was also prepared. This 
time the concentration was 5.76 mg/L 
3.14.4 EXTRACTION WITH FRESH MORPHINE GLUCURONIDE 
3.14.4.1 EXPERIMENTAL 
A blank MeOH extraction was carried out to determine if there was any carry over in the 
remainder of the instrumentation. As this was negative, an extraction of 200 µ1 of the new 
morphine glucuronide standard was carried out. No peaks were seen for morphine or d3- 
morphine thus, the glucuronide is not being broken down to free morphine by the 
extraction process and the results obtained from SFE and SPE should be directly 
comparable. 
Several case samples were run to see whether the results which were being obtained were 
in agreement with those seen by SPE. The results are shown in section 6.4.1.2. 
3.14.5 CHECK OF SFE CONDITIONS FOR THE DETERMINATION OF MORPHINE AND 6MAM 
3.14.5.1 EXPERIMENTAL 
The following samples were prepared for extraction in order to check for carryover and as a 
final check on whether or not the 6MAM was being broken down to morphine and/or 
effecting the morphine results: 
A) 6MAM: 0,50,100,150,200 µl + 100 µl d3-morphine 
B) 6MAM: 0,50,100,150,200 µl + 100 µl morphine + 100µl d3-morphine 
C) Morphine: 0,50,100,150,200 µl + 100 µl d3-morphine. 
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3.14.5.2 RESULTS AND DISCUSSION 
The results from these sets of extractions are shown in Table 3.15 on page 132. As can be 
seen from the results there is significant carryover from extraction to extraction as 
indicated in bold. The system was again flushed out and an extraction of morphine and d3- 
morphine was carried out successfully with no carryover 6MAM peaks. 
In addition to flushing out the system, the outlet tubing was further investigated. The 
narrower bore tubing was not providing a sufficient restriction (which is indicated by the 
collection solution becoming cold). In order to achieve better restriction, it would be ideal 
to use GC capillary tubing as a restrictor. GC capillary tubing was housed inside a piece of 
stainless steel tubing and connected to the flow outlet. By using this method, it was easier 
to change the outlet tubing more frequently thus decreasing any contamination risk. 
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3.14.6 INVESTIGATION OF M/Z 399 PEAK FOR VERIFICATION PURPOSES 
3.14.6.1 EXPERIMENTAL 
In addition to the m/z 400 peak, the 6MAM also has a m/z 399 peak which is stronger than 
the m/z 400 peak. As opposed to the m/z 340 and m/z 400 being used for the quantitation 
of 6MAM, the m/z 399 and m/z 340 peaks were investigated. The following mixes of 
standards were analysed by GC/MS. Both unextracted and extracted standards were 
injected. 
A) 6MAM only 
B) 6MAM + d3-morphine 
C) Morphine glucuronide only 
D) Morphine glucuronide + d3-morphine 
E) Morphine only 
F) Morphine + d3-morphine 
3.14.6.2 RESULTS AND DISCUSSION 
The results obtained for the six standard mixes are shown in Table 3.16. 




















A - - - 161349 141142 - - 0.875 - B 599159 - 26044 157900 147965 - - 0.937 0.247 
C - - - - - - - D 38703 - - - - - 
E 8632 293200 137351 - - 33.97 0.468 - - F 427511 345231 182786 - - 0.808 0.529 - - Extracted 
A 
B 31013 - - 17501 16879 - - 0.964 0.544 C - 8279 8603 - - - 1.039 - - D 7228 13359 7163 - - 1.848 1.284 - - E - 9166 17840 - - - 0.855 - - F 13317 15139 6208 - - 1.137 0.410 - - 
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From these results it appears that the contamination problems have been reduced. The only 
carry over peak appears to be in the unextracted morphine run. d3-morphine is observed at 
a low concentration. The extracted 6MAM yielded no peaks, however a high pressure 
blockage occurred during the extraction and thus some sample may have been lost. Peaks 
were seen at 414 and 429 for both glucuronide extracts. However, the ratio of the peaks 
were found to be 1.039 and 1.284 which means that they are not due to morphine. No 
corresponding peaks were seen in the unextracted glucuronide. 
3.14.7 LINEARrrY AvD LOD FOR 6MAM 
3.14.7.1 EXPERIMENTAL 
The linearity and limit of detection were calculated for 6MAM. The initial stock standard 
had a concentration of 1.33 mg/100 ml. This was diluted 1: 10 with methanol and this 
solution (1.33 mg/L) was used as the starting concentration for the linearity with 100 tL of 
d3-morphine. Serial dilutions of this solution were made down to a concentration of 0.665 
µg/L. 
3.14.7.2 RESULTSAND DISCUSSION 
The results obtained for the linearity of 6MAM are given in Table 3.17. 







0.000665 - - 
0.00133 - - 0.00655 0.00142 0.323 
0.0133 0.00293 0.587 
0.0655 0.0113 0.606 
0.133 0.0282 0.627 
0.655 0.1084 0.641 
1.33 0.421 0.599 
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From these results the limit of detection (where no 399 ion is present) was taken as 1.33 
ng/ml and the limit of quantitation as 6.65 ng/ml. The range of linearity is from 6.65 - 665 
ng/ml (r2 = 0.999, y=0.157 x+0.003, (y=Bx+A)) 
3.15 CONCLUSIONS 
From the work carried out in this section the conditions chosen for the extraction of 
morphine and 6-monoacetylmorphine were as follows: 
Support medium: Extrelut® 
Extractant Phase: C02: MeOH : Et3N (90: 8.5: 1.5) 
Temperature: 100 °C 
Pressure: 3500 psi 
Flowrate: 2.0 ml min-' 
Extraction Time: 30 minutes 
Collection Solvent: MeOH 
Analysis Technique: GC/MS (SIM) 
Derivatisation: BSTFA (1 %TMCS) at 90 °C for 15 minutes 
The samples were prepared as for the benzodiazepines by loading 100 µl of the samples 
onto Extrelut® and drying. The method was found to be reproducible and yield high 
recoveries. Again, the solvent usage was reduced, this time the total volume required per 
extraction was 6 ml (c. f. 27 ml for the SPE method). The results of case samples analysed 
using this methodology are given in Chapter 6. 
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4. METHADONE 
4.1 INTRODUCTION 
The discovery of methadone has been attributed to two German scientists Max Bockmühl 
and Gustav Ehrhart. 138 The drug was first created in 1937 and was initially given the name 
Hoechst 10820 which was later changed to polamidon. The patent application for 
methadone was filed in September 1941. Although, the new compounds' structure had no 
resemblance to morphine, its analgesic and spasmolytic properties were ascertained in 1942 
when it was handed over to the military under the code name Amidon®. At this point its 
use was not exploited to a great extent due to side effects, which were later attributed to the 
dosage being too high. 139 
In 1947, Isbell et al published experimental work on methadone stating that morphine 
addicts responded very well to the properties of methadone, but unless the manufacture and 
use were controlled, then addiction to it would become a serious health problem. 140 
Despite this, early advertisements in the UK claimed little chance of addiction and the 
general consensus was that it was a better analgesic than morphine. 
In 1955, the Home Office were aware of only 21 methadone addicts with this figure rising 
to 60 in 1960.141 In 1968 with the introduction of the Home Office Notification System, 
297 methadone addicts were registered and an even larger increase was observed by 1969 
with the introduction of new drug clinics (1687 addicts registered). Prior to the 1970's, 
addiction maintenance was mainly in the form of prescribing the abused drug to the patient 
at clinics. However, the dramatic increase in the number of heroin addicts throughout the 
1970's and 1980's promoted a change from this to the prescription of oral methadone as a 
means of addiction maintenance. 142 At present in the UK, most Health Authorities have a 
methadone prescribing service of some kind. All GP's have the right to prescribe 
methadone and more than half of all methadone addicts known to the Home Office are via 
GP's. 
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4.2 PRESCRIPTION 
Methadone is prescribed mainly for the treatment of opiate addiction, * however it is 
available as a linctus which is used for the treatment of coughing in terminal illness. There 
are five preparations of methadone: 
" Liquid Methadone lmg/lml 
This is the treatment of choice for opiate dependency. '43 It is available as a 
pre-prepared solution or as concentrate which is diluted at the pharmacy. 
9 Methadone Linctus 2mg/5m1 
9 This is a general medicine licensed in the UK for the treatment of coughing in 
terminal illness. It is not usually prescribed for the treatment of opiate dependency. 
" Methadone 5mg tablets - Physeptone® 
This is not licensed for the treatment of opiate dependency and prescription is 
discouraged due to the possibility of crushing and injecting the tablets. 
9 Methadone Suppositories 
These are rarely used in the treatment of dependency again due to the possibility of 
injection 
" Injectable Methadone 10mg/ml 
This is prescribed for subcutaneous or intramuscular injection. However, when 
obtained illicitly it is usually used intravenously. 
4.3 CHEMICAL STRUCTURE 
Methadone (6-dimethylamino-4,4-diphenyl-3-heptatone) has a relatively simple structure 
and has a complex and powerful range of effects on those who take it. The structure of 
methadone is shown in Figure 4.1. 




Figure 4.1: Structure of Methadone 
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Structurally, methadone appears to have two active regions: 
" The nitrogen atom, which is thought to act on the peripheral nervous system 
" The two phenyl rings, which are thought to be necessary for its opiate like action on the 
central nervous system. 
4.4 PHARMACOLOGY 
The pharmacology of methadone is very similar to that of the opiates (section 3.4). When 
used for the treatment of opiate addiction, the feeling "on methadone" is often described as 
an absence of withdrawal symptoms. The increase in anxiety and psychological discomfort 
experienced by many detoxification programme patients, compared to methadone 
maintenance patients, suggests that methadone contributes to a sense of relief from distress. 
4.5 METABOLISM 
Methadone is rapidly absorbed following oral administration and is widely distributed in 
tissues with higher concentrations in the liver, lungs, kidneys and spleen than in the blood. 
It undergoes extensive first pass metabolism and the main metabolic reaction is N- 
demethylation, which results in a substance which instantly cyclizes to form methadones' 
two major metabolites, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2- 
ethyl-5-methyl-3,3-diphenyl-l-pyrrolidine (EMDP), neither of which is active. 
Hydroxylation to methadol followed by N-demethylation to normethadol also occurs to 
some extent. Other minor metabolic reactions also occur and there are at least 8 known 
metabolites. 
The principle metabolic route of methadone is shown in Figure 4.2. 

















Figure 4.2: Metabolic Route of Methadone 
4.6 PHARMACOKINETICS 
In subjects on methadone maintenance, 20-60% of a dose is excreted in urine within 24 
hours with up to 33% as unchanged methadone, 43% as EDDP and 5-10% as EMDP. The 
half life of methadone is very much dependant on the type of dosing due to its high affinity 
for tissue in the lungs, kidneys and liver. For a single dose, the half life of methadone is 
between 12-18 hours (mean 15 hours) and for multiple dosing the half life is between 13- 
47 hours (mean 25 hours). 144 The estimated LD50 for methadone is 50 mg, however 
tolerance to the drug may build up, albeit slowly compared to the other opiates, and doses 
of 200 mg or more may be withstood. Other pharmacokinetic parameters for methadone 
are given below: 
VD: 5 L/kg 
Cl: 2 mUmin/kg plasma 
Plasma : whole blood distribution: 1.3 
Protein binding: up to 90% 
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4.7 LEGAL STATUS 
Methadone (Physeptone) is a Class A drug which is listed under Schedule 2 of the Misuse 
of Drugs Act. This means that it is illegal to possess methadone without a prescription or 
other authority. 
4.8 ANALYSIS OF METHADONE 
As with the other two groups of drugs, a literature review was carried out on previously 
used methadone extraction and analysis methods. As with the analysis for diamorphine 
and its metabolites, the method of choice for the analysis of methadone is GC/MS with 
SIM. 
Table 4.1 provides a review of the analysis and extraction methods for methadone. 





Sample Type Sample Volume 
145 1972 GC-FID LLE Plasma/ Urine 4/0.5-2 ml 
1975 146 GC-ECD LLE Serum <2 ml 





148 1977 GC/MS LLE Plasma/ Urine 1 ml 149 1981 GC-NPD LLE Blood/ Plasma/ Urine 1 ml 
19,82 GC-MS LLE Plasma/ Saliva/ Urine 0.5/0.5/1 ml 151 1987 HPLC LLE Blood/ Liver/ Brain 2 ml/250/500 mg 
1996 152 HPLC SPE Serum 5 ml 
1996 153 LC-MS SPE Blood 1 ml 
1997 CE LLE Serum/ Urine/ Hair 1/1 ml/50 m 
4.9 SFE ANALYSIS OF METHADONE 
No methodology was found to be available on the supercritical analysis of methadone or its 
metabolites other than for hair. This will be discussed in Chapter 5 
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4.10 STATUS OF CASES 
Page l 
Figure 4.3 shows the number of toxicology cases in which methadone was found over the 






Figure 4.3: Methadone Related Deaths 
In comparing this to the previous morphine related death figures, a trend between the 
decrease in morphine fatalities and the onset of methadone maintenance programmes is 
apparent. 
4.11 CURRENT METHODOLOGY 
For the analysis of methadone, the routine method used in the Forensic Science Laboratory 
was liquid-liquid extraction as detailed below. This methodology was used as a 
comparison with SFE. 
Into a screw capped test-tube, I ml of pH 10 carbonate buffer (1 M Na-, COz, IM NaHCO1), 
1 ml of blood, 100 µl of cyclizine standard and 5 ml of EtAc were pipetted. The test-tube 
was capped and rock and rolled for 15 minutes then centrifuged for 10 minutes. The EtAc 
layer was then transferred to a clean test-tube and 2 ml of 0.2 M HCl added. This test-tube 
was then rocked and rolled and centrifuged as before. The EtAc layer was then discarded. 
The acid layer was basified by the addition of 2 ml of pH 10 carbonate buffer. 3 ml of 
1992 1993 1994 1995 1996 1997 
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EtAc were also added at this stage. The rock and roll, centrifuge step was again repeated. 
Finally, the EtAc layer was transferred to a vial and evaporated to dryness under N2 and the 
residue reconstituted in 20 µl of EtAc. A1 µl aliquot of this was injected onto GC. 
4.12 EXPERIMENTAL 
4.12.1 ANALYSIS INSTRUMENTATION 
Methadone method development was initially carried out using a Hewlett Packard 5890 
Series II GC with flame ionisation detection (FID) using cyclizine as the internal standard. 
The GC conditions were as follows: 
Column: HP5 
Initial Temperature: 100 °C 
Rate: 10 °C/min 
Final Temperature: 300 °C 
Injection Temperature: 280 °C 
Detector Temperature: 300 °C 
Equilibration Time: 0.2 minutes 
Using these conditions, the methadone eluted at 19 minutes which meant that the run time 
was very long. For this reason, the initial temperature was changed to 120 °C which eluted 
the methadone at 15.4 minutes and the cyclizine at 13.9 minutes which is still too long. 
The run time was decreased by changing the conditions to the following: 
Initial Temperature: 150 °C for 1 minute 
Rate: 10 °C /minute 
Final Temperature: 300 °C for 5 minutes 
The injector and detector temperatures and the equilibration time were kept constant. 
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With these conditions, the methadone eluted at 12.8 minutes and the cyclizine at 11.6 
minutes which was satisfactory. 
4.12.2 GC INJECTION REPRODUCIBILITY 
4.12.2.1 EXPERIMENTAL 
In order to check the injection reproducibility of the GC-FID system, five injections of 
methadone (10.4 . tg/m1) and cyclizine (10.1 tg/m1) were made. 
4.12.2.2 RESULTS AND DISCUSSION 
The injection reproducibility results for five injections are shown in Table 4.2. 
Table 4.2: Injection Reproducibility for Methadone and Cyclizine 
Methadone Area Cyclizine Area PAR (Meth/C cl) 
8306 10569 0.786 
7142 9141 0.781 
7210 6426 0.765 
6779 8690 0.780 
5414 7276 0.744 
For the results in 't'able 4.2, the mean PAR was 0.771 with an RSD of 2.2% which is 
acceptable for this work at present. 
4.12.3 ExTRACTIoN OF METHADONE USING E'rAc AS A MODIFIER 
4.12.3.1 EXPERIMENTAL 
Extractions were carried out using ethyl acetate as a modifier at 0%, 1%, 5% and 10% in 
CO2. For each percentage of EtAc, 100 µl of methadone (10.4 µg/ml) and cyclizine (10.1 
µg/ml) in MeOH were loaded onto C18 and Extrelut® and extractions carried out from each 
support. The pressure for the extractions was 2500 psi, the temperature 60 °C and the 
flowrate 2.0 ml mini 1. The extraction time was 30 minutes. The collected extracts were 
evaporated to dryness under N2 and reconstituted in 20 µl of EtAc. 
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4.12.3.2 RESULTS AND DISCUSSION 
The runs at 0,1 and 5% were negative for both methadone and cyclizine. The run at 10% 
gave small peaks for both drugs from both Extrelut and C18. The standard methadone and 
cyclizine had to be reconcentrated before being observed on the FID therefore, if the 
extraction efficiency is poor then no peaks would be observed even if they were present. 
The unextracted standards were concentrated 10: 1 compared to the reconstitution of the 
extracted standards: 500 µl -+ 20 µl (5: 1). 
4.12.4 EXTRACTION OF METHADONE BY SFE USING MEOH AS A MODIFIER 
4.12.4.1 EXPERIMENTAL 
The modifier was changed to MeOH and extractions carried out at 0,2,4,6,8 and 10% 
MeOH in CO2. These extractions were carried out using C8 as a support medium. 500 µl 
of methadone (10.4 µg/ml) and cyclizine (10.1 µg/ml) were loaded onto the contents of a 
C8 SPE column and dried at room temperature. The pressure for the extractions was 3500 
psi, at a temperature of 60 °C and a flowrate of 2.0 ml min 1 for 30 minutes. The collected 
extracts were evaporated to dryness and reconstituted in 20 µl of EtAc. 
4.12.4.2 RESULTS AND DISCUSSION 
The results for the extraction of methadone and cyclizine using MeOH as a modifier at 
various percentages in CO2 are shown in Table 4.3. 
Table 4.3: Extraction of Methadone and Cvclizine Usim MeOH as a Modifier 





R. T. Cyclizine 
(min) 
Area Cyclizine 
Unextracted 12.792 7738 11.559 9585 
0% McOH 
2% McOH / / / / 
4% MeOH / / 11.570 1220 
6% MeOH / / 11.590 483 
8% McOH / / / / 
10% McOH / / 11.603 1109 
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As can be seen from these results, the extraction conditions are not of use for the extraction 
of methadone or cyclizine. 
4.12.5 
- 
EXTRACTIONS FROM C8 
4.12.5.1 EXPERIMENTAL 
Four extractions were carried out using C8 as a support medium. In each case the pressure 
was 2500 psi, the temperature 60 °C and the flowrate 2.0 ml miri 1.10% MeOH was used 
as a modifier. 
4.12.5.2 RESULTS AND DISCUSSION 
The results are shown in Table 4.4. 










1 1445 12.836 1032 11.597 1.400 
2 5144 12.883 506 11.596 10.167 
3 0 / 1604 11.582 0 
4 2085 12.815 8578 11.571 0.243 
From Table 4.4 it can be calculated that the PAR of the unextracted standard is (0.807), 
thus the method is not extracting methadone and cyclizine to the same extent. A 
requirement of the developed method is that the drug of interest (methadone in this case) 
and the internal standard (cyclizine) are extracted to the same extent and thus, further 
method development was necessary. 
In addition, the GC traces were very dirty and thus the peaks seen at 12.8 and 11.6 minutes 
may not be due to methadone and cyclizine. 
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4.12.6 DETERMINATION OF INTERFERING SYSTEM PEAKS 
4.12.6.1 EXPERIMENTAL 
Two EtAc blanks were extracted using these same conditions to determine if the peaks at 
11.6 and 12.8 minutes could be due to the support medium. The extraction traces were still 
quite dirty but no peaks were seen which would coelute with methadone or cyclizine. 
In order to clean up the extraction and determine how long the extraction would have to be 
run for, collections were made from 0-5 minutes, 5-10 minutes and then for 0-10 minutes 
for comparison. 
4.12.6.2 RESULTS AND DISCUSSION 
The 0-5 minutes extract showed peaks at 11.566 minutes (PA: 2066) and 12.802 minutes 
(PA: 2102) which would correspond to cyclizine and methadone respectively. The PAR of 
methadone to cyclizine was 1.017. In total 9 peaks were integrated, with the trace being 
less noisy than previously seen. 
The 5-10 minutes extract again had peaks at 11.547 minutes (PA: 5398) and 12.802 minutes 
(PA: 3633) and this time only 5 peaks were integrated and the PAR of methadone to 
cyclizine was 0.673. 
The combined areas for 0-5 and 5-10 minutes were 7464 for cyclizine and 5734 for 
methadone giving a PAR of 0.768. This compares well to the unextracted standard ratio of 
0.807. 
The 0-10 minute extraction recovered less than the 5-10 minute extraction but more than 
the 0-5 minutes extraction with cyclizine at 11.552 minutes (PA: 4352) and methadone at 
12.789 minutes (PA: 2383) and a PAR of 0.548 Nine peaks were integrated and there was 
more baseline noise than with the 0-5 minute extraction. 
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4.12.7 EXTRACTION OF METHADONE USING THE BENZODIAZEPINE SFE CONDITIONS 
4.12. %1 EXPERIMENTAL 
Methadone and cyclizine were extracted using the benzodiazepine extraction conditions 
but at a temperature of 58 °C Three extractions were carried out and injected onto the GC 
along with an unextracted standard at the same concentration. 
4.12.7.2 RESULTSAND DISCUSSION 
Large peaks were observed at 14.7 minutes and 16.0 minutes but none corresponding to the 
methadone (12.811 minutes, PA 5731) and cyclizine (11.584 minutes, PA : 7687) of the 
unextracted standard (PAR : 0.746). 
It was initially thought that the methadone and cyclizine had deteriorated as they had been 
loaded onto the C8 for 4 days. Fresh standards were prepared on C8 and these were 
extracted under the same conditions. However, the same two peaks were observed and no 
peaks at 11.6 or 12.8 minutes. 
C8 was extracted on its own to see if the peaks were due to the support medium. The peaks 
were again observed. However, as the peaks are not coeluting with the methadone or 
cyclizine its was decided to keep using the C8 as a support medium as it had yielded the 
best results to date. 
4.12.8 EXTRACTIONS USING ETAC AND C8 
4.12.8.1 EXPERIMENTAL 
A1 ml aliquot of each of the standards was loaded onto the contents of three C8 SPE 
columns, which had been emptied into a weighing boat. Five extractions were carried out 
using this support. 
(1) 10% EtAc, 1 ml miri 1,65 °C, 3000 psi 
(2-5) 5% EtAc: 2 ml mini 1,65 °C 
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For extractions 1,2,3 and 4, the extraction vessels were filled. For extraction 5 there was 
only enough silica to half fill the extraction vessel. No methadone or cyclizine was 
extracted for any of the runs. 
4.12.9 Ex RAc 0NS wrFH ETAC AND C8 CONTINUED 
4.12.9.1 EXPERIMENTAL 
The following extractions were run in duplicate with 100 tl methadone and cyclizine 
standards from C8: 
(1) 5% EtAc: 2 ml miri 1,65 °C, 3000 psi 
(2) 10% EtAc, 2m1 mini', 65 °C, 3000 psi 
(3) 15% EtAc, 2 ml miri t, 65 °C, 3000 psi 
Again, no methadone or cyclizine were recovered. 
4.12.10 EXTRACTIONS USING ALTERNATIVE SUPPORTS 
4.12.10.1 EXPERIMENTAL 
The next set of duplicate extractions were carried out using various different supports at 
5% EtAc: 
(1) DCM washed silica gel 
(2) Unwashed silica gel 
(3) C8 
(4) DCM washed Extrelut® 
None of these extractions recovered methadone or cyclizine. 
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4.12.11 CHECK OF SFE SYSTEM 
At this point the benzodiazepines extraction was checked to see if the system was 
functioning. The drugs were extracting but the recoveries were poor. Modifications to the 
system were made using the benzodiazepines (see section 2.15.6) and once it was 
functioning satisfactorily, method development of methadone was continued as follows. 
4.12.11.1 EXPERIMENTAL 
Two methadone and cyclizine extractions were carried out at 67 'C, 3000 psi and 5% EtAc 
and four at 10% EtAc. 
4.12.11.2 RESULTS AND DISCUSSION 
The results are shown in Table 4.5 
Table 4.5: Extractions at 67 °C. 3000 psi and 5% EtAc 











Std 12.785 40660 11.341 41472 0.980 
5 12.773 21327 11.341 37754 0.565 
5 / 0 11.618 16316 / 
10 12.805 7423 11.365 13341 0.556 
10 12.672 10970 11.369 14194 0.773 
10 / 0 11.321 5758 / 
10 / 0 11.346 6844 / 
The first 10% EtAc, 3000 psi, 67 °C extraction gave the closest PAR to the unextracted 
standard with 27% and 34% recoveries for methadone and cyclizine respectively. The 
other two 10% EtAc extractions were unsuccessful. 
4.12.12 SYSTEM FLUSH 
After being left over the weekend, the SFE was flushed with EtAc to see if there was any 
remaining methadone or cyclizine in the system. The flush was very dirty with 23 peaks 
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observed and small peaks were seen corresponding to methadone (12.818 minute PA: 
1540) and cyclizine (11.318 minutes PA: 1580). 
4.12.13 NEW RETENTION TIMES FOR METHADONE AND CYCLIZINE 
4.12.13.1 EXPERIMENTAL 
The retention time of the methadone and cyclizine had changed due to the head pressure 
being altered as the flows had been switched off. The methadone was now eluting at 14.5 
minutes and the cyclizine at 13.2 minutes. The column head pressure was set to 10 psi, the 
air at 40 psi, the H2 at 20 psi and the carrier gas to 35 psi. The previous pressure had not 
been noted. 
Three methadone and cyclizine extractions were carried out at 5% EtAc, 67 °C and 3000 
psi, 3500 psi and 2500 psi. 
4.12.13.2 RESULTS AND DISCUSSION 
The runs at 3000 psi and 2500 psi had high pressure errors in the middle of the extractions. 
However some peaks were observed for methadone and cyclizine. The results are shown in 
Table 4.6. 
Table 4.6: Extractions at 5% EtAc 









Std / 14.517 1714 13.248 2214 0.774 
5 2500 14.528 16482 13.240 4373 3.769 
5 3000 14.477 19785 13.197 14923 1.326 
5 3500 / 0 / 0 / 
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4.12.14 REPEAT OF EXTRACTIONS WTTH NEW PRESSURE REGULATOR 
4.12.14.1 EXPERIMENTAL 
The pressure restrictor in the SFE system was replaced as it was not holding pressures 
above 2000 psi. With the new restrictor in place, extractions of methadone and cyclizine 
were carried out. 
4.12.14.2 RESULTS AND DISCUSSION 
The following results were obtained at 5% EtAc and 3000 psi (Table 4.7). 
Table 4.7: Methadone Extraction Results with new Pressure Regulator 
Methadone Cyclizine 
Sample Area R. T. (min) Area R. T. (min) PAR 
Unext. 1714 14.517 2214 13.248 0.774 
Ext. 1 2757 14.496 3508 13.216 0.786 
Ext. 2 11003 14.472 22619 13.190 0.486 
The recoveries were better than had previously been seen and in the case of the first 
extraction, the PAR was comparable to the unextracted standard. 
4.12.15 EXTRACTIONS AT VARIOUS PRESSURES 
4.12.15.1 EXPERIMENTAL 
More methadone extractions were carried out at various pressures from 2500-4000 psi at 
5% EtAc and 67 T. 
4.12.15.2 RESULTS AND DISCUSSION 
The results for the extraction of methadone and cyclizine at various pressures are shown in 
Table 4.8. 
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Table 4.8: Recoveries of Methadone at Various Pressures 
Methadone Cycl izine 
a (Si) Area %Rec Area 
%Rec PAR 
HP error 1470 6.86 1463 6.88 1.005 
3000 1737 8.11 5989 28.20 0.290 
3000 0 0 0 0 - 
4000 3 682 17.19 2465 11.59 1.494 
4000 0 0 0 0 
2500 0 0 2257 10.61 0 
2500 0 0 0 0 - 
Unext. 21422 - 21276 - 1.007 
Once again it can be seen that the extraction method is not appropriate. 
4.12.16 INVESTIGATION OF pKA 
The method development so far was carried out using the same modifiers, temperatures 
and pressure that had been used for the temazepam method development. The pKa values 
of the drugs being investigated was examined. 
Methadone pKa: 8.3 
Morphine pKa: 8.0,9.9 
Temazepam pKa: 1.6 
Thus the pKa of methadone is more like morphine than temazepam so the effect of adding 
Et3N which works well in the extraction of morphine was investigated. 
4.12.17 EXTRACTION USING MORPHINE CONDITIONS 
4.12.17.1 EXPERIMENTAL 
C18 was tried as a support instead of the Extrelut® used for the extraction of morphine at 
the following pressures: 3400,3200,2800,3300,2700,3000 psi. 500 µl of methadone and 
cyclizine were extracted in each case. The extractions were run for 20 minutes at 65 °C, 
90% C02: 9% McOH: 1% Et3N at 1 ml min''. 
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4.12.17.2 RI: SUL7: S ANI) I)ISCUSSION 
The results obtained are shown in Table 4.9. 
Pa el4 
Table 4.9: hxtraction of'Methadone Using Morphine Modifier at Various Pressures 













Unext 13.195 150387 / 14.463 183047 / 1.217 
3400 13.186 26011 17 14.447 25794 14 0.992 
3200 13.178 3798 2.5 14.442 3033 1.7 0.799 
2800 13.166 7674 5 14.429 5332 3 0.695 
3300 13.172 2636 1.7 14.430 2579 1.4 0.978 
2700 13.177 1172 0.8 14.431 1200 0.7 1.024 
3000 / 0 0 / 0 0 0 











2700 3300 2800 
Pressure (psi) 
3200 3400 
Figure 4.4: Effect of Pressure on the 1'AR and Recovery of Methadone and ('ycli-ine 
ý.. inmxa¢; ýmeý ---- 
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In general the recoveries for the extraction are higher at higher pressures and the PARs are 
closer to that of the unextracted standard. 
4.12.18 MORPHINE MODIFIER METHADONE EXTRACTION 
4.12.18.1 EXPERIMENTAL 
The conditions used for the extraction of morphine (3.13) were repeated for the extraction 
of methadone and cyclizine standards at various concentrations. MeOH and Et3N (85: 15 
v/v) were mixed with CO2 at 10%. The temperature for the extraction was 40 °C, the 
pressure 3600 psi and the flowrate 0.5 mlmin'. The extractions were run for 25 minutes. 
Seven vials were prepared in duplicate containing 1.0,0.75,0.5,0.4,0.3,0.2 and 0.1 ml of 
methadone (10.4-1.04 µg/m1) and cyclizine (10.1-1.01 µg/m1) to ensure that the PAR of 
methadone : cyclizine remained constant at all concentrations and that the concentrations 
were linear over the range being studied. At each concentration the contents of one vial 
were extracted and the other vial was evaporated to dryness under a stream of nitrogen at 
60 °C, reconstituted in 50 µl of EtAc and injected directly onto GC-FID. 
4.12.18.2 RESULTSANDDISCUSSION 
The results from the linearity of methadone and cyclizine using the conditions described in 
Section 3.13 are shown in Table 4.10. 
















0 0 75427 0 0 71978 0 0 95 
0.1 17698 16531 1.071 14089 14755 0.955 89 80 
0.2 41858 29106 1.438 0 0 0 0 0 
0.3 44902 29351 1.530 61015 43740 1.395 136 149 
0.4 72076 54014 1.335 58995 50815 1.1 11 82 94 
0.5 100726 88014 1.144 11450 8268 1.385 11 9.4 
0.75 146326 130282 1.121 168548 121128 1.392 115 93 
1.0 296935 264296 
, 
1.125 0 0 0 0 0 
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From these results it is obvious that the addition of the internal standard is of utmost 
importance. The PAR's are comparable in all cases where a result was obtained, but where 
the unextracted standard areas are linear over the range for both methadone (r2=0.925) and 
cyclizine (r2=0.915), no linearity is seen for the extracted standards using these conditions. 
4.12.19 LINEARITY OF METHADONE WTTH CYCLIZINE AS THE INTERNAL STANDARD 
4.12.19.1 EXPERIMENTAL 
A calibration graph for methadone with cyclizine as the internal standard was carried out 
over the concentration range 187.2 µg/ml to 1.04 p. g/ml. Two separate curves were drawn 
on from 208 - 10.4. tg/ml with cyclizine at 40.4 pg/ml and the other from 20.8 - 1.04 pg/ml 
with cyclizine at 4.04 pg/ml. For the first set of standards, 11 vials were prepared 
containing 1000,900,800,700,600,500,400,300,200,100 and 0 µl of methadone 
methanol standard with 200 t1 of cyclizine. The contents of each vial was evaporated to 
dryness under nitrogen at 60 °C and reconstituted in 50 µl of EtAc to yield the 
concentrations shown in Table 4.10. For the second set of standards, a 1: 10 dilution was 
made of the methadone stock standard (10.4 µg/ml -,, 0.104 µg/ml) which was then used in 
the same way as the concentrated stock standard to prepare 17 vials. 
4.12.19.2 RESULTS AND DISCUSSION 
The results from the calibration curves for methadone and cyclizine are given in Table 
4.11. 
Two separate linear ranges were plotted as shown in Figures 4.5 and 4.6. From Figure 4.5 
(0-208 mg/L), r2=0.989; A=0.110 and B=0.024. From Figure 4.6 (0-20.8 mg/L), the graph 
was found to be linear over the range 0.82-20.8 mg/L (r2=0.981; A=0.754; B=0.299. Thus 
by using cyclizine as the internal standard and GC-FID as the analysis technique, the limit 
of detection of methadone is approximately 1 mg/L. 
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Table 4.11: Calibration of Methadone with Cyclizine as the Internal Standard 
Methadone Conc' 
( /m1) 
Area Methadone Area Cyclizine PAR 
208 193128 35148 5.495 
187.2 215655 45211 4.770 
166.4 209796 54360 3.859 
145.6 211982 58894 3.599 
124.8 109939 36884 2.981 
104 95235 36122 2.636 
83.2 66454 31957 2.079 
62.4 78870 51204 1.540 
41.6 57141 50441 1.133 
20.8 20391 30837 0.661 
10.4 20129 36228 0.556 
0 0 20073 0 
20.8 7397 1006 7.353 
18.72 16979 2700 6.289 
16.64 10832 1957 5.535 
14.56 11967 2532 4.726 
12.48 9558 2296 4.163 
10.40 5512 1192 4.13 
8.32 10575 3647 3.400 
6.24 4717 1735 2.719 
4.16 1720 717 2.400 
2.08 485 492 1.586 
1.04 1284 2249 0.971 
0.832 532 947 0.562 
0.624 744 1214 0.613 
0.416 877 1438 0.610 
0.208 1702 2032 0.835 
0.104 1669 2510 0.665 
0 0 2736 0 
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Figure 4.6: Methadone Linearity over the Range 0-20. S ing I 
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4.12.20 GC/MS ANALYSIS OF METHADONE 
4.12.20.1 EXPERIMENTAL 
Method development was now changed to the GC/MS with d3-methadone as the internal 
standard. The GC/MS was the same as that described in section 3.12. The GC conditions 
for the analysis of methadone are shown below. 
Initial Time : 1 minute 
Initial Temperature: 150 °C 
Final Temperature: 300 °C 
Temperature Ramp: 15 °C/min 
Final Hold Time: 5 minutes 
Injector Temperature: 250 °C 
The detector was run in the SIR mode and the mass to charge ratios (m/z) detected were 72 
and 165 for methadone and 75 for d3-methadone. For confirmation of a positive 
methadone peak, the ratio of m/z 165/72 should be less than 0.1. 
Extracted MeOH standards and blood standards were compared to unextracted MeOH 
standards to ensure that they gave comparable results. 
4.12.20.2 RESULTS AND DISCUSSION 
The results for the extraction of methadone and d3-methadone for MeOH and blood 
standards are shown in Table 4.12. 
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Table 4.12: Methadone and d3-Methadone MeOH and Blood Extractions 
Page] 51 
Conc' (m 7 L) Unext MeOH PAR Ext. MeOH PAR Ext. Blood PAR 
0 0 0 0 
0.0107 0.185 0.161 0.201 
0.0153 0.204 0.216 0.226 
0.0214 0.245 0.237 0.274 
0.0535 0.345 0.398 0.398 
0.107 0.515 0.503 0.503 
0.153 0.623 0.619 0.619 
0.214 0.759 0.727 0.782 
0.535 1.129 1.132 1.249 













From these results a calibration graph was plotted, however only the lower concentrations 
were linear. The highest concentration in each case was omitted from the calibration as at 
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Using GC/MS, a 100 fold reduction in the limit of detection was found with the calibration 
being linear over the range 0.0107 to 0.214 mg/L (r2 = 0.989, y=2.842x+0.177 unextracted; 
r2 = 0.964, y=2.709x+0.186 MeOH extracted; r2 = 0.986, y=2.749x+0.203 blood 
extracted). 
4.13 CONCLUSIONS 
Initially method development for methadone was carried out using GC-FID. Using this 
apparatus and the conditions developed for the extraction of morphine in Chapter 3, a limit 
of detection of approximately 1 mg/L was obtained. A the majority of samples being 
analysed for methadone will contain less than 1 mg/L, the methodology was changed and 
GCIMS was used as the analysis method. By this method, the limit of detection was 
decreased 100 fold to 0.01 mg/L. 
The conditions for the extraction are the same as those developed for the extraction of 
morphine from blood and vitreous humor (p127) and indeed, both extractions can be run 
simultaneously by adding both internal standards to the Extrelut® prior to the extraction. 
The reduction in the use of solvent was not as pronounced in this case (6m1 for SFE and 8 
ml for LLE), however the SFE extracted less endogenous material to provide a cleaner 
extract. 
JwJes rb: iq 
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5. HAIR ANALYSIS 
5.1 INTRODUCTION 
The analysis of hair is becoming increasingly accepted as a tool for the determination of 
use and abuse of drugs of forensic interest. lss The importance of hair analysis stems from 
the fact that, at present, no toxicological method is available for the confirmation of long 
term drug use. Drugs pass into the hair from body fluids and remain there, thus each hair 
strand should provide a fixed record of past use. 156 Hair analysis cannot pinpoint the actual 
dose of drug consumed but, by carrying out a segmental analysis, it can provide 
information regarding the approximate period of time of drug usage which cannot be 
determined from blood or urine. 
Since 1979, hair has been used to document chronic drug exposure. 157 To date more than 
400 articles concerning hair analysis have been published with applications in clinical and 
forensic toxicology. The main practical advantage of testing hair, compared to blood or 
urine, is its longer surveillance window (weeks to months depending on length compared 
to 2-4 days for fluid analysis). 158 For practical purposes, the two compliment each other in 
that biological fluid, analysis yields short term information, whereas hair analysis provides 
long term histories of drug use. The severity and pattern of an individuals drug use can 
also be determined without many of the problems associated with conventional analysis. 
The accumulation of drugs in hair of drug users has been confirmed by several independent 
laboratories in the US, Japan and Europe. 159,160,161,162,163 with the drugs investigated 
including cocaine, heroin, amphetamines and phencyclidine. In addition to its obvious 
utility in the drug abuse area, hair analysis also offers applications in the monitoring of 
compliance of medication intake, 164 establishing toxic chemical exposure'58 and for 
monitoring the control of diabetes by measuring the glycosylation of hair proteins. '65 
The main advantages of hair analysis are summarised below. 166 
" The test cannot be thwarted by temporary abstention from drug use or adulteration of 
the sample. 
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9 Hair can be collected under close supervision without embarrassment. 
"A second sample can be collected and compared to the first by its appearance, by 
microscopic examination and by DNA analysis. 
9 The specimen and analytes are stable even under adverse environmental conditions and 
can be stored almost indefinitely without refrigeration. 
9 The test provides information on the temporal pattern and severity of drug use. 
In conjunction with the wide detection window, hair analysis is therefore much more 
efficient than biological fluid analysis for the identification of drug abusers. 
5.2 STRUCTURE OF HAIR 
5.2.1 INTRODUCTION 
Head hair grows at approximately 1 cm per month and the identification of a drug in hair 
depends on the length and type of hair. Its analysis can reveal drug use from one week to 
months prior to sampling166 depending upon the length of the hair. 
In order to interpret the results of hair analysis tests accurately, and to understand the 
appropriate role of hair analysis in drug abuse testing, it is necessary to have a basic 
understanding of hair biology. 
5.2.2 ANATOMY OF HAIR 
Hair is a complex structure, the biology of which is only partly understood. 167 It is 
composed of cylindrical structures or shafts made up of tightly compacted cells that grow 
from small sac-like organs called follicles. 168 In man, the diameter of these shafts may 
range from 15-120 gm depending on the type of hair and the region of the body. Hair 
contains a family of sulphur-rich proteins known as keratins which form long fibrils in the 
shaft which become tightly bound through the replacement of S-H bonds with S-S bridges. 
These bridges produce a tough, highly stable structure. 
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5.2.3 CHEMICAL COMPOSITION OF HAIR 
Hair is essentially a cross-linked, partially crystalline, oriented polymeric network 
containing a number of functional chemical groups (e. g. acid, base, peptide) which have 
the potential to bind small molecules. Depending on the moisture content, human hair is 
between 65-95% protein, 5-35% water and 1-9% lipids. Mineral content is between 0.12- 
0.95% on a dry weight basis. Essential trace elements and heavy metals can also be 
found. 168 
The lipid material in hair is derived from sebum and apocrine secretions. It consists of free 
fatty acids, mono-, di-, and tri-glycerides, wax ethers, hydrocarbons and alcohols. Human 
hair contains relatively large amounts of side-chain amino-acids (e. g. glycine, threonine, 
cysteine). 169 
5.2.4 THE HAIR FOLLICLE 
This is a highly complex skin appendage consisting of both epithelial (matrix and outer 
root sheath) and dermal (dermal papilla and connective tissue sheath) tissues and may be 
considered as a miniature organ. There are approximately 80,000-100,000 hair follicles on 
the head and the number decreases with age. 170 The structure of the hair follicle is shown 


















Figure 5.1: Structure of the Hair Follicle 
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The follicles are embedded in the epidermal epithelium of skin approximately 3-4 mm 
below the surface. They are closely related to the sebaceous and apocrine glands . In most 
body parts, the hair follicle and the sebaceous gland are fused both anatomically and 
functionally into a pilosebaceous unit. The ducts of both sebaceous and apocrine glands 
empty into the follicle. 171 
There are three functional zones along the hair shaft: 
169 
" The innermost zone in and around the bulb is the site of biological synthesis of hair 
cells. 
" The keratinogenous zone where keratinization of the cells occurs is directly above the 
bulb. Here hair undergoes hardening and solidification. 
" The region of permanent hair. Here the hair shaft consists of dehydrated cornified cells 
which have formed fibrils fused by intercellular binding. 
Hair growth begins in cells located in a germination centre (matrix) located at the base of 
the follicle. As the cells divide, increase in volume and elongate, they move up the hair 
shaft to the keratinogenous zone where melanin is synthesised. Long fibrils are formed 
through cross-linking of sulfhydryl groups in the amino-acids. Gradually the cells die, 
decompose by elimination of the nucleus and water, and coalesce into a dense "horny" 
mass. 
5.2.5 SECRETORY GLANDS 
Secretions by glands bathe the hair shaft and therefore, may be possible sources of trace 
elements in the hair and vehicles for the transfer of drugs into hair. 168 The linkage between 
various types of glands and the hair fibre is indicated in Figure 5.2. 
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Figure 5.2: Linkage Between the Secretory Glands and a Hair Fibre172 
5.2.5.1 SEBACEOUS GLANDS 
These glands are present over the entire body surface except on the palms and the soles and 
dorsum of the feet. 168 They are located just below the surface of the skin and their ducts 
exit directly into the tunnel of the hair follicle. This means that the permanently formed 
hair shaft is bathed in serum just before it emerges from the skin. The exception to this is 
the beard follicle whose complimentary sebaceous gland has a duct which opens directly 
onto the skin surface. Sebaceous glands are at their largest and most numerous on the 
scalp, forehead, cheeks and chin. The sebum which they secrete gives unwashed hair its 
oily appearance. 
The composition of the sebum depends on its anatomical area but in general consists of one 
third aqueous as free fatty acid, one third as combined fatty acid and one third as 
unsaponifiable material e. g. squalene, cholesterol and waxes. 
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5.2.5.2 APOCRINE GLANDS 
These are localised in the axilla, external auditory meatus, eyelids and perennial region. 168 
They are different from the sweat glands on the scalp in that they secrete by the separation 
of cytoplasm from secretion cells. They discharge directly onto the hair follicle rather than 
the skin surface. Apocrine gland secretions are oily, colourless, odourless substances about 
which little is known other than that their bacterial breakdown results in body odour. 
5.2.5.3 SWEAT GLANDS (ECCRINE OR MEROCRINE) 
These are distributed all over the body surface and originate in the dermal layer. 168 Their 
ducts exit near to the follicles but they are not directly in contact with them. They exist as 
simple tubules consisting of a coiled segment in the dermis and a straight duct which opens 
onto the epidermis. 
The quantity and concentration of fluid secretions from sweat glands varies largely 
depending on the individual and the environment. The principal ingredients of the fluid are 
water, salts (sodium and potassium), urea, amino-acids, lactate and pyruvate. 
5.2.6 THE DERMAL PAPILLA AND BLOOD SUPPLY TO THE FOLLICLE 
The main source for the transport and delivery of blood elements to hair is the vascularized 
dermal papilla which contains a population of fibroblast-like cells and endothelial cells. 167 
Due to the enormous amount of amino acids, lipids and carbohydrates required to produce 
hair and its sheaths, fenestrated vessels with thin diaphragm type membrane areas for 
accelerated transport are present. 173 As in many tissues the common source of energy in 
the hair follicle is glucose, which becomes phosphorylated and directed through the major 
pathways like Embden Meyerhof, the pentose cycle and the tricarboxylic cycle. The major 
activity of glucose-6-phosphatdehydrogease is found in the matrix and upper bulb region. 
Most drugs undergo metabolic transformations including oxidative, reductive, hydrolytic 
and conjugative reactions in the body. The main site of drug transformation is the liver, 
but other tissues like the hair follicle may also participate. It was found that a mono- 
oxygenase system is operative in the hair follicles which is comparable to the 
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corresponding system in the liver. The fact that the follicle contains cytochrome P-450 
may be interesting for toxification reactions. These findings present strong evidence that 
biotransformations in drugs of forensic interest may also occur within the hair follicle, 
prior to fusion in the hair shaft. 174 
Hair follicles are surrounded by two dense capillary networks, whose patterns are different 
in active and quiescent follicles. 168 The lower third of an actively growing follicle is 
surrounded by a rich vascular plexus composed of long parallel vessels connected by cross- 
shunts. The second network is located at the level of the sebaceous glands and extends to 
the skin surface. Therefore, both the growing hair bulb and the sebaceous glands are richly 
vascillarized. The two networks are connected by a simpler parallel system of larger 
vessels which descends along the sides of the follicle. 
5.2.7 STRUCTURE OF THE HAIR SHAFT 
Each shaft consists of three types of cell: 
5.2.7.1 OUTER CUTICLE 
This consists of a single layer of elongated overlapping individual cells each between 0.5- 
1.0 tm long. 168 Its function is to anchor the hair shaft in the follicle and protect the interior 
fibre. The cuticle can become damaged or destroyed by chemicals, heat light or 
mechanical injury and as a result becomes less intact towards the distal end of the shaft and 
may become frail and fall apart. 
Assuming that drug substances are mainly located inside the hair fibre, the fact that the 
weight contribution of the cuticle depends on the fineness of the hair, may imply possible 
minor variations of the drug content in hair analysis as a function of the hairs diameter. 
5.2.7.2 CENTRAL CORTEX 
The cortex forms the bulk of the hair shaft and is composed of long keratinized cells which 
form into long fibrils approximately 100 µm long. 168 They are held together by a special 
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chemical cement. Between the cells are very small air spaces called fusi. In the living 
portion of the hair roots, these are fluid filled but as the hair grows, the fluid dries out and 
is replaced with air. Pigment granules are also found in the cortex and their alignment give 
hair its colour. As with the skin and eyes, melanin is the main pigment. It is synthesised in 
special organelles known as melanosomes. These are located within the hair bulb in small 
bodies called melanocytes where the enzyme tyrosinase acts on tyrosine to produce 
melanin. 
The associated proteins forming the cortex matrix consist of two large families of 
nonhelical proteins, the "high sulphur" and the "high glycine/tyrosine" proteins 167,175 The 
intermediate filaments of a cortex cell are embedded in a matrix of globular proteins with 
the interactions of the molecular chains. The space in the matrix for small molecules is 
limited by the globular proteins and it has been demonstrated for water molecules that the 
microfibrils or intermediate filaments absorb much more water than the interfilament 
associated proteins of the matrix. 176 In the polypeptide chains of the intermediate filaments 
and in the associated protein, a large number of binding sites (including hydrogen bonding, 
ionic, amide, disulphide and electrostatic) are present. Thus, different drug substances may 
be easily built in during the keratinization process of the cortical cells. Since the cortex 
makes up the main part of the hair fibre both by weight and volume, drug binding within 
the cortex is believed to dominate the analytical results, but this is not yet proven. '77 
5.2.7.3 CENTRAL MEDULLA 
Medullar cells are initially loosely packed but as the hair grows they dehydrate leaving a 
series of vacuoles along the fibre axis. 168 In general, the number of medullar cells increases 
as the fibre diameter increases. In human hair the medullar cells comprise only a small 
percent of the mass of the hair and in some cases may be totally absent, continuous along 
the centre or discontinuous. 
The hair medulla is difficult to isolate and has an insoluble fraction. 178 It seems to be rich 
in proteins and lipids and has been shown to have E(-glutamyl)lysine cross linkages. It also 
contains cutrulline, has a very low cystine and sulphur content and consists of relatively 
large amounts of acidic and basic amino groups and hydroxyamino acids. 169 Drug 
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substances have been found in the medulla thus, it can be speculated that the type of 
medullation and the medullary index (ratio of width of medulla to hair diameter) in a hair 
sample may also have an influence on the analytical results. 167 
5.2.8 THE MELANIN GRANULE 
Melanin granules are the cell components of melanocytes, which are situated at the apex of 
the dermal papilla. 167 They release branches filled with melanin granules during the anagen 
phase of the growth cycle. The matrix cells, which are to become cortex cells later, 
actively phagocytose the granules as they pass by the melanocyte region on their way 
upwards to the keratinization region. As the cortical cells harden during keratinization, the 
melanin granules become fixed between the ketatinous fibrils. Melanin granules are spread 
throughout the cortex but are more concentrated towards the periphery. They are observed 
in the medulla, are rarely present in the spaces between the cortical cells and are usually 
absent in the hair cuticles. 179 
Hair colour depends on the number of melanin granules present, their size, arrangement 
and distribution in the hair shaft and their melanin composition. When pigment is deficient 
or lacking, the hair appears grey or white. 
Melanins are polymers which are basically composed of indole-5,6-quinone units which 
can occur in different stages of oxidation with units of 5,6-dihydroxyindole carboxylic 
acids present. The macromolecules are formed by condensation on active sites in a soluble 
protein matrix of the immature melanin granule within the melanocytes and they are 
extremely conjugated. 180 They act as unique biological absorbers. In vitro experiments 
demonstrate that even high concentrations of different drugs can be taken up by isolated 
granules. 167 The melanin affinity for drugs is dependent on the drugs chemical nature. The 
maximum affinity group is characterised by the presence of a series of highly conjugated 
double bonds as seen in chloroquinine. The loading of pigment granules also seems to be 
influenced by the quantity of pigment and the concentrations of the offered drug as well as 
the morphology and chemical composition of the granules themselves. '8' The molecular 
binding mechanism is not well known. It is believed to be a type of adsorption in which 
forces occur which may be due to charge transfer reactions, the melanin being the electron 
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acceptor, as well as electrostatic forces. For many drugs which are present as cations at 
physiological pH's with known melanic affinity, ionic attraction also occurs between the 
positively charged molecules and the anionic carboxyl groups of the melanin polymer. 182 
This means that the measurement of drugs in hair may be biased by its pigmentation, thus 
the results should be interpreted in light of particular drug interactions with melanin 
polymers. 
5.2.9 THE GROW M CYCLE 
Hair growth is cyclic in humans and is asynchronous and varies in its rate depending on the 
follicle type from 0.1-0.45 mm per day. 167 The rate shows vestiges of seasonal changes 
and is affected by endocrine dysfunctions, metabolic and genetic disorders, nutrition, 
hormones and drugs which target the follicular segments and interfere with the cell kinetic 
of hair growth. 
5.2.9.1 ANALEN PHASE 
The length of this phase determines the length and type of hair. The onset of the anagen 
phase is accompanied by an increase in the metabolic activity of the matrix cells located at 
the base of the follicle just above the papilla. 168 The bottom of the follicle is pushed more 
deeply into the dermis by continual cell division. New hair begins to grow as new cells 
elongate and form a thin filament then push their way upward into the follicular canal. 
Here the hair cells differentiate into cuticle, cortex and medullar types and the 
keratinization process begins. 183 It is thought that drugs and trace elements are 
incorporated into hair at this time. When radioactive compounds e. g. 35S labelled cysteine 
are administered, appreciable radioactivity is seen in the keratinogenous zone but little 
activity is seen in the follicular bulb. When radioactive glucose is administered, the 
opposite is observed. This implies that the hair follicle receives nutrients from the vessels 
surrounding the bulb but other chemicals are incorporated at the keratinogeneous level. 
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5.2.9.2 CATAGEN PHASE 
This is the transitional phase. Cell division stops and the base of the shaft becomes fully 
keratinized and forms the dry, white node characteristics of a club hair. The bulb begins to 
degenerate and the follicle becomes considerably shorter. 168 
5.2.9.3 TELOGEN PHASE 
The follicle enters a quiescence or resting period in which the hair shaft stops growing and 
is retained in the upper portion of the follicular canal where it can be easily removed by 
pulling. The length of this period depends on the body area and the age of the individual. 
For scalp hair this period is relatively short (- 10 weeks) compared to the general body 
surface (2-6 years). ' 84 
5.2.9.4 SUMMARY 
Each hair follicle has its own growth cycle. The percent of hairs growing compared to the 
percent resting, varies depending on the area of the body. The longer the type of hair, the 
longer the growing phase. On the scalp, approximately 15% of the hairs are resting and the 
remaining 85% are growing. This process can be complicated by disease states, nutritional 
deficiencies and pregnancy. 
5.2.10 RATEof GROwrt 
Hair usually grows at 1 cm/month. This is an oversimplification as not all hair is in the 
growing phase at any one time and the percent of follicles in the growing phase varies with 
anatomical location and age. The range of growth is from 0.6 cm/month to 3.36 cm/month. 
Hair type and anatomical region are the most important factors. Scalp hair grows faster 
than pubic or axillary hair which grows faster than beard hair. Caucasian hair grows faster 
than Asian hair. In general the rate decreases with age. All of these factors are important 
when considering where to take a sample of hair from. Usually hair in the vertex region of 
the scalp is chosen as the best specimen, as it has the largest amount of hair in the telogen 
phase and the fastest growth rate. 168 
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Provided that exogenous factors have neither removed or added to the drug in the hair, the 
presence of a drug at a particular distance from the scalp should reflect that the drug was 
available to the hair at that time of formation and keratinization of that hair section. Thus, 
analysis of the hair segments as recording filaments at different distances from the scalp 
should provide retrospective information. If sufficient information on the rate of growth is 
available, a rough correlation between the distance of a section from the scalp and the time 
interval since that section was in the follicle can be made. 172 
New hairs take about three weeks to reach the surface of the scalp. 167 Thus, if a sample of 
hair is taken by cutting as opposed to plucking, the first segment of the hair strand was 
formed more than four weeks earlier and does not represent the drug uptake in the month 
prior to sampling. 
5.2.11 SCALP HAIR V BEARD HAIR V PUBIC HAIR AS A SPECIMEN168 
5.2.11.1 SCALP HAIR 
This type of hair is the easiest to collect but there exists considerable variation in growth 
rates in the various regions which makes the choice of sampling area important. Scalp hair 
has the highest growth rate of all the hair types therefore is probably the most variable. 
Also, as the ducts of the sebaceous glands discharge directly into the hair follicles, the hair 
shaft is exposed directly to sebaceous secretions before it emerges from the skin. Scalp 
hair is exposed also to sweat and external contamination. Finally the chemistry and 
physiology of scalp hair may be modified by the use of cosmetic treatments whose impact 
on hair analysis is not yet fully understood (e. g. bleach, perm lotions). 
5.2.11.2 BEARD HAIR 
Beard hair is thick and its follicles in comparison to other types are enormous. It has the 
slowest growth rate. The fact that the hair shaft and sebaceous gland ducts exit from the 
skin in two separate channels means that this hair is less likely to be contaminated by 
sebaceous excretions. However, when beard hair is obtained by shaving, it may contain 
parts of the epidermis. External contamination is as likely here as it is with scalp hair. 
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5.2.11.3 PUBIC HAIR 
This type of hair has the apparent advantage in that it may be less contaminated through 
environment exposure or cosmetic treatment. However, contamination due to urine is an 
important issue which must be considered. Hair in the axillae and pubic region is curled 
rather than straight which makes segmental analysis difficult. Pubic hair is exposed to 
sebum and sweat secretions and to the secretions of the apocrine glands which are present 
in significant numbers only in the axilla and pubic areas. These glands discharge their 
secretions directly into the follicle. Pubic hair grows slower than scalp hair and has a 
longer resting period. 
5.2.12 SUMMARY 
Hair is quite an attractive indicator in forensic science because it is easy to obtain and 
easily stored. Nevertheless, it is a very complex material which requires sophisticated 
analytical techniques and profound knowledge to interpret the results. For hair analysis, 
the formation and the morphology of the hair fibre are suggested to be key structures but 
much more information than already available is needed to answer the open questions and 
to evaluate hair analysis in an adequate manner. 
5.3 TRANSFER OF DRUGS INTO HAIR 
The precise mechanism(s) involved in the incorporation of drugs into hair, or the factors 
influencing it, have yet to be determined. 172 The generally accepted mechanism is one in 
which chemicals present in blood move via passive diffusion into the rapidly growing cells 
of the hair follicle. ' 85 As the cells die and fuse to form hair strands, the drugs become 
trapped. 
It has been suggested that the passive diffusion of drugs into growing cells may be 
augmented by the drugs binding to intracellular components of the hair cells, e. g. pigment. 
This is especially so for amphetamine and methamphetamine which are chemically similar 
to tyrosine and DOPA (3,4-dihydroxyphenylalanine), the precursors of melanin. This 
mechanism is probably not too important as drugs may be found in the hair of albinos and 
only a small amount of drug is found in the melanin fraction of hair. ' 86 Bonding of the 
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drugs to hair could also be due to sulfhydryl containing amino acids, especially for drugs 
which can form stable direct covalent bonds e. g. divalent cations. 
5.3.1 SIMPLE PASSIVE TRANSFER MODEL 
This is the simplest model to describe drug binding in hair. Drugs move by passive 
diffusion from the bloodstream into the growing cells at the base of the follicle, then 
become tightly bound in the interior of the hair shaft during keratogenesis. The model is 
dependent on the concentration of drug in blood and thus the quantity of the drug 








Zone of hair Blood 
Synthesis 
Figure 5.3: Simple Passive Transfer Model 172 
Hair is assumed to grow at a constant rate, thus the position of the drugs along the hair 
shaft can be correlated with the time that the drug was in the bloodstream. This model also 
forms the basis for segmental analysis. As techniques for hair analysis improve, newer 
findings suggest that this model is somewhat oversimplified. 
5.3.2 PROBLEMS WITH THE SIMPLE PASSIVE TRANSFER MODEL 
Some elements/drugs have shown good correlation between the concentration of ingested 
drug' 87 and the concentration of drug in hair, others correlate badly. 188 Although, some of 
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this can be put down to external contamination, it has been proposed that another possible 
method involved is "pooling". 172 This introduces the concept of multiple equilibria and 
steady states. This proposal is element and exposure dependent, but only after transfer 
from pool to pool via multiple equilibria and steady states. It has not yet been verified 
experimentally. 
5.3.2.1 CORRELATION 
Baumgartner et al have reported a positive correlation between self reported drug use and 
concentration in hair for heroin, 189 marijuana, 19' cocaine'9' and PCP (phencyclidene)'92 by 
RIA (radioimmunoassay). More recent studies using GC-MS have also shown a positive 
correlation e. g. Nakahara et a1193 found good correlation between methoxyamphetamine 
intake and hair concentration. In a two person study by Cone et al194 good correlation 
between opiate dose and concentration in beard hair was found. Puschel et a1195 also 
analysed opiates in the hair of cancer patients on morphine and found poor correlation with 
the highest concentration corresponding to patients who had received the lowest doses. 
Poor correlation has also been shown for cocaine and its metabolites in hair, urine, blood 
and sweat. 172 However, in general with cocaine the concentration found in hair increases 
with dose. Intersubject variability has been found to be high, therefore the estimation of 
dose is very difficult to make. This variability cannot be assigned solely to plasma 
pharmacokinetics. 
5.3.2.2 DRUG METABOLITE RATIOS 
Perhaps the greatest challenge to the passive transfer model is the relatively high parent 
drug to metabolite ratio e. g. heroin is highly metabolic and 6-MAM which is a relatively 
short lived metabolite is found in high concentrations in hair. 196 
5.3.2.3 TIME COURSE OF DRUG INCORPORATION 
Two assumptions are made for segmental analysis 
1) Hair grows at a constant rate of -1 cm/month 
2) No diffusion occurs along the hair shaft 
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Some investigators have shown that the presence of drug does correspond to the time of 
injection, 194 but not all. This leads to the belief that a more complex multicompartment 
model exists. For example, hair obtained after a single administration of deuterated 
cocaine showed that the position of the d5-cocaine along the hair shaft did not always 
correlate with the time of drug injection. 172 
5.3.3 MULTIc0MPARTMENr MODE. 
A suitable model to describe the incorporation of drugs into hair would have to explain 
findings such as: 
" Why drug and metabolite ratios in hair are different from those in blood. 
" Why the time for drugs to appear in hair varies between subjects. 
" Why the distribution along the hair shaft is not always consistent with what is predicted 
from hair growth. 
" Why the drug and metabolite concentrations in hair vary to a great extent between 
subjects receiving the same dose. 
5.3.4 PROPOSED MODEL 
This involves three pools172 as indicated in Figure 5.2, Section 5.2.5. 
a) Blood during formation of the hair shaft. 
b) Sweat and sebum after formation of the hair shaft. 
c) External contamination after formation of the hair shaft and after hair has emerged 
from the skin. 
In addition, the drugs and metabolites may be transferred from multiple body 
compartments or pools in the tissues surrounding the hair follicle. 
5.3.4.1 TRANSFER VIA SWEAT, SEBACEOUS AND APOCRINE GLANDS 
Nearly all drugs of abuse have been found in sweat, often in concentrations higher than 
those found in blood. 172 In order to determine the contribution of drugs in sweat to drugs 
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in hair, Henderson carried out an experiment where subjects who had ingested cocaine 
under supervision held uncontaminated hair in their hands two hours after ingestion. 
Subsequent analysis showed significant amounts of cocaine in the hair, in some cases even 
after washing. In the experiment, the inter-subject variability was found to be high and 
therefore, this contribution is more significant for some individuals than others. 
Contributions due to sweat and sebaceous excretions in the hair are not separable and 
therefore, inter-individual differences of drug levels in subjects consuming known amounts 
of a particular drug may be partially explained by this. This phenomena also goes some 
way to explaining the apparent band broadening seen in some individuals known to have 
used drugs over a certain time period, i. e. excretions in the sweat may explain why drugs 
are found in longer areas of hair than expected. If glandular secretions are significant 
routes for incorporation, interlaboratory variability in washings and extraction procedures 
could also result in variable findings. 
5.3.4.2 TRANSFER FROM THE EXTERNAL ENVIRONMENT 
External contamination can come from a variety of media including air, water and cosmetic 
treatments and is possibly the reason why it is difficult to establish a baseline concentration 
for trace elements in hair. '72 For example, hair analysis cannot distinguish smokers from 
non-smokers. External contamination in addition to coating the hair can be intradermally 
transferred especially for highly lipid soluble drugs. 
5.3.4.3 TRANSFER FROM DEEP COMPARTMENTS IN THE SKIN 
Skin has been shown to act as a reservoir for certain drugs, especially lipophiles. t72 More 
specifically this occurs in the epidermis and hypodermis. When drugs penetrate from the 
external environment across the skin, they are retained by the lipid layers of the stratum 
corneum and are released slowly into the bloodstream. Conversely, when drugs move from 
the systemic circulation to the surface they are retained primarily by the adipose tissue of 
the hypodermis and secondarily by the stratum corneum. Both the stratum corneum and 
the hypodermis are in intimate contact with the hair follicle and its associated glands and 
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the capillaries surrounding the hair bulb could maintain an equilibrium between these 
structures and any pool in the adjacent tissues. 
5.4 ANALYSIS 
5.4.1 QUANwATTVE ASPECTS OF HAIR ANALYSIS 
Figure 5.4 represents the change in concentration of a drug with time for various sample 
types. 158 For body fluid analysis (BFA), the area under the curve correlates to the amount 
of drug taken. The figure indicates that BFA can be used for a set time period and there is 
no way of monitoring whether the sample was taken on the ascending or descending part of 
the curve and thus there is no relation to amount taken (i. e. small amount recently or large 
amount some time ago). Therefore, this is not very practical for long term drug screening. 
With hair analysis, the drug recirculates in the bloodstream in direct proportion to 
concentration. In this respect, hair acts as an integrating monitor. The concentration in the 
bloodstream depends on the amount taken, the mode of administration, the metabolic rate, 










Figure 5.4: Concentration of Drug Versus Time for Various Matrices 
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The most important considerations in developing a hair analysis method are: 162 
" Washing and digestion (extraction). 
" Measurement of the metabolite : drug ratio. 
" Reproducibility of results with a second sample. 
Wash procedures are used to remove external contamination and are based on the 
following properties with respect to exogenously applied drugs. 
" Cocaine, opiates, amphetamines and marijuana (and their respective metabolites) do 
not bind strongly to keratin proteins and therefore are readily removed by washing. 
" Metabolites are not formed by contact with hair. 
" Deposition of endogenous and exogenous drugs in the hair involves three hair domains: 
0 Surface domain 
This is readily accessible to exogenous drugs, e. g. from vapours and powders. 
However these will be loosely bound and readily accessible to even non hair- 
swelling solvents e. g. EtOH and are removable in this way. 
0 Accessible interior domain 
This is located in the interior structures of the hair and offers moderate resistance 
to penetration of exogenous drugs. These are not easily removed by non-hair- 
swelling solvents but are readily removed by water. As this section of the hair 
also contains endogenous drugs these too may be removed. However the 
percentage of endogenous drug will be small in comparison to that found in the 
inaccessible interior domain. Therefore, washing will not have a significant effect 
on the overall result. 
0 Inaccessible interior domain 
This is very rarely accessible to exogenous drugs and aqueous solvents under 
realistic conditions, and endogenous drugs cannot be easily removed from it with 
the use of solvents. In general, it is the largest of the three domains and depends 
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on the type of hair and its condition. Endogenous drugs are usually released 
from this domain by liquefaction of the hair specimen. 
The high resistance of the inaccessible domain to exogenous drugs, their ready removal 
from the accessible interior domain and surface domain and the absence of metabolic 
formation by contact, all combine to greatly reduce the possibility of evidentiary false 
positives. In contrast, the probability of evidentiary false positives with BFA is greatly 
increased by active inhalation of drug vapours, by ineffective barriers to drug penetration in 
the lung and gastrointestinal tract, and by the formation of metabolites. 
5.4.2 WASH PROCEDURES 
Two types of wash procedure are adopted in hair analysis: 162 
is Extended wash 
" Truncated wash 
Extended washes are continual washes which are carried out until a plateau drug 
concentration has been reached. The duration and number of washes is determined by the 
results obtained with a particular hair specimen and therefore, involves the analysis of 
wash solutions while the wash procedure is being performed. 
Truncated wash procedures involve a fixed number of washes over a fixed duration. The 
results can be mathematically related to the extended criteria. This type of wash is used for 
mass production testing whereas, the extended wash procedure is used for individual 
forensic specimens. 
In general, wash procedures consist of two steps. A solvent wash is carried out first 
(usually with an alcohol e. g. MeOH, EtOH) to ensure that and oils or greasy hair 
applications do not diminish the efficacy of the wash procedure and to remove loosely 
adhering drugs from the surface domain. This is followed by aqueous washings, which 
allow the hair to swell and thus allow penetration into the accessible interior domain. A 
final rinse in solvent may be advisable as this will facilitate drying of the hair. 
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5.4.3 DIGESTION / EXTRACTION PROCEDURES 
The rate of extraction is firstly due to the solubility of the analyte in the supercritical fluid 
and secondly due to transfer of the mass of the solute outside of the matrix. There are four 
mechanisms of mass transport. 
1. Diffusion of analyte across internal volume of sample. 
2. Desorption from surface of sample. 
3. Diffusion of analyte across boundary layer on surface of sample. 
4. Transfer into core of supercritical fluid. 
If step 1 is predominant then the extraction is dependant on particle size and therefore 
pulverisation will consequently increase the rate of extraction. If steps 2 or 3 are more 
important then the extraction will be improved by addition of a more polar modifier. 
The typical analysis is therefore a four stage process: 
1. Wash - elimination of contamination. 
2. Pre-treatment e. g. elution by aqueous solvent, hydrolysis. 
3. Extraction e. g. LLE, SPE. 
4. Analysis e. g. GC/MS. 
If solvent extraction procedures are used, complete extraction of the drugs from the hair 
cannot be guaranteed since the extraction efficiency depends on the physical properties of 
the hair. The amount of melanin present, may give rise to racial or colour biases especially 
if the major portion of the drug is in the melanin granules. In some digestion methods the 
melanin is removed and the drugs are not released from this fraction during digestion. 197 
Sample preparation techniques and procedures for hair analysis are often time consuming, 
costly and can require the use of toxic solvents. For example: 198 
" Acid hydrolysis requires an 18 hour incubation period. 
Enzymatic methods use ß-glucuronidase and aryl-sulphatase which are expensive. 
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" The presence of 6-MAM is conclusive proof of heroin intake however 6-MAM is 
hydrolysed to morphine under alkaline conditions meaning that it is not possible to 
distinguish between drug abuse and medical intake. 
" Direct methanolic extraction requires 5 hours sonication. 
As an alternative to the current wet extraction methods, there has been an increasing 
interest in the use of SFE for the extraction of drugs from hair samples. By using an SFE 
system for the analysis of drugs washing, pretreatment, extraction and final analysis can be 
carried out using the same apparatus, thus minimising many of the potential problems 
associated with other techniques. 199 
5.4.3.1 BENZODIAZEPINE HAIR ANALYSIS 
The detection of benzodiazepines in human hair (the most abused pharmaceuticals world- 
wide)200 appears mostly undocumented. At the time of this study, only five papers were 
found to report their detection. Diazepam was readily found in hair samples, 201,202 
however, alprazolam and lorazepam were not detected in patients receiving therapeutic 
doses of these drugs. 203 Yegles et a120° detected diazepam, desmethyldiazepam, oxazepam, 
flunitrazepam, lormetazepam and lorazepam in the hair of deceased polydrug addicts. 
Other benzodiazepines which have been detected include flunitrazepam and 
alprazolam. 204,205 
5.4.3.2 OPIATES HAIR ANALYSIS 
Hair analysis for opiates has been around for almost three decades however, it was not until 
1985 that RIA findings could be supported by a second independent method as demanded 
by the courts. 206 Initially, it was assumed that the hair had to be totally dissolved and then, 
the drugs determined quantitatively in order to differentiate between heroin and codeine 
consumption. The hair samples were dissolved in NaOH and then treated in the same way 
as urine samples. However, not all illegal drugs can withstand NaOH treatment therefore, 
a method was developed whereby the hair was completely dissolved using enzymes and the 
solution extracted using Bond Elut Certify® columns. More recently, procedures have been 
developed where the hair is only partially dissolved. Several methods for this exist in the 
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literature. Of these, two are used routinely, one developed by Moeller and Fey207 and the 
other developed by Kauert et a1.208 
5.4.3.3 METHADONE HAIR ANALYSIS 
Hair analysis with methadone is of extreme importance as it provides a means of 
monitoring the compliance of patients on methadone maintenance programmes and also 
allows for the detection of other non-prescribed drugs. In the case of urinalysis a positive 
morphine in urine may indicate that a small amount of heroin was used by the patient the 
night before the test or that the patient had been regularly using heroin but had thought it 
wise not to do so for a few days leading up to the test. By using hair analysis, the 
difference between these two patterns of use can be determined. 
Hair analysis for methadone in maintenance clinics has been incorporated since the early 
1990's. 209 Recent literature on the methodology usually involves a basic hydrolysis 
procedure with GCIMS as the favoured analysis technique. 210 
5.4.3.4 SFE HAIR ANALYSIS 
The use of supercritical fluids in the extraction of drugs from hair was first reported in 
1992 by Sachs and Uhl. 211. The quantitative determination of opiates in hair using SFE 
was also first investigated by Sachs. 212 Hair was collected from sixteen subjects who had 
died after a fatal heroin overdose. Levels of morphine detected ranged from 0.17-1.54 
(0.69) ng/mg and 6-MAM 0.15-14.90 (3.78) ng/mg. Cocaine and cannabinoids were also 
extracted using the same procedure. In 1994, Edder et a1213 also investigated the possible 
use of SFE for the extraction of opiates from drug addict hair samples while Morrison et 
a1214 investigated their use for the extraction of cocaine. Both types of drugs were 
extracted effectively with high recoveries. More recently, in 1995, a method for the 
supercritical fluid extraction of opiates form hair was also investigated by Cirimele et al. 198 
They extensively investigated the effect of parameters such as temperature and modifier 
volume on the extraction recovery of morphine and 6-MAM. In 1996, Staub et al'99 
applied a modified version of the method by Edder et a1213 to the extraction of opiates and 
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methadone. Three cases were successfully analysed for the presence of morphine 6-MAM 
and methadone. 
5.4.4 Avomuvc FALSE PosmvEs 
5.4.4.1 CONTAMINATION 
Hair analysis allows a trilevel reporting system to be used. 
" No drug use. 
" Drug use. 
" Contaminated but no drug use. 
This is useful in criminal justice type situations where neither drug use or being in the 
presence of drugs is permissible for parolees or probationers. 
Contamination can be divided into two subsections 
a) Trivial contamination 
This is characterised by contamination levels exceeding the endogenous cut-off values by a 
small amount and is reported as being either zero or trivial. This situation may arise when 
non-drug user is constantly in the presence of drug users 
b) Extensive contamination 
This is characterised by contamination levels exceeding the cut-off levels by a large 
margin. This situation arises from individuals who are frequently exposed to high levels of 
drugs e. g. non-drug using drugs dealers or manufacturers. 
5.4.4.2 MEASUREMENT OF METABOLITES 
This is used in conjunction with the other methods to avoid evidentiary false positives. 
Metabolites can sometimes be formed by non-metabolic processes (e. g. the hydrolysis of 
cocaine to benzoylecgonine) therefore, the preferred method is to measure the metabolite : 
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drug ratios rather than simply the concentration of the metabolite. Thus, the use of the 
wash procedures is still very important and allows monitoring of the contribution that the 
hydrolysis process may make in the digestion. In the case of cocaine, a hydrolysis control 
is always included. 215 
With opiates, a number of metabolic approaches may be taken to distinguish between 
external contamination and drug use. Morphine is a metabolite of heroin and the presence 
of monoacetyl morphine has been reported in hair. The most convenient and sensitive 
metabolite procedure is based on the detection of morphine glucuronide. This involves the 
measurement of the increase in free morphine following hydrolysis by glucuronidase. 
Due to the unfavourable signal to noise ratio of endogenous : exogenous cannabinoids in 
hair, wash procedures have no use. Instead, the use of cannabis is determined by the 
presence of 11-nor-09-tetrahydrocannabinol-9-carboxylic acid (09-THCCOOH) which has 
not been found to be present in marijuana smoke. 
It is important to realise that the determination of accurate metabolite : drug ratios as well 
as the endogenous cut-off levels, depend critically on effective wash procedures therefore, 
the measurement of metabolites is not a substitute for effective washings. Similarly, good 
wash procedures critically determine the reproducibility of results with a newly collected 
specimen. Reproducibility of results is a very important criteria for excluding external 
contamination since contamination is usually characterised by highly variable results. 
5.5 METHOD DEVELOPMENT FOR HAIR ANALYSIS 
Method development of hair samples was carried out using hair samples obtained from 
persons known not to have used any drugs being investigated in this study. The hair 
samples were prepared and spiked with the appropriate standards as described in the 
following sections. 
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5.5.1 PREPARATION OF HAIR STANDARDS. 
5.5.1.1 WASH PROCEDURE 
In order to remove grease and cosmetic preparations, which might be present in the hair 
samples, they were first of all washed using distilled water (dH2O), MeOH, dH2O and 
CHC13. At each wash stage, the appropriate solvent was added to the hair and sonicated for 
15 minutes at room temperature. The solvent was then decanted off and the next solvent 
added. Once the CHC13 wash had been carried out, the samples were dried overnight in an 
oven at 60 °C. 
5.5.1.2 GRINDING PROCEDURE 
In order to maximise the extraction from authentic forensic hair samples, it was decided to 
grind the hair samples to provide the largest possible surface area to particle size ratio. 
Several methods were attempted for this. The first method which was tried was the use of 
an electric razor. This method was found to be extremely time consuming and wasteful of 
sample. In addition, the best method for "fixing" the hair in order to facilitate shaving was 
to glue the ends of the hair to a piece of card meaning that this part of the hair was 
unavailable for analysis. Some of the case samples were to be segmented and this method 
would mean that the shortest length which could be analysed would have to be at least 5 
cm long and thus, no roots could be ground for analysis. 
As an alternative method of grinding, a Janke and Kunkel electric grinder was tested. 
However, when hair samples were placed in the grinding chamber, they wound round the 
central axis and did not grind. After consulting with the manufacturers, a star shaped cutter 
was purchased which when used with C02(s) produced a fine powder which was similar to 
that achieved by the shaving method but was less wasteful of sample and less time 
consuming. Approximately 5g of blank powdered hair were obtained using this method. 
Additional hair for standards was obtained from the beard shavings of a person also known 
not to use any of the drugs of interest to this study. Although this hair was from a different 
source and may be contaminated with some skin fragments, the wash procedure developed 
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for it was more rigorous including two additional MeOH washes and a DCM wash. The 
results obtained from spiked samples were the same. 
5.5.2 HAIR SPIKING PROCEDURE 
The powdered hair samples were spiked with MeOH standards of the drugs of interest as 
follows. 
For a ing/mg standard, 100 µl of the standards to be used (e. g. temazepam, diazepam and 
desmethyldiazepam for the benzodiazepines in hair) at a concentration of 1 mg/L was 
added to the powdered hair (100 mg) in a glass vial. 500 µl of MeOH was added to ensure 
that all the hair was coated and the vial sealed and sonicated before being placed in an oven 
at 60 °C for 30 minutes. The vial was then sonicated again at room temperature for 10 
minutes and left to soak overnight. The vial was then opened and the hair allowed to dry at 
room temperature. 
Although the use of this method of spiking was not ideal as most of the drug would be on 
the surface of the hair and not incorporated into the hair structure, an additional wash step 
was not used as this would mean that the exact concentration of the drugs in the hair 
standards would not be known. 
Internal standards were used for all extractions (prazepam for the benzodiazepines, d3- 
morphine for opiates and d3-methadone for methadone) and were added to the hair either 
prior to insertion of the hair into the extraction cell or at the modified static extraction step 
as discussed later. 
5.6 EXTRACTION METHODOLOGY 
For the analysis of benzodiazepines, opiates and methadone in hair, the method reported by 
Cirimele et al198 for the determination of opiates in hair was attempted and found to be 
successful. The next sections detail how this method was introduced to the system and 
describes the method development which was subsequently carried out. 
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5.7 METHOD DEVELOPMENT FOR THE EXTRACTION OF BENZODIAZEPINES FROM HAIR 
5.7.1 PRELIMINARY EXTRACTIONS 
5.7.1.1 EXPERIMENTAL 
For this section the same three benzodiazepines which had been determined in blood and 
vitreous humor were investigated. Spiked hair samples were prepared at -20 ng/mg by 
pipetting 100 µl of 20 µg/ml standards onto 100 mg of hair. 
Once dried, these hair standards were extracted as follows: 
Cleanup: CO2 pumped for 20 minutes 
Extraction: MeOH : Et3N (85: 15 v/v) introduced at 10% for 30 minutes. 
Temperature: 100 °C 
Pressure: 3500 psi 
Flowrate: 2.0 ml min-1 
As before, the extracts were collected into MeOH in a HypoVial® at the flow outlet. The 
extracts were then evaporated to dryness under a stream of nitrogen and reconstituted in 
100 µl of mobile phase. 25 µl was then injected onto the HPLC system using the 
previously described conditions (Section 2.12). 
5.7.1.2 RESULTS AND DISCUSSION 
Some pressure problems were encountered with the modifier, possibly due to the added 
water in the system. However, by opening and closing the pressure regulator throughout 
the extraction it was possible to keep the pressure reasonably constant. 
The first run of temazepam from hair was done without the addition of prazepam to the 
extraction. An area of 367611 units was obtained for temazepam extracted from hair as 
compared to the unextracted standard at 357771 units corresponding to a recovery of 
103%. This high recovery indicated that the extraction was sufficiently successful. It 
should also be noted that the initial extractions were carried out without the use of static 
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mode and the extractions were 15 minutes with CO2 only and 25 minutes with C02: 
MeOH: Et3N (90: 8.5: 1.5). 
5.7.2 EXTRACTION OF TEMAZEPAM, DESMETHYLDIAZEPAM AND DIAZEPAM 
5. %2.1 EXPERIMENTAL 
Spiked benzodiazepine hair (105.2 mg) was prepared at 23.0 ng/mg temazepam, 20.2 
ng/mg desmethyldiazepam and 26.2 ng/mg diazepam. Two aliquots of this hair (37.7 mg 
and 26.6 mg) were analysed using the aforementioned method with the static mode in 
operation as described later in section 5.8. No drugs were seen to elute in the CO2 extracts. 
The prazepam was added with the modifier to the extraction cell. An unextracted standard 
of the benzodiazepines, at the concentration the hair was spiked at, was also injected onto 
HPLC in order to calculate the recovery of each of the drugs 
5.7 2.2 RESULTS AND DISCUSSION 
The results obtained for the extraction of temazepam, desmethyldiazepam and diazepam 
are shown below in Table 5.1. 
Table 5.1: Extraction of Temazepam, DMD and Diazepam from Spiked Hair 
Temazepam PAR DMD PAR Diazepam PAR 
Std 1: 37.7 mg 0.197 0.155 0.320 
Std 2: 26.6 mg 0.118 0.091 0.216 
Unextracted 0.958 0.802 1.198 
[Std 1] 13.2 n /m 10.9 n /m 19.6 n /m 









It should be noted that the standards were added to the hair after the initial weight had been 
recorded but prior to weighing into the extraction vessel and thus, the weights reported will 
be for the hair in addition to the drugs and any residual MeOH. A check of the 
contribution of the weight of drug was carried out by adding 100 µl of temazepam to a 
blank hair sample which had been weighed at 32.6 mg. On reweighing, the hair weight 
was found to be 34.9 mg which corresponds to an increase of 2.3 mg. If this is taken into 
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account for all three drugs being added the approximate error in weight is 6.9 mg (6.6 %). 
Thus, the weight of the Ist standard will be 35.2 mg and the 2nd standard 24.9 mg making 
the recoveries for temazepam, DMD and diazepam 57 %, 53 % and 78 % respectively. 
5.7.3 EFFECT OF TEMPERATURE ON THE EXTRACTION OF TEMAZEPAM FROM HAIR 
5.7 3.1 EXPERIMENTAL 
A temperature recovery study was carried out for temazepam and prazepam at 60,70,80, 
90 and 100 °C. In addition to using MeOH: Et3N: H20 as a modifier, EtAc was attempted at 
each temperature. In each case 300 µl of modifier were added directly to the extraction 
vessel. 
5. Z3.2 RESULTS AND DISCUSSION 
The results for the extraction of temazepam from hair using MeOH: Et3N: H20 (mod) and 
EtAc as modifiers are shown in Table 5.2. 
Table 5.2: Effect of Temperature and Modifier on the Extraction of Temazepam 




Temaz/Praz % Recovery 
Temazepam 
Unext. Std. 10.30 7.15 1.44 n/a 
60 Mod 5.10 4.90 1.04 49.5 
60 EtAc 2.05 0.95 2.16 19.9 
70 Mod 1.20 2.15 0.56 11.7 
70 EtAc 5.65 3.20 1.77 54.9 
80 Mod 1.10 1.30 0.85 10.7 
80 EtAc 10.40 7.00 1.49 101 
90 Mod 4.00 3.30 1.21 38.8 
90 EtAc 4.10 1.60 2.56 39.8 
100 Mod 0.35 0.25 1.40 3.4* 
100 EtAc 2.80 1.75 1.60 27.2 
i: nua-uvu . wa%,. 
From the results in Table 5.2, the best extraction conditions appear to be 80 °C with EtAc 
as a modifier and 60 °C with MeOH: Et3N: H20 as a modifier. However, during the 100 °C 
Chapter Five: Hair Analysis Page 183 
extraction with the latter modifier a leak occurred in the extraction cell and some of the 
modifier escaped. 
5.7.4 EFFECT OF TEMPERATURE ON THE EXTRACTION OF BENZODIAZEPINES FROM HAIR 
WITH ETAc AS A MODHMR 
5.74.1 EXPERIMENTAL 
The temperature study previously carried out for temazepam and prazepam only was 
carried out for temazepam, desmethyldiazepam and diazepam using EtAc as a modifier. 
5. Z4.2 RESULTS AND DISCUSSION 
The results are shown in Table 5.3 
Table 5.3: Recoveries of Temazepam. DMD and Diazepam at Various Temperatures with 














0.938 0.954 1.266 65/33 72/37 85/44 
0.541 0.579 1.043 37/13 44/15 70/25 
0.733 0.851 1.083 50/26 64/33 73/25 
r 2.307 2.453 1.493 159/57 185/69 101/38 
100 °C 1.387 1.100 1.600 95/95 83/85 108/104 
Unext. 1.453 1.327 1.483 n/a n/a n/a 
Recoveries x/y: x= recovery nasea on FAX, y= recovery based on area 
From these results it can be seen that for all three drugs the recoveries in terms of PAR and 
area are best at 100 °C. 
5.7.5 EFFECT OF TEMPERATURE ON THE EXTRACTION OF BENZODIAZEPINES FROM HAIR 
WITH MEOH: ET3N: H2O AS A MODIFIER 
5.7.5.1 EXPERIMENTAL 
The experiment in section 5.3.4 was repeated using MeOH: Et3N: H20 as the modifier. 
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5. Z5.2 RESULTS AND DISCUSSION 
The results are shown in Table 5.4 
Table 5.4: Recoveries of Temazepam, DMD and Diazepam at Various Temperatures with 













50 0.948 0.472 1.339 64/48 35/26 86/66 
56 0.798 0.482 1.316 54/40 36/27 84/64 
60 0.958 1.335 1.543 64/134 100/208 99/206 
86 1.024 0.979 1.423 69/147 73/138 91/173 
103 0.773 0.197 0.735 52/30 58/10 47/33 
Unext. 1.490 1.340 1.560 n/a n/a n/a 
This time the best recoveries appear to be at 60 °C, however, the extractions previous to 
the 60 °C extraction were very low in recovery and thus the high recoveries were possibly 
due to carryover. For this reason, the extraction at 86 °C was chosen to be the best for 
using the MeOH: Et3N: H20 modifier. 
5.7.6 EXTRACTION OF AN AUTHENTIC HAIR SAMPLE 
5.7 6.1 EXPERIMENTAL 
An extraction of an authentic hair sample was carried out using both 100 °C with EtAc and 
86 °C with MeOH: Et3N: H20. The extraction at 86 °C worked but the one at 100 °C with 
EtAc did not, indicating that the EtAc is not a strong enough modifier to remove the drugs 
from within the hair matrix. 
The same case was extracted at 86 °C and 100 °C with the MeOH: Et3N: H20 for a 
comparison at these two temperatures. The results which were obtained at 100 °C were 
better fitting to results published in the literature and showed less endogenous material 
being extracted. Thus, although the recoveries appeared to be less at 100 °C, this 
temperature was chosen for running authentic samples as it was thought that the drugs 
being extracted were more likely to be from within the hair sample then that at 80 °C. 
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5.7.7 LINEARITY FOR THE EXTRACTION OF BENZODIAZEPINES FROM HAIR 
5.7.7.1 EXPERIMENTAL 
Sets of hair spikes were prepared for temazepam, desmethyldiazepam and diazepam over 
the concentration range of 0.1 to 100 ng/mg in order to determine the linearity over this 
range for the extraction method. All three drugs were extracted in the same run and 
samples were run in triplicate. 
5.7.7.2 RESULTS AND DISCUSSION 
The linearity results for the extraction of temazepam, desmethyldiazepam and diazepam for 
spiked hair samples is shown in Table 5.5. 
Table 5.5: Extraction of Temazenam, Desmethyldiazenam and Diazepam for Spiked Hair 
Sam 








103.2 15.612 95.1 14.564 92.7 17.394 
68.8 11.436 63.4 10.713 61.8 12.596 
34.4 5.741 r2: 0.996 31.7 4.871 r2: 0.996 30.9 6.489 r2: 0.997 
17.2 3.102 A: 0.170 15.9 2.703 A: 0.083 15.5 3.410 A: 0.259 
8.6 1.258 B: 0.155 7.9 1.305 B: 0.157 7.7 1.594 B: 0.190 
3.44 0.461 3.17 0.444 3.09 0.582 
1.15 0.198 1.06 0.174 1.03 0.237 
0.57 -ve 0.52 -ve 0.52 -ve 
0.29 -ve 0.26 -ve 0.26 -ve 
From this, very good linearity was seen over the full range. The lower two concentrations 
in each case were not detected, thus based on a 50 mg hair sample, the limits of detection 
for the three drugs are as follows: 
Temazepam: 1.15 ng/mg 
Desmethyldiazepam: 1.06 ng/mg 
Diazepam: 1.03 ng/mg. 
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5.8 METHOD DEVELOPMENT FOR THE EXTRACTION OF MORPHINE FROM HAIR 
5.8.1 PRELIMINARY CHECK OF METHODOLOGY 
Three extractions of morphine spiked hair were carried out using the same methodology as 
was used for the initial extraction of temazepam. 
All 3 CO2 cleanup extracts were found to be negative for morphine. For the three modified 
extracts, the following results were obtained as shown in Table 5.6. 
Table 5.6: Preliminary Morphine Extractions 
Extraction m/z ratio 429/432 m/z ratio 414/429 
1 0.839 0.605 
2 0.594 0.652 
3 0.687 0.643 
Extraction three yielded the largest areas which may be as a result of the extraction being 
run for a longer time due to a high pressure error during the extraction. 
At this point the system was set up for use in the static mode. The Rheodyne set up for 
operation of the static mode is shown in Figure 5.5. 
61` 
Xt 










Figure 5.5: Schematic Representation of Static SFE Set-up 
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When the first (top) Rheodyne is at the load position, flow passes from position 2 to 
position 3 and bypasses the second Rheodyne. When the first Rheodyne is in the inject 
position, flow is diverted from position 2 to position 1 and then to position 2 in the second 
(bottom) Rheodyne. In order to carry out a static extraction, the Extraction cell is 
pressurised by placing the second Rheodyne in the inject position. Once the required 
pressure has been reached, the second Rheodyne is switched to the load position and flow 
is diverted back to position 4 in the first Rheodyne, via position 3 to the pressure regulator 
and the collection vessel. Once the static extraction has been carried out for the required 
length of time, the second Rheodyne is put to the load position and the supercritical fluid 
and any extracted material from the extraction cell, flushed out. 
5.8.2 EFFECT OF TEMPERATURE ON THE EXTRACTION OF MORPHINE FROM HAIR (INTERNAL 
STANDARD ADDED PRE-EXTRACTION) 
5.8.2.1 EXPERIMENTAL 
A temperature investigation was carried out for the extraction of morphine from spiked 
hair. 10 spiked hair samples were prepared with 100 µl of morphine and d3-morphine and 
extractions carried out in duplicate at 60,70,80,90 and 100 °C. 
5.8.2.2 RESULTS AND DISCUSSION 
The results are shown in Table 5.7. It should be noted that the hair was not added to the 
extraction column for the second extraction at 100 °C and therefore no result has been 
reported. 
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Table 5.7: Temperature Recovery Study for Morphine Spiked Hair 
Relative Recovery (Ext/U next) n=3 Ratio Average 




Unext. Std. na na na 0.520 1.146 
60/1 14 5 10 1.105 0.403 
60/2 19 15 16 0.587 0.866 
70/1 126 106 105 0.535 0.967 
70/2 40 33 37 0.592 0.946 
80/1 75 60 64 0.582 0.909 
8012 163 146 137 0.509 1.021 
90/1 30 26 28 0.504 0.975 
90/2 42 39 40 0.556 1.065 
100/1 103 98 98 0.541 1.095 
From these results, although the best recoveries appear to be at 80 °C, at 100 °C the 
recoveries are still high and the ratios more comparable to the unextracted standard. 
5.8.3 EFFECT OF TEMPERATURE ON THE EXTRACTION OF MORPHINE FROM HAIR (INTERNAL 
STANDARD ADDED POST-EXTRACTION) 
5.8.3.1 EXPERIMENTAL 
This study was repeated but this time the internal standard was added post extraction to 
obtain absolute recoveries. It should be noted that when the internal standard is added 
directly to the weighed hair, losses in transferring the hair to the extraction vessel do not 
effect the results. However, transfer losses will decrease the recoveries when the internal 
standard is added post extraction. 
5.8.3.2 RESULTS AND DISCUSSION 
The results are shown in Table 5.8. 
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Table 5.8: Temperature Study Results with d? -Morphine Added Post-Extraction 
Run m/z ratio 414/429 m/z ratio 429/432 % Recovery 
Unext. Std. 0.498 1.252 n/a 
60/1 0.754 0.114 9.1 
60/2 0.858 0.095 7.6 
70/1 0.703 0.158 12.6 
70/2 0.651 0.194 15.5 
80/1 0.678 0.166 13.3 
80/2 0.660 0.146 11.7 
90/1 4.750 0.008 -ve 
90/2 0.702 0.148 11.8 
100/1 0.586 0.229 18.3 
100/2 0.847 0.196 15.7 
Again from these results, the extraction at 100 °C gives the best recoveries. Based on these 
results and the results in Table 5.7, it would appear that the losses on transport are high and 
thus the internal standard should be added directly to the weighed hair. 
5.8.4 DIRECT COMPARISON OF PRE AND POST ADDING OF INTERNAL STANDARD 
5.8.4.1 EXPERIMENTAL 
A comparison of d3-morphine added pre and post-extraction was carried out to compare the 
two on the same day in the same GC/MS run. 
5.8.4.2 RESULTS AND DISCUSSION 
The results are shown in Table 5.9. These extractions were only run once in order to 
extract all samples within the same day. 
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Table 5.9: Pre- and Post-Extraction dg-Morphine Addition 
Run m/z ratio 414/429 m/z ratio 429/432 % Recovery 
Unext. 0.501 0.865 n/a 
60Post 0.626 0.258 29.8 
60Pre 0.433 0.101 11.7 
70Post 0.518 0.103 11.9 
70Pre 0.472 1.081 125 
80Post 0.518 0.103 11.9 
80Pre 0.662 0.417 48.2 
90Post 0.473 0.857 99.1 
90Pre 0.521 1.681 194 
l00Post 0.504 0.879 102 
10OPre 0.513 0.946 109 
The pre-extraction recoveries represent how well the PAR of the extracted and unextracted 
standards compare and the post-extraction recoveries represent the actual recoveries for the 
extraction. Again from this it was decided to stay with a temperature of 100 °C for the 
morphine hair extractions. 
5.8.5 INTRODUCTION of 6MAM To HAIR EXTRACTIONS 
5.8.5.1 EXPERIMENTAL 
At this point, 6MAM was introduced to the system. A spiked hair sample was prepared as 
previously described by pipetting 100 µl of morphine (8.5 mg/L) and 100 µl of 6MAM 
(13.3 mg/L) onto 100 mg of hair. This sample was split into three portions which were 
then extracted using the developed conditions at 100 °C. 
5.8.5.2 RESULTS AND DISCUSSION 
The results for the extraction of morphine and 6MAM from spiked hair samples are shown 
in Table 5.10. 
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Table 5.10: Extraction of Morphine and 6MAM from Spiked Hair 









Unext. 0.875 1.304 na 0.543 1.097 na 
1 0.792 1.216 93 0.468 0.855 78 
2 0.843 1.143 88 0.410 1.139 104 
3 0.894 1.197 92 0.525 0.991 90 
From this it can be seen that the extraction conditions yield good recoveries of the 6MAM 
from spiked hair. In addition to this, a spiked 6MAM sample with no morphine was 
prepared and extracted as before to determine if the extraction was hydrolysing the 6MAM 
to morphine. The ratio of 340/399 was found to be 0.742 and the ratio of 340/432 1.079. 
No morphine was recovered. 
5.8.6 LINEARITY OF MORPHINE AND 6MAM 
5.8.6.1 EXPERIMENTAL 
Morphine and 6MAM spikes were prepared at 0.085 ng/mg to 85ng/mg and 0.133 to 133 
ng/mg respectively in order to determine if the extraction was linear over this range and to 
determine the limit of detection for each of the drugs. In each case the drugs were spiked 
onto approximately 50 mg of hair and the d3-morphine concentration was approximately 5 
ng/mg. 
5.8.62 RESULTS AND DISCUSSION 
The results for the linearity and limit of detection for morphine and 6MAM are shown in 
Table 5.11. 
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0.085.0.133 no peaks -ve no peaks -ve 
0.17/0.27 no peaks -ve 0.698 0.084 
0.34/0.53 1.239 -ve 0.853 0.135 
0.85/1.33 0.653 0.264 0.842 0.279 
2.13/3.33 0.649 0.634 0.796 0.446 
4.25/6.65 0.558 1.147 0.742 0.983 
8.5/13.3 0.524 2.367 0.831 1.992 
17.0/26.6 0.613 4.597 0.739 3.675 
25.5/39.9 0.598 6.861 0.856 7.268 
34.0/53.2 0.499 10.394 0.816 9.883 
85/133 0.515 25.468 0.875 19.684 
For morphine, r2=0.999 and the equation of the line is y=0.301x - 0.200. For 6MAM, 
r2=0.987 and the equation of the line is y=0.152x + 0.211. The limits of detection for 
morphine and 6MAM were taken as 0.85 ng/mg and 0.27 ng/mg respectively for a 50 mg 
hair sample. Both sets of drug concentrations were found to be linear over the range 
studied. 
5.9 METHOD DEVELOPMENT FOR THE EXTRACTION OF METHADONE FROM HAIR 
At this point methadone method development was still being carried out using the FID and 
not GC/MS. This caused problems due to extracted endogenous material which the FID 
was sensitive to as highlighted in Figure 5.6. It should be noted that the methadone and 
cyclizine elute between 10 and 15 minutes and thus, unless they were present in high 
concentrations, they would not be seen above the background. 
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Figure 5.6: GC/FID Trace of Background Noise for Methadone Extraction 
This endogenous material did not interfere with the morphine on the GC/MS or 
benzodiazepines on the HPLC/UV. At this point the modifier was being added using the 
second pump and not directly to the extraction cell. By extracting the modifier on its own, 
most of the endogenous peaks were still being observed and thus, method development for 
methadone was switched to the GC/MS. In addition, as the hair had already been spiked 
with cyclizine this was used as the internal standard and was not detected in any of the 
traces. Three extractions were carried out using the methodology described previously and 
methadone was found in all three modified hair extracts. As with the morphine extracts, 
the CO2 cleanup extracts were negative. 
When the internal standard for methadone was first attempted with d3-methadone, it was 
discovered that the wrong internal standard had been ordered from Sigma (deuterated at the 
wrong part of the molecule). Two spiked samples were extracted and methadone was 
observed in both cases. However, the methadone peak will contain contributions from 
5101 . 25 2O 2Z 
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both the methadone and the d3-methadone and thus even area based recoveries could not be 
calculated. 
As the method development for the benzodiazepines and for the morphine/6MAM had 
been successful and these drugs were both extracted efficiently by the same method, it was 
decided to use the method for all three types of drug. A recovery study was carried out 
over the range 0.112 to 71.68 ng/mg methadone. The results obtained are shown in Table 
5.12. 
Table 5.12: Linearity of Methadone in Hair 
Concentration (n /m) m/z ratio 72/75 m/z ratio 72/165 
0.112 -ve no 165 
0.56 0.105 0.096 
1.12 0.186 0.064 
2.24 0.349 0.063 
5.60 0.507 0.073 
11.2 0.794 0.054 
22.40 2.169 0.037 
33.60 3.947 0.051 
44.80 5.671 0.029 
56.0 7.931 0.039 
For methadone over this concentration range, the coefficient of correlation was found to be 
0.982 with the equation of the line as y=0.135x - 0.599. The limit of detection for a 50 mg 
hair sample was 0.56 ng/mg. 
5.10 CONCLUSIONS 
For the extraction of benzodiazepines, morphine and methadone from hair samples, the 
SFE method developed by Cirimele et a1198 was successfully applied. Good reproducibility 
was found within extractions of the same concentration of spiked standard and high 
recoveries were obtained. 
The actual conditions used for the extraction of the hair samples is detailed below: 
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In order to maximise the surface area, the hair samples were prepared by grinding under 
liquid nitrogen to produced a fine powder. The hair to be analysed was weighed and 
transferred to the extraction vessel. The extraction consisted of two stages. First of all a 
clean up step was employed to remove exogenous compounds from the surface of the hair. 
This consisted of running the SFE in the static mode for 10 minutes followed by a dynamic 
extraction for 15 minutes. The extraction cell was then removed from the SFE and 300 µl 
of modifier (MeOH: Et3N: H20 2: 2: 1) and 100 µl of the internal standard added. Once the 
extraction cell had been replaced in the SFE system, a second static extraction was carried 
out for 15 minutes. This was followed by a dynamic extraction for 20 minutes and the 
analytes were collected in to MeOH at the flow outlet. 
For all steps, the flowrate was 2.0 ml miri I, the pressure was 3500 psi and the temperature 
100 °C. 
Linearity over a wide range was seen for benzodiazepines analysed by HPLC and for 
morphine and methadone analysed by GC/MS. The detection limits are low enough to 
permit detection of the drugs in hair even when the sample size is relatively small 
(temazepam: 1.15 ng/mg, desmethyldiazepam: 1.06 ng/mg, diazepam: 1.03 ng/mg, 
morphine: 0.85 ng/mg, 6MAM: 0.27 ng/mg, methadone: 0.1 ng/mg based on a 50 mg hair 
sample). 
It terms of comparison with other methodology for the extraction of drugs from hair, the 
method offers several advantages. Firstly, all three drug types were extracted using the 
same method without degradation. In addition the total extraction time was 1 hour which 
makes the extraction much quicker than conventional methods e. g. acid hydrolysis requires 
an 18 hour incubation and methanolic extractions require 5 hours sonication. 
Mr Justice Avovq, I924 
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6. CASE STUDIES 
6.1 INTRODUCTION 
The ultimate aim of any method developed for toxicological analysis is its application to 
authentic samples. Method development for the extraction of an analyte from a spiked 
sample is the best way of imitating an authentic sample however, in reality, other factors 
will come into effect when an authentic sample is put through the developed extraction 
process. Of particular importance to SFE is the effect that other analytes or matrix 
artefacts will have on the extraction efficiency of the analyte of interest. 
6.2 CASE INFORMATION 
For this study 48 post-mortem cases were investigated. Samples were obtained for 
suspected drug abuse cases from the pathologist in charge of the postmortem. Blood, 
vitreous humor and hair samples were requested and in most of the cases all three sample 
types were made available. Summary information on each of the cases investigated, 
including the samples made available is given in Table 6.1. A more detailed description of 
the circumstances surrounding the death is given in section 6.2. 
Hair samples were taken from the posterior vertex and were about the thickness of a pencil. 
Initially the roots and tips of the hair samples were not kept aligned and this made 
sectioning of the hair very time consuming. After a visit to the mortuary it was decided 
that the easiest way to keep the roots of the hair together was to tie a piece of string round 
the centre of the sample which had been pulled and then place the tied hair sample in a 
glass universal container. 
Blood and vitreous humor samples were also collected in glass universal containers 
however, no information was made available on the site of blood sampling and whether the 
vitreous came from one or two eyes. 
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Table 6.1: Case Summary Information 
Case Age/Se #Days Cause of Death Suspected Drugs Hair Vit. Blood # of Alc 
Died-PM (As PM re ort) Humor Drugs 
K96 01 241F 12.1.96 a)PO &C propanolol,  X. x 2 x 
b)Prothiaden cannabis, 
and propanolol prothiaden, 
OD speed, Valium 
K96 0 26/M 6 a)I. G. C. temazepam,    I  
b)Morphine and procyclidine, 0 
alcohol intox. em esic, heroi 
K96 0 34/M 12.1.96 a)AFDL b)acute cocaine, heroin, V V V 3  
alcohol intox. alcohol 0 
K96 0 23/M 12/1/96 a)PO &C Librium®, V x  5 V 
b)Drug related nitrazepam, OB 
death DHC, oxazepam 
diazepam, 
insulin 
K96 0 36/M 16/1/96 a)Pneumonia methadone, V x x I x 
b) IVDA heroin, M 
benzodiaze ines 
K96 0 22/M 17.1.96 )I. G. C. nitrazepam,  X. X. 1 X. 
DHC, heroin, M 
cannabis 
K96 0 34/F 3 a)PO &C heroin, Diconal" V V  3 X 
)Heroin and temazepam, OB 
temaz. intox. Librium®, 
methadone 
K96 0 39/M 5 )Septis methadone,    3 X. 
yndrome diazepam, BM 
Chronic IVD cocaine 
K96 0 29/M 16.2.96 a)Morphine and heroin  x x 2 x 
emaz. intox. BM 
K96 1 38/M 6 a)PO &C alcohol,    1 x 
Heroin intox. cannabis, heroin 0 
K97 11 27/F 21.3.96 a)I. G. C. heroin V V  4 x 
b)Drug related OB 
death 
1(9 11 30/M 21.3.96 a)PO &C solvents,    1 x 
b)Morphine sulpiride 0 
intox. 
K96 13 25/M 18.7.96 a)PO &C diazepam, heroin  V  4  
b) Drug related BMT 
eath 
K96 1 25/M 6 )PO &C none  V  3  
)Heroin intox. OB 
K96 1 35/F 9 a)PO & C; methadone, V V V 4  
b)Methadone cannabis, heroin BM 
intox. 
K96 1 30/F 29.7.96 )PO & C; heroin    2 x 
,b )Heroin intox. 0 
K96I 26/M 3 )Morphine heroin,  V  
I 
1  
overdose procyclidine, 0 
de ixol, losac 
w- 
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Case Age/Se #Days Cause of Death Suspected Drug Hair Vit. Blood # of Alc 
Died-PM (As PM report) Humor Drugs 
K96 18 33/M 7 a)Morphine heroin,    4 X. 
overdose temazepam, OBM 
methadone 
K9619 32/M 3 a)I. G. C. heroin x   1 x 
b )Heroin intox. O 
K96 20 39/M 7 a)PO & C; cannabis, heroin    3 X. 
b )heroin intox. OB 
K96 21 29/F 5 a)PO &C methadone,    5 X. 
b)Heroin intox. heroin, OBM 
temazepam, 
diazepam 
K96 22 27/F 7 a)PO. methadone,    4 X. 
b)Heroin and heroin OBM 
temaz intox. 
K96 23 171M 4 a)I. G. C. DHC, Valium®,    4  
b)Methadone, cannabis, BM 
iaz., cannabis & alcohol 
alcohol intox. 
K96 24 20/F 21.10.96 a)Methadone, methadone,    4 X. 






K96 25 25/M 7 a)I. G. C. heroin, Valiums    3 x 
b)Morphine & Librium®, DHC, OB 
iaz. intox. LSD, cannabis, 
temgesic, 
temaze am 
K96 26 24/M 3 a)Asphyxia due heroin    0 x 
to hanging 
K96 27 261M 8 a)Morphine & heroin, DHC,    4  
temaz. intox. temazepam, OB 
methadone 
K96 28 21/M 4 a)PO &C oxazepam,    3 x 
)Morphine nitrazepam OB 
intox. 
K96 29 33/M 5 a)AGC temazepam,    3 x 
)Heroin and heroin OB 
temaz. intox. 
K96 30 17/F 10.12.96 a)I. G. C. related heroin,    3 x 
b)Drug related temazepam, B 
death iazepam 





K97 02 35/M 5 )Methadone, diazepam,  x x 5 x heroin, temaz. & methadone OBM 
iaz. intox 
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Case Age/Se #Days Cause of Death Suspected Drug Hair Vit. Blood # of Alc 
Died- (As PM report) Humor Drugs 
PM 
K97 03 23/M 14 a)I. G. C. methadone,  x  2 x 
b)Methadone and Valium® M 
CE intox 
K97 04 24/M 12 a)PO &C heroin,  x  1 x 
)Heroin intox diazepam, 0 
Voltarol®, 
Remedeine® 
K97 05 19/M 10 )Hanging None    1  
K97 06 26/M 7 )PO &C trazodone,   x 5  
)Heroin & cannabis, OB 
emazepam temazepam, 
intoxication Valium® 
K97 07 40/F 8 a)PO&C heroin    1  
Heroin intox. O 
K97 08 29/M 4 Unascertained heroin,   x 5  
methadone OB 
K97 09 32/F 6 a)PO &C alcohol, heroin    2  
)Heroin & OB 
temaz. intox 
K97 10 30/M 5 a)Drug related cannabis,    9 x 
death cocaine, OB 
temaze am 
K97 11 30/F 5 a)Chlor., diaz. & heroin, x   4 x 
morphine temazepam, OB 
(heroin) intox. diazepam 
K9712 29/M 11 a)PO&C heroin,  x  3  
b)Heroin, diaz. methadone, OB 
alcohol intox. diazepam 
K97 13 18/M 5 )I. G. C. methadone,    2  
heroin M 
K97 14 271F 7 a)A. G. C. heroin    2 x 
OB 
K97 15 29/M 6 a)A. G. C alcohol, DHC,    2  
b)Heroin intox. Coproxamol, 0 
Codydramol 
K97 16 20/M 4 )Heroin & diaz. heroin, x   3 x 
intox. amitryptiline OB 
K97 17 35/M 12.6.97 )Alcohol, diaz. heroin, alcohol x   2  
& heroin intox. OB 
K97 18 36/M 12.6.97 a)Heroin & heroin x   1 x 
methadone intox. M 
Abbreviations: M: male; F: female; PO&C: pulmonary oedema and congestion; AFDL: 
acute fatty degeneration of the liver; A/IGC: aspiration/inhalation of gastric contents; 
DHC: dihydrocodeine; 0: opiate; B: benzodiazepines; M: methadone; #: number; Alc: 
alcohol; : detected; x: not detected 
A graph of the range of ages, for each sex was plotted and is given in Appendix III. 
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6.3 CIRCUMSTANCES SURROUNDING DEATH AND OTHER RELEVANT INFORMATION 
The following section summarises the information available from the post-mortem and 
police reports for each of the cases examined. 
K96 01 
Multiple needle puncture marks (NPMs) on right side of neck (post-mortem), front of right 
shoulder, groin, and arms. History of taking cannabis and speed. Use of harder drugs 
denied. Diabetic (perhaps explains needle marks). Recently prescribed Valium®. On 
night of death swallowed most of the contents of Propanolol and Prothiaden bottles. Taken 
to hospital hypotensive and unresponsive. Given Gelofusion and Inotrapses to raise blood 
pressure and Boprenailin, adrenaline and Sluragon intravenously. Resuscitation proved 
unsuccessful. Died in hospital. 
K96 02 
History of long-standing schizophrenia. Known intravenous drug abuser (IVDA). 
Admitted injecting temazepam and temgesic 6 years ago. Denied the use of other drugs at 
this time. On Procyclidine for schizophrenia (5 mg, twice daily). Thought to have been 
supplied heroin. Two possible fine needle marks on right antecubital fossa. Died at home 
with syringe still in hand. Last seen previous evening. 
K96 03 
Known to have abused heroin for 14 years and also thought to abuse cocaine. Alcohol 
abuse for 5 years. Previous heroin overdose. Not on any medication at time of death. No 
evidence of needle puncture marks. Drinking heavily on day of death and complaining of 
stomach pains. Returned home 1900 drunk and left to sleep in the recovery position. 
Found dead in the morning 0855. 
K96 04 
Diagnosed diabetic. Severe insulin dependence. Recently admitted to hospital with 
diabetes ketoacidosis, but failed to go back for check ups. Received one months supply of 
insulin and Valium, ® did not reattend clinic for more. Records show the deceased to be a 
registered drug abuser as late as one month prior to death. No evidence of needle puncture 
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marks. Complained of feeling unwell night before death but refused medical attention. 
Found dead the next morning in bed. 
K96 05 
Infected injection site on right arm. Thrombosed veins on left arm. Signs of injection in 
both sides of groin. Previous year admitted to hospital with abscesses and blood clots in 
legs and groin. General poor health due to drugs. On a series of programmes for 12 years 
to curtail drug problem. On methadone programme but failed to pick up last prescription. 
Admitted still abusing heroin and benzodiazepines. Last seen 16 days before being found 
dead at home. Hypodermic syringe, needles, sterilised pads, Abdine powders and heroin 
found in the vacinity. 
K96 06 
No fresh or old needle puncture marks identified. Thought to smoke heroin and cannabis 
but, not an IVDA. Six months prior to death attended surgery with respect to drug 
dependency problem with heroin and cannabis. Administration of dihydrocodeine (DHC) 
since then. Thought to be overcoming drug problem. One month prior to death, suffered 
sleeping difficulties and prescribed nitrazepam. On night of death, went to bed at around 
2130. Found dead in bed the next morning 
K96 07 
No petechial haemorrhages. Needle marks and scarred sinuses in groins. Recent NPM on 
right side. Both lungs oedematous and congested. Rigor beginning to wear off. In prison 
for three weeks, released two days prior to death. IVDA for 17 years. Abused heroin, 
Diconal and heroin/temazepam. Took overdose of heroin two years ago. Recently 
prescribed methadone and Librium. "' On day of death, took drugs between 1400 and 1430 
hours then became unwell. Found dead at 1610 hours with a syringe in close proximity. 
K96 08 
No petechial haemorrhages. Marked oedema in lungs. Needle puncture marks on both 
sides of neck. Evidence of old puncture marks at groin and possibly on arms. Signs of 
chronic IVDA on shins and ankles. Prescribed methadone (50 ml daily) and diazepam (15 
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ml daily). Complained of swollen testicles as the result of an assault and attended hospital. 
Swelling thought to be due to injection on the right side of the groin, but could have been 
due to assault. Further investigation found cellulitus of the abdominal wall, infection under 
the skin round the groin due to long term injection. Resulted in sceptic shock. Died in 
hospital. Thought to have been off heroin for about two years, but had started snorting 
cocaine. 
K96 09 
Body badly burned and hair singed. Needle and syringe clasped in right hand. 80% burns. 
No obvious signs of chronic drug abuse. No violence evident. History of drug abuse. 
Abused heroin regularly. Thrombosis in right leg prior to death. Appears to have 
overdosed and fallen onto a fire. Life pronounced extinct at 1410. Burning post mortem 
therefore cause of death is overdose and not fire (no CO in blood). 
K96 10 
Known drug abuser. Last seen alive in the afternoon three days before being found dead. 
May have been seen on video surveillance camera night before death. Needle and syringe 
in hand (still injected). History of alcohol abuse and smoked cannabis. Reported using 
"smack". No medical records of drug use, but treated for alcoholism and asthma. Vene- 
puncture mark on back of left hand. 
K9611 
No fresh needle marks although some old ones possibly. Taking drugs for 11 years and 
most recently heroin. Overdose seven years ago. One week before death given sick line 
from doctor for nervous debility. Released from prison 8 days before death. On day of 
death, said to have been "sniffing". Fell asleep at 1900. Found collapsed on the floor at 
2030. Ambulance called but no signs of life. 
K9612 
No sign of chronic IV use but one puncture mark on the left antecubital fossa perhaps due 
to resuscitation. Suffered from mental illness and was on medication. Diagnosed psychotic 
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on sulpiride. Known solvent abuser. Last thought to be alive at around 2130. Found two 
hours later. Needles, syringe and suicide note found in the vacinity. 
K96 13 
Died in hospital. Taken in as having problems breathing. Resuscitation carried out. 
Adrenaline, atropine, diazepam, streptokinase and intravenous fluids given. Condition 
deteriorated. Died at 2157. Four needle puncture marks in right antecubital fossa (two 
with bruising) three on front of right wrist, one on front of right ankle, one on right side of 
left ankle. Suggestion of scarring on both sides of groin. Being assessed for suitability for 
rehabilitation and treatment at a Drug Clinic. Extensive evidence of IVDA. No 
medication at time of death 
K96 14 
Possible needle marks on right forearm at the elbow and left arm just above the elbow. 
Fresh needle mark on the back of the left hand. Rigor mortis established. Lungs 
oedematous and highly congested. Last seen by family doctor two months previously 
suffering from anxiety neurosis. Seen at 1500 in apparently good health. Found dead at 
home at 2000 with syringe in close proximity. 
K9615 
Petechiae confined to areas of hypostasis. Early decomposition setting in. Rigor mortis 
diminished. Lungs congested and oedematous. Right arm, three old healed puncture 
marks. History of drug abuse. Known drug abuser for eight years. Registered drug abuser. 
Not known what medication she was on at time of death. Released from prison day before 
death after a three month sentence. Overdosed on methadone at fpm on day of release and 
admitted to hospital. Treated with Narcan and discharged at 2.30 p. m. At around 8 p. m., 
at friends house drinking heavily and smoking cannabis. Went to bed at 10 p. m. Found to 
be dead at 9 am following morning. 
K9616 
No petechial haemorrhages. Rigor mortis diminished. Lungs congested and oedematous. 
Left front forearm, two healing puncture marks. Back of left forearm, 1 healing puncture 
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mark. Two puncate abrasions on back of left hand. On maintenance prescription in the 
form of painkillers to treat serious bums received three years earlier. Two months prior to 
death, admitted to hospital due to heroin overdose. Needle marks found on groin and arm. 
At 2pm on day of death, started drinking heavily. 8.30pm, returned home and continued 
drinking then fell asleep. Found dead in living room at 11.15pm 
K96 17 
Petechial haemorrhages noted in left anterior axillary fold and the adjacent axilla. Rigor 
mortis well established. Moderate to severe oedema and congestion in lungs. Possible 
recent puncture mark on left antecubital fossa. Past medical history of schizophrenia and 
known IVDA. Prescribed procyclidine, depixol and Losec. Referred to a Drugs Centre 
one month before death. Last seen by doctor two weeks before death and prescribed 
procyclidine. Collapsed suddenly at home after injection of heroin. Resuscitation attempts 
failed. Seized syringe from outside flat. 
K9618 
No petechial haemorrhages. Rigor mortis wearing off. Moderate to severe oedema and 
congestion of the lungs. Recent puncture mark on radial border of left wrist. Pock mark 
scarring in groin region. Thought to have become involved with drugs eight years ago. 
Had drug counselling as part of probation. Abused heroin and temazepam. First medical 
history of drug abuse seven years ago. On methadone for one year, 45 ml daily. Last 
prescribed five months previously. Registered drug addict. On night of death went to 
friends at about 10.15 p. m. Went out for alcohol (20 minutes) then watched video till 0230 
before going to bed. At 1430 the next day found dead (1-2 hours only). Found blood filled 
syringe on floor, shoelace round left wrist, spoon and open Abdine health drink sachet. 
K9619 
A few petechial haemorrhages on the conjunctivae. Mouth filled with vomit. Limbs still 
rigid. Lungs showed haemorrhage and oedema consistent with death in cardiac failure with 
superimposed inhalation changes. Fresh needle puncture mark on dorsum of right hand 
plus some small similar old wounds. No fresh needle marks anywhere else on the body. 
Known IVDA. In prison for several weeks prior and released two days before death. First 
Chapter Six: Case Results Page205 
note of IVDA four years before death. Attending drugs counselling since then. Known to 
have Hepatitis B. At around lpm on night before death visited friends with heroin and 
appropriate drug paraphernalia, apparently under the influence of drugs. From then till 
midnight, smoked hash. Fell asleep around midnight. Found dead 0945 the next morning 
with syringe and needle in right hand. 
K96 20 
No conjuctival petechial. Possible needle puncture mark on back of right hand. No other 
fresh or recent NPMs. Rigor mortis diminished. Lungs markedly congested and 
oedematous. History of alcohol and drug abuse for 18 years. Previous overdose. 
Prescribed methadone one year prior to death. Only prescribed once as doctor felt he no 
longer needed it. Prescribed GNT spray for angina five months before death. Also on 
ventalin. Regular smoker of cannabis and heroin. Not known to inject over the past two 
years. On night of death, went to bed drunk. In morning found dead in bathroom with 
hypodermic syringe and other drug paraphernalia on the floor (-7am). Possible needle 
puncture mark on back of right hand. No other fresh or recent needle puncture marks. 
K96 21 
Hypostatic petechiae on right upper eyelid. Rigor mortis diminished. Lungs congested and 
oedematous. Lower limbs showed multiple old healing needle puncture marks of varying 
ages with associated purple and greenish bruising. Scabbed sinus in left groin with fresh 
needle puncture mark and blood dot at its base with tissue paper attached to it. Multiple 
skin popping marks round knees and calves of both legs. Long history of drug abuse. On 
methadone treatment and obtained prescription of 9x 10 mg diazepam prescribed day 
before death which was consumed at the pharmacists. Three days before death found 
collapsed after injecting herself with drugs in the toilet. Recovered sufficiently to refuse 
treatment by the time the ambulance had arrived. Last seen alive 1700. Following 
morning found dead in room with trousers and pants at knees and syringe nearby. Been on 
several detox programmes but resumed habit on leaving. On diazepam on daily dispensing 
reducing course for temazepam addiction. Week before death requested methadone detox. 
Suffered seizures due to temazepam abuse and thrombosis in legs due to IV injection in 
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groins. Seized from the premises: paper fold containing white powder, used syringe, 2 
syringes, spoon with substance thereon. 
K96 22 
Multiple fine petechiae on the upper eyelids and the congunctivae. Rigor mortis 
diminished. Lungs showed oedema on sectioning. Needle puncture marks on breasts, 
arms, thighs, shins, and ankles. History of drug abuse for nine years. At the time of death, 
was on methadone treatment. Last seen at 0930. Didn't pick up methadone from the 
chemists. At about 1215, witness became concerned and investigated bedroom. Found 
lying in a semicrouched position on the floor with needle and syringe inserted into left leg. 
Ambulance called, but found to be dead. 
K96 23 
No fresh needle marks on body. Two years prior to death, told doctor he had a problem 
with temazepam and was referred to drug abuse clinic. Failed to turn up. Overdosed on 
alcohol and diazepam seven months prior to death. Seen to take 5 double strength 
dihydrocodeine and 7 yellow Valium® tablets at party night before. Also seen to drink 
lager and smoke cannabis. Walked dog at 0430, and returned to flat. 1030 found dead. 
Small amount of blood emitting from nose. 
K96 24 
No recent needle puncture marks or evidence of old scars around groin areas. No recent 
needle puncture marks on arms. Known drug abuser but not intravenous injection. Said to 
have had a slight drug problem - taking temazepam when depressed. Suffered from 
anxiety, depression and panic attacks and prescribed Paroxetine 4/96. Not on any 
medication at time of death. Week before death admitted to taking Valium, ® temazepam 
and smoking heroin. Night before death, having withdrawal symptoms. Returned home at 
2100. Went to bed around 0300 next morning. Around 0940 found to be dead. Seized: 48 
ml bottle of methadone mixture - empty, 5 mg diazepam tablets bottle - empty, 400 mg 
ibuprofen tablets, 400 mg ibuprofen tablets and 1 mg Loprazolam tablets. 
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K96 25 
Face and conjunctivae congested with a few small petechial marks. Limbs still rigid. 
Lungs extremely congested and oedematous. Right arm showed small crusted wound over 
the medial aspect of the front of the elbow joint. No signs of recent or chronic drug abuse 
on arms. Both legs showed pitted scars on linear aspect of the shins consistent with healed 
ulcerated lesions associated with IVDA. No evidence of fresh needle marks. History of 
chronic IVDA. Recently in prison. Released day before death. Two months prior to 
death, given a prescription for Librium® and dihydrocodeine. Before this had been 
prescribed DHC on several occasions and admitted to having a £30 per day heroin habit. 
Five years prior to death noted to be using heroin and temgesic. Overdose seven years 
prior to death. Claims to have used LSD, cannabis, temazepam, DHC and temgesic. On 
release from prison, went home. Thought to be under the influence (Valium®). Later, left 
house to buy drugs. Returned home 0730 and went to bed. Last seen returning home 
around 1530 apparently well. Around 2140, witness found deceased slumped in a sitting 
position with string tied round right arm and needle lying next to him. Appeared to have 
been dead for several hours. Several drug related items were removed from the locus (not 
noted in police report). 
K96 26 
Ligature mark round neck. Fresh needle puncture mark on antecubital fossa of left arm. 
Admitted to prison. No drug use for one week although known to be an IVDA. Found 
hanging within cell at around at 1100. IV abuse of heroin (£60-80 per day). Moderate 
drinker and smoker. 
K96 27 
Eyes congested with some large petechiae in right sclera and conjunctivae. Rigor mortis 
worn off. Lungs congested and oedematous. Greenish discoloration of the abdomen due 
to decomposition. Possible recent puncture mark over radial border of left mid forearm. 
Known IVDA. Two weeks prior to death, found unconscious with syringe in arm. Day of 
death at 0020 returned home. At about 0900 found in room sitting on bed apparently dead. 
Large amount of blood and vomit on the floor. Syringe still injected in arm. Various items 
of drug paraphernalia seized from the locus. Admitted to hospital due to drug abuse for 
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first time ten years previously for IVDA of heroin. Continued to abuse heroin and other 
drugs. Admitted to drug dependency three and a half years prior to death. At this stage 
also suffering from epilepsy. On release continued to abuse methadone, dihydrocodeine, 
temazepam and heroin intravenously. Admitted to various hospitals due to overdoses. 
Attended psychiatric unit for drug abusers, but still continued to abuse drugs. 
K96 28 
Scleral haemorrhage in left eye. Many incorporated petechial haemorrhages within 
hypostasis on face and trunk. Rigor mortis passed off. Moderate congestion and oedema 
in lungs. Possible venepuncture mark on left antecubital fossa with associated bruising. 
No other venepuncture marks. Suffered from anxiety and had a drink and drug problem. 
Prescribed oxazepam. and nitrazepam. Last seen 1700 hours. Three days later at 1400 
found dead in bed with flex tied round left arm. Bloody fluid coming out of mouth and 
nostrils. Syringe and white substance found at the locus. 
K96 29 
No petechial haemorrhages. No recent puncture marks on either arm. Lungs oedematous. 
Four heeling needle puncture marks overlying right groin with faint bruising. Multiple 
recent and fresh puncture marks overlying left groin with surrounding bruising, several 
with overlying blood clots. Long history of drug abuse. Lunchtime, day of death, 
purchased temazepam and heroin. Seen to swallow 5 temazepam tablets then prepared 
heroin and injected himself. Went to sleep until around 1430 when witnesses noted blue 
coloration and vomit. Resuscitation attempts were unsuccessful. 
K96 30 
Possible old needle puncture mark on right forearm. Day before death purchased £10 bag 
of heroin and shared half then fell asleep. Woke up in morning and smoked other half then 
went back to sleep again. Found later on "foaming at the mouth". Resuscitation attempts 
failed. Known drug abuser for 2 years. Smoked heroin daily. Attempted suicide two years 
prior to death - temazepam. Previous overdose on diazepam - temporary coma and 
pneumonia. In months leading to death, attending Drug Dependency Unit. Seized 2 rolled 
cigarette papers and 1 piece of tinfoil with brown substance thereon. 
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K97 01 
No fresh needle puncture marks on either arm. Known IVDA. Cirrhosis of the liver 
recently diagnosed. On methadone treatment at time of death. Aneurism due to IVDA on 
right femural artery requiring treatment. Last seen by doctor two weeks prior to death for 
methadone. Last seen alive three days prior to death heavily under the influence of alcohol. 
Found dead at home. 
K97 02 
No fresh needle puncture marks. Puckered scarring on left groin. Suspected hepatitis C. 
15 year drug history. Attending various clinics for drug abuse with mixed results. 
Prescribed diazepam and methadone daily. Last seen alive 2200. Found dead 1430 
following day. Syringes found in bedroom. 
K97 03 
Medical needle puncture marks on both sides of neck. Fresh needle puncture mark on 
radial aspect of right antecubital fossa. No evidence of old scarring or needle puncture 
marks. Drug abuser for 2/3 years. Attending rehabilitation and prescribed methadone and 
valium. Not known IVDA but police found fresh needle puncture mark on left arm.. 
Escorted home by police at 2000 as heavily under the influence, ambulance summoned. 
Attempts made at resuscitation. 2126 arrived at the hospital after having an apparent 
cardiac arrest. Never regained consciousness. Pronounced dead 2142. 
K97 04 
Foamy white froth in mouth. No petechial haemorrhages, Lungs congested and markedly 
oedematous. Fresh needle puncture mark at front of right elbow. Healing needle puncture 
marks on right arm above wrist crease and radial wrist crease. No needle puncture marks 
on left arm. Two possible needle puncture marks at right ankle. History of asthma and 
known to smoke heroin. On voltarol, remedeine and diazepam at time of death. Last seen 
alive 1600.2300 following day, found fully clothed, dead on bed. Medication at time of 
death: Voltarol, Remedeine, Diazepam. Drug paraphernalia seized from locus. 
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K97 05 
No petechial haemhorrages. ECG monitoring pads on chest and front of right elbow. 
Dressing over therapeutic puncture mark. Ligature mark on neck with several linear 
petechial bruises along the axis. Multiple healing excoriated abrasions with small circular 
scars over whole body due to scabies. Therapeutic puncture mark on front of right elbow. 
Multiple healing needle puncture marks on right forearm overlying vein. On left arm, outer 
side of elbow, needle puncture mark, four at the front of the elbow and one on the back of 
the hand. Rigor mortis diminished. Hypostasis on back of body. Lungs oedematous with 
congested lower lobes. Arrested day before death. Taken into custody and given 7 days in 
prison. Ate meal at 1630, heard talking to inmates in next cell at 1730 and found hanging 
in cell at 1930. Heroin addict suffering from withdrawal symptoms when last seen. 
Inmates next door heard scrapping of bed across floor and banging of pipes at -1900. 
Found by guard on duty at 1930. Resuscitation attempts failed. 
K97 06 
Needle puncture mark due to post-mortem sampling on left side of neck. Front of right 
elbow, overlying antecubital fossa, needle puncture mark with medical dressing. Front of 
left antecubital fossa, fresh needle puncture mark with associated bruising. Rigor mortis 
diminishing. History of drug abuse. Last seen by doctor one month prior to death. 
Complained of sleeping difficulty said to be using cannabis, temazepam and Valium. ` 
Asked for methadone, but told this was not available until blood tests had been carried out. 
Following tests, prescribed one months supply of trazodone. Given weeks supply but 
didn't pick up the rest. Night before death went drinking. Found the following morning 
still sitting on the couch. Called ambulance but resuscitation attempts unsuccessful. Life 
pronounced extinct 1010. 
K97 07 
No petechial haemorrhages. Front of right arm several circular skin popping scars. 
Multiple circular and oval skin popping scars over both lower limbs, thighs and lower legs. 
Right groin, scarred sinus with fresh blood clot related to needle puncture mark. Left 
groin, old healed scarred sinus overlying femoral vein. Rigor diminished. Lungs 
congested and oedematous. Ten year history of heroin IVDA. Admitted for detox 
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rehabilitation in previous year for two months. Following treatment, said only to smoke 
heroin occasionally. Went to bed 2300 and found following morning found at 0820 dead 
on living room floor. Syringe, spoons and Abdine powder nearby. Fresh injection site 
noted in left groin. 
K97 08 
No petechial haemorrhages. Mouth full of black fluid. Advanced signs of decomposition. 
Not possible to identify recent needle puncture marks in either antecubital fossa, groins or 
ankles. Rigor mortis worn off. Internal organs showed moderate decomposition changes. 
Moderate oedema in lungs. Registered drug abuser. Previous heroin overdose. Previously 
prescribed methadone. Released from prison one month prior to death. Last seen alive 
three days prior to death. On day found dead, strange smell coming from room. Found 
dead inside with trousers round ankles and used needle nearby. Life pronounced extinct at 
1340. Due to decomposition, insufficient blood to carry out full drug screen. Overall 
findings consistent with drug related death, probably heroin. 
K97 09 
No petechial haemorrhages. Post-mortem needle puncture mark on left side of neck. 
Single tiny fresh needle puncture mark on left arm at the front of the elbow. Old scarred 
sinus in both groins overlying femoral veins. No fresh needle puncture marks on groins. 
Rigor mortis diminished. Lungs congested and oedematous. History of drug abuse. 
Heavy drinker. In prison for 11 days. On day before release was overheard saying she was 
going for a hit as soon as she got out. Following day arrived at train station at 0902. Found 
dead within cubicle of toilets at 1350. Syringe and needle, teaspoon and paper fold with 
white granules seized from locus. Drug dependant for 12 years. 
K9710 
Petechial haemorrhages over mid chest and clavicles. No evidence of needle puncture 
marks or scars in groins. No fresh marks injuries or fresh/old needle puncture marks on 
arms. Lungs bulky, congested and oedematous. History of long term drug abuse. Known 
to abuse cannabis, cocaine and temazepam but not known to be an IVDA. Last seen alive 
1700. Following night found dead in bed. 
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K9711 
No needle puncture marks in arms or groins. Limbs flaccid. Both lungs congested and 
oedematous. History of drug abuse. Known to have taken temazepam and had suffered 
seizures as a result therefore prescribed chlordiazepoxide at this point. At one point treated 
with diazepam to control seizures. Taking sleeping tablets and temazepam in the days 
leading up to death. Not seen by family since 9pm two days prior to death. Forced entry 
into flat and found her lying face down in the bedroom. Telephoned for ambulance but 
found to be dead 1910. When last seen, suspected to have been smoking heroin. 
K9712 
Face and conjunctivae congested. Needle puncture marks on both sides of neck (PM). 
Circled needle puncture marks on both groins. Right arm, needle puncture mark in outer 
aspect of antecubital fossa (circled). Rigor mortis wearing off. Methadone addict. Known 
drug abuser for 10-15 years. Released from prison month before death. Prescribed 10 mg 
x4 diazepam daily. Known to use heroin. 1740, forced entry and found deceased face 
down on bedroom floor unconscious. Tried resuscitation and phoned ambulance. 
Resuscitation unsuccessful. Seized 2 spoons, belt fastened as a tourniquet and brown 
resinous material in silver foil. 
K9713 
No petechial haemhorrages. Rigor mortis worn off. No needle puncture marks. Lungs 
contained food, oedematous and congested. On methadone maintenance programme. 
Smoked heroin for approximately one year. Prescribed methadone but didn't return for 
repeat prescriptions. Three months prior to death recommenced on methadone 
maintenance programme and one month prior to death had daily amount increased from 
50-60 mg. Taken at chemists. Last spoken to at 1245.1545 witness checked on him and 
thought to be asleep. Checked again at 2200 before going to bed and still "sleeping". 0930 
tried to wake him but couldn't. Second witness found him to be dead and covered in 
vomit. 
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K97 14 
No petechial haemorrhages. PM needle puncture marks on neck. Two old pale circular 
scars on front of right elbow overlying vein. No recent needle puncture marks on either 
arm. Old circular scars overlying vein on left elbow. Lower limbs, innumerable small 
bruises, some overlying veins, many associated with overlying healing small needle 
puncture marks. Multiple old circular and oval slightly depressed scars. Front of left 
thigh, 2 cm above the medial edge of the kneecap, fresh needle puncture mark. Rigor 
mortis diminishing. Lungs congested and oedematous. Widespread aspiration of gastric 
contents into airways. Long history of drug and alcohol abuse. Attended drug 
rehabilitation but thought to have recently relapsed. Last seen by doctor one month prior to 
death. Day of death found by cleaner in toilets of health centre on all fours. Found needle 
and syringe inserted just above left knee. 
K9715 
Intravenous line in right elbow. Possible tiny needle puncture mark at front of left elbow. 
Rigor mortis diminished. Hypostasis on back. Lungs congested and oedematous. Heavy 
drinker. Known to abuse painkillers. Previous overdose of co-dydramol. Day before 
death prescribed 100 co-proxamol in relation to back pain. Also recently prescribed 
dihydrocodeine and still on co-dydramol. Not known if IVDA or not. 1800 found 
kneeling with face on floor appeared to be dead but tried resuscitation anyway. Ambulance 
arrived 1806 and continued resuscitation to no avail. Found prescribed drugs and syringe 
in bin near deceased's right hand. 
K9716 
Few petechiae in conjunctivae of left lower eyelid. No evidence of IVDA. Lungs 
congested and oedematous. Rigor still present in some parts of the body. Referred 
psychiatric hospital - five years prior to death and revealed drug and alcohol problem. Six 
months prior to death saw psychiatrist. Said to be depressed. Doctors prescribed 
amytriptyline 10 mg/day due to back pain. Night before death appeared to be under the 
influence of drugs. 0725 following morning found in living room, obviously dead. Dead 
some time. Rigor still evident. Drug paraphernalia seized from locus. 
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K97 17 
Needle puncture mark in right anticubital fossa. No previous signs of IVDA. Rigor still 
present. Lungs congested. Said to be a binge drinker and heroin user. Six months prior to 
death, prescribed 4 week course of antidepressants. 1745, appeared to be under the 
influence of alcohol. 1750 bought some heroin (2x£10 bags) to share with friend. 
Prepared heroin, both injected at same time from the same solution. Deceased closed eyes 
almost immediately after, but thought to be OK. 1940 found apparently unconscious in the 
same position. Attempted basic first aid but no success. Called ambulance but found to be 
dead. 
K97 18 
Conjunctivae congested. Multiple needle puncture marks in right groin (medical ? ). Small 
sinus in left groin consistent with chronic IVDA. Right groin bleeding with 5 needle 
puncture marks. Rigor still present. Lungs congested and oedematous. Heroin abuser for 
13 years. 1015, awake in bed. Got up -1100 and out at 1145.1250 found lying face down 
on the living room floor with head in rubbish bag and jeans pulled down below groin area, 
syringe sticking out of groin. Not breathing and blood coming from mouth and nose. 
Tried resuscitation. Phoned ambulance. Arrived 1303. Taken to hospital but resuscitation 
unsuccessful. Found spoon and paper fold in kitchen. 
6.4 RESULTS AND DISCUSSION 
6.4.1 BLOOD AND VITREOUS HUMOR 
6.4.1.1 BENZODIAZEPINES 
6.4.1.1.1 Analysis of PM and RTD Blood Samples 
In addition to the 48 post-mortem cases previously described, 15 post-mortem (PM) and 
road traffic drug (RTD) blood samples which had been analysed in the routine laboratory, 
were extracted by SFE. The results were then compared to those obtained using SPE for 
temazepam only. In both cases the analyses were carried out using the same standards 
(temazepam: 4.04 mg/100 ml, prazepam 4.89 mg/100 ml) for direct comparison of the 
results and the samples were extracted at approximately the same time. 
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In most cases the analyses were carried out in triplicate. The results are shown in Table 
6.2 and a correlation graph of these results is shown in Figure 6.1. An example of the 
method used to determine the concentration of drug present in the extracts is given in 
Appendix I. 
Table 6.2: Case Blood Analysis for Tema: epum 
Case SFE Ter mL SPE Ter m7L 
RTD1 3.17 3.96 
RTD2 1.34 1.18 
RTD3 8.04 7.57 
RTD4 2.38 2.13 
RTD5 1.85 1.89 
RTD6 3.20 3.23 
RTD7 1.08 1.22 
PM I 3.08 3.42 
PM2 2.01 2.41 
PM3 1.97 2.07 
PM4 2.52 2.65 
PM5 2.04 2.26 
PM6 4.51 4.51 
PM7 1.89 1.58 















Figure 6.1: Correlation Between SPE and S1, E for 1271) und YM Sumples 
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For the 15 cases analysed, good correlation was found between SFE and SPE. The 
equation of the best fit line through the points was calculated as y=0.97x + 0.06. For both 
methods to be extracting the temazepam to the same extent, the gradient of the line should 
be 1.0. From the equation of the line it is therefore apparent that there is no significant 
difference between the values obtained by the two techniques. 
6.4.1.1.2 Blood and Vitreous Humor Case Samples by EIA and RIA 
Before commencing with SFE of the blood and vitreous humor samples, it was decided to 
screen the cases by enzyme-immunoassay and radio-immunoassay to determine which of 
the drugs of interest were present. Table 6.3 shows the results obtained. 

















K96 01 na / na / na / na / 
K96 02 - IS - IS + IS + IS 
K96 03 - - + + - - - + 
K96 04 - na + na + na + na 
K96 05 na / na / na / na / 
K96 06 na / na / na / na / 
K96 07 - - + + + - + - 
K96 08 + + + + - + - + 
K96 09 na / na / na / na / 
K9610 - - - - + + + + 
K9611 - - + + + + + + 
K9612 - - - - + - + + 
K9613 + + + + - - + + 
K9614 - - + + - + + + 
K9615 + + + + - - + + 
K9616 - - - - + + + + 
K9617 - - - - + + + + 
K9618 - / + + / 
K9619 - - - - - + + + 
K96 20 - - + + + / + + 
K9621 + + + + + / + + 
K96 22 + + + + + / + + 
K96 23 + - + + - - + + K96 24 + + + + - - - - K96 25 - - + + + + + + 
K96 26 - - + - - - - - 
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K96 27 - - + + + - + + 
K96 28 - n/1 + n/I + n/1 + n/1 
K96 29 - - + + + / + + 
K96 30 - - + + - / + + 
K97 01 na 
1(97 02 + 
K97 03 na / + / - / - / 
K97 04 - / + / + / + / 
K97 05 - - + - / / - - 
K97 06 - - + + + / + + 
K97 07 - - + + - / + + 
K97 08 - - + + - / + + 
K97 09 - - + + + / + + 
K9710 - + + + + / + + 
K9711 - - + + + / + + 
K9712 - / + / + / + / 
K9713 + + + - - / - - 
K9714 - - + + + / + + 
K9715 - - + - / / + + 
K9716 - - + + / / + + 
K9717 - - - - / / + + 
K9718 + + - - / / + + 
+: Positive result as determined as a results of any deviation from the negative calibrator. 
-: Negative result. 
The cases from Table 6.3 which were positive for benzodiazepines were extracted by SFE 
to determine the concentration of benzodiazepine drugs present. Both blood and vitreous 
humor samples were extracted where applicable. For comparison, some of the samples 
were also extracted by SPE. 
Although, all cases had been previously analysed in the laboratory, these results were not 
used for comparison as the samples used for this study were taken separately at post- 
mortem (and possibly from a different site). In addition, there was a time delay in the 
analysis by the two techniques of up to one year. 
Table 6.4 shows the results obtained for blood by SFE and SPE and for vitreous humor. 
Where more than one analysis was carried out the number of extractions is indicated in 
brackets. 
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Table 6.4: Benzodiazepine Blood SFE and SPE and Vitreous Humor Results 
Case SFE Blood SFE Vitreous SPE blood Blood Vitreous 
mg/L mg/L mg/L EIA/RIA EIA/RIA 
n /m n /m 
K96 02 Temaz: 1.22 Temaz: 1.19 NA NA NA 
Diaz: 0.18 
K96 03 Temaz: 0.20(2) * NA 1255 181 
DMD: 0.31 
Diaz: 0.17 
K96 04 Temaz: 0.27(4) * Temaz: 0.22 >2500 
DMD: 0.53 DMD: 0.50 
Diaz: 0.49 Diaz: 0.42 
K96 07 Temaz: 0.72(6) Temaz: 0.71(2) Temaz: 0.60 >2500 1015 
DMD: 0.06 DMD: 0.42 DMD: 0.06 
Diaz: 1.98 Diaz: 0.63 Diaz: 0.94 
K96 08 DMD: 0.14(3) DMD: 0.17 DMD: 0.23 >2500 1751 
Diaz: 0.44 Diaz: 0.39 Diaz: 0.25 
K9611 Temaz: 0.48 - Temaz: 0.35 >2500 616 
DMD: 0.47 DMD: 0.39 DMD: 0.55 
Diaz: 1.01 Diaz: 0.74 Diaz: 0.76 
K96 13 DMD: 0.55(3) - NA + >2500 
Diaz: 0.47 Diaz: 0.47 
K9614 DMD: 0.29(2) - NA + 638 
Diaz: 0.15 Diaz: 0.15 
K96 15 DMD: 0.20 DMD: 0.37 DMD: 0.44 + 1368 
Diaz: 0.29 - Diaz: 0.27 
K96 18 Temaz: 1.24 * Temaz: 0.99 + 
DMD: 1.54 DMD: 0.85 
Diaz: 0.08 - 
K96 20 DMD: 0.38 * DMD: 0.51 + 646 
Diaz: 0.39 Diaz: 0.44 
K96 21 Temaz: 0.01 - - + 91 
DMD: 0.39 DMD: 0.35 DMD: 0.54 
Diaz: 0.55 - Diaz: 0.77 
K96 22 Temaz: 1.30 Temaz: 0.76 Temaz: 0.92 + 3353 
DMD: 0.68 DMD: 0.27 DMD: 0.46 
- Diaz: 0.62 - 
K96 23 DMD: 0.18 DMD: 0.025 DMD: 0.19 >2500 731 
Diaz: 0.45 Diaz: 0.068 Diaz: 0.40 
K96 24 Temaz: 0.25(2) Temaz: 0.08 Temaz: 0.20 + >2500 
DMD: 0.29 DMD: 0.10 DMD: 0.24 
Diaz: 0.03 Diaz: 0.01 Diaz: 0.10 
K96 25 DMD: 0.08 DMD: 0.07 DMD: 0.03 + 713 
Diaz: 0.27 Diaz: 0.10 Diaz: 0.35 
K96 26 Temaz: 0.06 - NA + -ve DMD: 0.23 DMD: 0.10 
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Table 6.4: Continued 
Case SFE Blood SFE Vitreous SPE blood Blood Vitreous 
mg/L mg/L mg/L EIA/RIA EIA/RIA 
n /m n /m 
K96 27 Temaz: 0.78 Temaz: 0.35 Temaz: 0.81 >2500 1056 
DMD: 0.22 DMD: 0.12 DMD: 0.18 
Diaz: 0.08 Diaz: 0.10 Diaz: 0.08 
K96 28 Temaz: 0.11 Temaz: 0.11 NA >2500 NA 
DMD: 0.11 - 
Diaz: 1.51. Diaz: 1.25 
K96 29 Temaz: 0.36(3) Temaz: 0.17(2) NA + 529 
DMD: 0.52 DMD: 0.52 
K96 30 Temaz: 0.23(3) Temaz: 0.19(3) NA + 497 
DMD: 0.20 DMD: 0.28 
Diaz: 2.62 Diaz: 2.48 
K97 02 Temaz: 0.20 * NA + * 
DMD: 0.44 
K97 04 Temaz: 0.38 * NA + 
DMD: 0.26 
Diaz: 1.13 
* Vitreous not available for analysis 
NA Not analysed 
+ Some of the EIA/RIA results were for the laboratory samples. Where this was the case, + 
has been inserted as opposed to the value to indicate that the result was positive. 
As can be seen by looking at the results obtained by HPLC and EIA/RIA, there is no 
correlation between the results. For this reason none of the EIA or RIA results were 
displayed graphically. 
The results obtained by SFE for blood and vitreous humor were graphed to determine if 
any correlation existed as shown in Figure 6.2. 
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Figure 6.2: Correlation between Blood and Vitreous Humor 7ema: epam Levels hýS/ 
From this, the coefficient of correlation (r2) for temazepam in blood and vitreous is 0.692 
indicating that there is some correlation between the two extraction media. The gradient 
of the best fit line through the results was 0.75 indicating that the level of temazepam in 
vitreous is generally lower than the corresponding level in blood. 
It should be noted, that in some cases, larger blood samples were analysed (up to 500 µL). 
Due to the small amount of vitreous humor available, only 100 pL were analysed at any 
one time. This means that in some of the samples where only a small amount of 
temazepam was present, the level may have been too small to be detected. 
The correlation between the blood levels of temazepam determined by SFE and SPE was 
also graphed and is illustrated in Figure 6.3. 
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Figure 6.3: Correlation between SI-E and SPE Blood Tema. epam Levels 
From this, the coefficient of correlation was found to be 0.949 with a gradient of 1.23 
indicating that the SFE method is extracting more temazepam than the SPE method. 
The blood versus vitreous and SPE versus SFE graphs for temazepam were repeated for 
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Figure 6.4: Correlation Between Blood and Vitreous Decmethyldia: epam Levels by SE 
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Figure 6.6: Correlation Between Blood and Vitreous 1)iu: erum by Sl'1 
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Figure 6.7: Correlation Between SFE and SPE for Blood Dia: epum Levels 
For the comparison between blood and vitreous humor for desmethyldiazepam, r2 = 0.143 
indicating that no correlation exists between the two media. In comparing SFE with SPE 
for desmethyldiazepam, a coefficient of correlation of 0.711, was found with the gradient 
of the best fit line at 1.40, again indicating that higher drug levels are being found by SFE 
than by SPE. 
For diazepam, the correlation between blood and vitreous was reasonably good (r` = 0.714, 
gradient = 0.70) and in comparing the results obtained by SFE with SPE results a 
coefficient of correlation of 0.739 (gradient = 1.51) was obtained. 
In the case of all three drugs in blood by SFE, reasonable correlation with results obtained 
by SPE was achieved. It should be noted that the SPE was carried out only once as 1 ml of 
blood is required and the sample volumes obtained from the pathologists were low. 
For the comparison between blood and vitreous humor, temazepam and diazepam 
correlated well, with levels in blood being generally higher than the equivalent vitreous 
values. For desmethyldiazepam, no correlation was seen between blood and vitreous 
humor. It is not known whether or not any metabolic reaction of the benzodiazepines 
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occurs in the vitreous humor, however in the cases where a large drop was observed 
between the diazepam level in blood and vitreous humor, a corresponding increase in 
desmethyldiazepam was also observed (cases: K96 07, K96 11, K96 15, K96 21). 
6.4.1.2 MORPHINE AND 6MAM IN BLOOD AND VITREOUS HUMOR 
As with the benzodiazepines, the EIA (opiate) / RIA (morphine) results were investigated 
before commencing analysis of the samples by SFE. Cases which were found to be 
positive were analysed for the presence of morphine. The results for the analysis of the 
case blood and vitreous humor samples for morphine are shown in Table 6.5. Blood and 
vitreous humor were analysed where applicable and some of the cases were also analysed 
by SPE for comparison. 
It should be noted that 6MAM analysis was not initially carried out and thus, some of the 
blood and vitreous samples were not analysed for 6MAM. Where this was the case n/c has 
been inserted. 
Table 6.5: Morphine Blood SFE and SPE and Vitreous Humor Results 

















K96 02 0.79 0.45 0.68 n/c n/c 728 na 
K96 04 0.13 -ve 0.18 n/c n/c 257 na 
K96 07 1.05 na 1.06 n/c na 646 - 
K96 08 0.13 0.04 na n/c n/c - 162 
K9610 0.23 -ve 0.3 n/c n/c 237 291 
K9611 0.15 0.18 0.08 n/c n/c 467 924 
K9612 0.25 0.08 0.14 n/c n/c 399 359 
K96 14 0.10 0.086 0.06 n/c n/c + 411 
K96 16 0.62 0.46 0.6 0.13 0.032 + 1470 
K96 17 1.35 1.03 na n/c n/c + 383 
K9618 0.91 1.94 0.7 -ve -ve + na 
19 1-0.42 0.69 na n/c 0.73 + 375 
K96 20 0.85 0.67 na n/c 0.057 + 6989 
K96 21 1.97 1.48 1.7 -ve 0.96 + 10762 
K96 22 2.21 1.67 1.94 -ve 0.011 + 7355 
K96 25 0.48 0.067 0.45 0.005 -ve + 630 
K96 27 0.19 0.12 0.26 -ve 0.048 268 1264 
K96 28 0.39 na 0.34 n/c na 321 na 
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K96 29 0.79 0.62 0.51 n/c n/c + 6794 
K97 04 0.13 * 0.23 0.012 * + * 
K97 07 0.45 0.16 0.36 0.084 0.016 + 6293 
K97 09 0.19 0.31 0.42 0.088 -ve + 6467 
K9710 0.17 0.18 na 0.38 -ve + 5978 
K9711 0.054 -ve 0.11 -ve -ve + 4646 
K9714 0.74 0.71 na -ve 0.02 + 7110 
K9715 0.20 0.25 na 0.23 0.20 + 5897 
K97 16 0.20 0.23 0.15 0.051 0.006 + 6018 
K9717 0.14 0.27 na 0.011 0.084 + 4494 
K9718 0.26 0.55 0.53 0.16 0.11 + 5132 
A correlation graph of blood versus vitreous morphine by SFE was produced from these 
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Figure 6.8: Correlation Between Blend and Vitreous Humor Morphine Levels by Sb7' 
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Figure 6.9: Correlation Between S1,7; and SPE Blood Morphine Levels 
The correlation between blood and vitreous humor morphine levels was good, r2 = 0.712. 
As with the benzodiazepines, in general the levels found in vitreous are lower than the 
corresponding levels in blood (gradient of best fit line = 0.79). 
For the comparison between SFE and SPE for morphine in blood, again a good correlation 
was seen between the two methods (r2 = 0.977) and the gradient of the best tit line was 
1.13 thus, taking into account experimental error, the two techniques yield the same drug 
concentrations. 
6.4.1.3 MI1,7'HADON1; IN BLOO/) ANI) VI"1'REO JS HIIMQJ? 
The final drug to be analysed from blood and vitreous humor samples was methadone. As 
with the other two sets of drugs, EIA and RIA results were obtained. In addition to the 
methadone it was noted during the final stages of this study that EDDP was also being 
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extracted from blood and vitreous humor samples. As no method development was carried 
out for this metabolite it could not be quantitated. Where EDDP was detected in blood or 
vitreous humor it has been noted with the corresponding methadone level. 
The results obtained for the SFE of methadone from blood and vitreous humor samples are 
given in Table 6.6. The levels obtained by LLE for some of the cases are also noted. 
Table 6.6: Methadone Blood SFE and LLE and Vitreous Humor Results 











K96 08 0.44 0.35 0.36 263 315 
K96 23 0.25(EDDP) -ve 0.23 96 -ve 
K96 21 0.56 0.20 0.32 + 47 
K96 22 0.28 0.12 0.12 + 68 
K96 24 0.55 0.14 (EDDP) 0.36 + 78 
K97 03 0.94 EDDP 0.21 (EDDP) 0.98 + na 
K96 13 2.18(EDDP) 0.46 1.76 + 38 
K96 15 0.72 0.16 (EDDP) 0.68 + 295 
K97 10 0.10 0.08 -ve + 17 
K97 13 0.41 0.34 -ve + 355 
K97 18 0.48(EDDP) 0.10 (EDDP) 0.30 + 143 
A graph was plotted of the correlation between blood and vitreous humor methadone levels 
obtained using SFE (Figure 6.10). 
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Figure 6.10: Correlation Between Blood and Vitreous Humor Methadone Levels by . S1.7; 
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Figure 6.11: Correlation Between SI, T and 111,, ' Blood Methadone Levels 
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From Figure 6.11, the coefficient of correlation for blood and vitreous humor methadone 
by SFE was calculated to be 0.478. Thus, the correlation between blood and vitreous 
humor is lower than has been seen for some of the other drugs, however there is still a 
slight correlation between the results. In addition to this, the gradient of the best fit line 
through the points is only 0.17 indicating that the levels in vitreous are much lower than 
the corresponding blood levels. 
The coefficient of correlation for methadone levels obtained using SFE and SPE was 
calculated as 0.934. The gradient of the best fit line was 1.06. 
6.4.2 HAIR ANALYSIS 
As can be seen from Chapter 5, the analysis of benzodiazepines, morphine (6MAM) and 
methadone from hair samples can be carried out using the same SFE method. Prior to 
being extracted, the hair samples were washed in MeOH, dH2O and MeOH. Once dried, 
some of the samples were then sectioned. In most cases the hair samples were less than 6 
cm long and the sectioning consisted of separating the roots from the bulk hair. In cases 
where the hair samples were longer than 6 cm, they were sectioned in 6 cm or 3 cm 
lengths. The sections are highlighted after the case numbers in the results tables below. 
Once the sectioning was completed, the hair was finely ground under liquid nitrogen using 
a mortar and pestle before being weighed and extracted using the conditions defined in 
Chapter 5. 
The, following three tables show the results obtained for the hair analysis. Only the cases 
which were deemed positive have been reported. The method used for the calculation of 
the drug concentrations in hair is given in Appendix II. 
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K96 01/uncut 50.46,25.80 3.53 (2) 7.36 7.31 
K96 02 uncut 29.85 8.44 15.99 14.16 
K96 04/uncut 28.33 0.78 -ve -ve 
K96 05/R 16.27 -ve -ve -ve 
K96 05/lst3 34.77,39.14 1.04 (2) 1.36 0.95 
K96 05/B 31.19,49.26 2.06 (2) 2.45 2.36 
K96 07/uncut 37.49 9.15 -ve -ve 
K96 08 uncut 27.94,15.61 5.00 (2) 3.98 3.23 
K96 09 uncut 26.83 23.55 -ve -ve 
K96 11 uncut 86.27 111 -ve -ve 
K96 16/lst6 32.35 2.33 -ve -ve 
K96 16/2nd6 19.67 10.23 12.13 16.09 
K96 16/B 36.92 61.83 52.05 49.46 
K96 16/R 12.68 -ve -ve -ve 
K96 16 uncut 112.31 2.18 -ve 1.36 
K96 21/R 20.03 -ve -ve -ve 
K96 21/lst6 33.43 5.70 8.60 7.83 
K96 21/2nd6 28.85 5.29 9.88 8.19 
K96 211B 28.85 56.79 34.58 38.24 
K96 2318 14.68 -ve -ve -ve 
K96 23/B 22.15,14.39 45.43 (2) 25.28 80.14 
K96 24/R 16.44,24.49 2.52 (2) 3.03 4.62 
K96 24/6 45.37 23.89 18.78 20.08 
K96 24/5 53.35 6.06 3.83 13.53 
K96 24/B 54.81 37.05 57.38 16.04 
K96 24/B 54.81 4.22 2.69 12.11 
K96 29/R 25.14 -ve -ve -ve K96 29/3 10.38,26.94 13.50 (2) 12.84 10.81 
K96 30/R 9.64 -ve -ve -ve 
K96 30/5 49.11 0.93 1.17 0.85 
K96 30/B 16.80 9.13 3.67 24.25 
1(97 OUR 46.04 13.34 13.24 17.18 
K97 01B 72.25,21.35 -ve 7.91 (2) 4.96 
1(97 06/R 7.37 4.30 -ve 5.00 
K97 06/B 14.80 10.32 10.00 7.30 
K97 10/R -ve -ve -ve K97 10B 38.09 1.98 2.29 1.67 
K: KOOLS 
B: Bulk 
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K96 13/uncut 51.75 10.18 0.78 13.05 
K96 15/R 14.72 -ve -ve - 
K96 15/B 14.72 13.4 63.6 0.21 
K96 17/uncut 10.27 14.04 9.23 1.52 
K96 18/uncut 12.14 55.24 42.75 1.29 
K96 20/R 15.31 -ve -ve - 
K96 20/B 43.10 -ve -ve - 
K96 21/R 20.03 77.6 203.8 0.38 
K96 21/lst6 33.43 18.2 22.6 0.81 
K96 21/2nd6 28.85 40.5 64.0 0.63 
K96 22/R 14.16 41.5 41.5 1.00 
K96 22/3 34.68 15.8 -ve - 
K96 22/B 29.64 4.24 1.41 3.01 
K96 24/R 30.90 0.65 2.07 0.31 
K96 24/6 91.26 1.15 1.28 0.9 
K96 24/5 53.53 1.57 2.62 0.60 
K96 24/B 87.59 1.06 0.75 1.41 
K96 25/B 22.67 10.37 5.56 1.87 
K96 26/R 12.85 -ve -ve - 
K96 26/B 83.26 99.1 16.61 5.97 
K96 29/R 7.41 40.77 5.36 7.61 
K96 29/3 8.71 46.82 -ve - 
K96 29B 15.47 12.25 n/c 
K96 30/R 10.19 57.42 9.70 5.92 
K96 30/5 84.05 18.7 1.43 13.08 
K96 30/B 47.58 36.14 7.25 4.98 
K97 03/R 17.58 10.53 5.80 1.82 
K97 03/B 45.84 2.07 0.20 10.35 
K97 05/R 20.93 9.14 8.49 1.08 
K97 05/B 71.44 1.10 4.39 0.25 
K97 07/R 15.95 -ve -ve - K97 07/3 84.54 13.51 4.31 3.13 
K97 07/B 61.11 5.44 7.69 0.71 
K97 08/R 14.63 70.93 72.31 0.98 
K97 08/B 30.00 2.97 8.08 0.37 
K97 12/R 8.83 -ve -ve - K97 12/B 56.72 -ve -ve - K97 13/R 34.81 3.65 0.97 3.76 
K97 13/B 112.84 1.43 1.48 0.97 
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Table 6.8: Methadone Positive Hair Cases 
Case Weight (mg) Methadone (m /L) EDDP 
K96 13/uncut 51.75 24.02  
K96 15/R 16.98 -ve x 
K96 15/B 14.72 20.20  
K96 17/uncut 10.27 1.26 x 
K96 18/uncut 12.14 0.70  
K96 20/R 15.31 0.91  
K96 20/B 43.10 2.12  
K96 21/R 14.16 16.7  
K96 21/lst6 33.43 4.16  
K96 21/2nd6 28.85 -ve x 
K96 22/R 14.16 7.81  
K96 22/3 34.68 1.78 x 
K96 22/B 29.64 2.42 x 
K96 24/R 30.90 5.53  
K96 24/6 91.26 8.09  
K96 24/5 53.53 1.78 x 
K96 24B 87.59 -ve x 
K96 25B 16.50 0.40  
K96 25/R 26.28 0.53  
K96 25/B 22.67 1.68  
K96 29/R 7.41 9.07  
K96 29/3 8.71 10.53  
K96 29/B 15.47 5.93  
K96 30/R 10.19 1.22 x 
K96 30/5 84.05 -ve x 
K96 30/B 47.58 -ve x 
K97 0318 17.58 63.93  
K97 03/B 45.84 11.92  
K97 05/R 20.93 -ve x 
K97 05/B 71.44 -ve x 
K97 07/R 15.95 1.90 x 
K97 07/3 84.54 8.37 x 
K97 07B 61.11 -ve x 
K97 08/R 14.63 -ve x 
K97 08/B 30.00 -ve x 
K97 13/R 34.81 -ve x K97 13B 112.84 -ve x 
As with the t ooa ana vitreous humor samples, EDDP was detected but not quantitated. 
: Detected; x: not detected. 
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In addition to analysing the SFE hair extracts for the presence of drugs, the final MeOH 
hair wash was also analysed. All washes were found to be negative for the drugs being 
investigated. 
6.5 COMPARISON OF SFE RESULTS WITH CASE HISTORIES 
For this final part of this study, the cases histories were individually compared firstly with 
the results from blood and vitreous humor and secondly with the hair results. The first 
comparison relates to the circumstances surrounding the death of the deceased and the 
second related to their drug history over the past year. In each case, an example of how the 
comparisons were made will be given. This will be followed by a summary table for the 
remainder of the cases. 
6.5.1 COMPARISON OF CASE HISTORY WITH BLOOD AND VITREOUS HUMOR RESULTS 
The case which will be discussed here is K96 22 which was found to be positive for 
temazepam (1.30 mg/L blood; 0.76 mg/L vitreous humor), desmethyldiazepam (0.68 mg/L 
blood; 0.27 mg/L vitreous humor), diazepam (none detected in blood; 0.62 mg/L vitreous 
humor), morphine (2.21 mg/L blood; 1.67 mg/L vitreous humor), 6MAM (none detected in 
blood; 0.011 mg/L vitreous humor) and methadone (0.28 mg/L blood; 0.12 mg/L vitreous 
humor). The case was that of a 27 year old female and from the post-mortem report it was 
ascertained that the cause of death was due to heroin and temazepam intoxication. The 
time between the death of the deceased and post-mortem was 7 days, indicating that a 
degree of decomposition will have occurred. 
From the police report which accompanied the case, the information available implied that 
the cause of death was heroin related as a syringe was found in-situ. The deceased was 
also on a methadone maintenance programme although she failed to pick up her last 
prescription. No mention was made in the report of the use of benzodiazepines. 
If no police report had been available, with only the blood results, it would not have been 
possible to say for definite that the case of death was due to heroin intoxication as no 
6MAM was present in the blood. However, the analysis of vitreous humor shows that 
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death was in fact heroin related as a small amount of 6MAM was detected indicating that 
heroin had been used shortly before death. 
Table 6.10 gives a brief summary of the cases which were positive, drugs which were 
detected, and expected and whether the results obtained agree or disagree with the drug 
history. 
Table 6.10: Comparison of Case Results with PM and Police Reports 
Case Drugs Detected Drugs Expected Agree / Heroin 
Differ Abuse 
M 6M Meth Benzo Heroin Meth Benzo Confirmed 
K96 02  n/c x   x  A -ve* K96 03 x x x   x x D -ve K96 04  n/c x  x x  D +ve* 






























































































































































































x x x  D +ve K x X X  X  D -ve* 
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Table 6.10: Continued 




M 6M Meth Benzo Heroin Meth Benzo Confirmed 
K97 13 x x  x   x D -ve* 
K9714   x x  x x A + 
K97 15   x x x x x D +ve 
K9716   x x  x x A + 
K9717   x x  x x A + 
K9718    x  x x D + 
M: Morphine; 6M: 6MAM; Meth: Methadone; Benzo: Benzodiazepine. 
+: heroin confirmed by presence of 6MAM in blood and/or vitreous 
-, heroin not expected and not determined 
-*: heroin not expected, morphine not detected but 6MAM not analysed for 
+ve: heroin determined but not expected 
-ve: heroin expected but not determined 
-ve*: heroin expected but not determined however, morphine positive and 6MAM not 
analysed for 
: expected or detected 
x:: not expected or not detected 
6.5.2 COMPARISON OF CASE HISTORIES WITH HAIR RESULTS 
As mentioned previously, the second comparison which was carried out was to use the 
results obtained by hair analysis to confirm past drug abuse. Case K96 24 was chosen as 
an example. 
Case K96 24 was found to be positive for all three types of drug. As the hair sample was 
reasonably long, it was sectioned into three parts (roots (R), next 6 cm, final 5 cm) in 
addition to this some of the hair was left unsectioned as a bulk (B) sample. As can be seen 
from Tables 6.7-6.9, the sample contained the amounts of drugs shown in Table 6.11. 
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Table 6.11: Summary of HairAnalvsis Results for Case K96 24 
Section Benzod iaze ines (n /m) Opiate (n /m) Methadone 
Temaz DMD Diaz Morphine 6MAM (n /m ) 
Root 2.52 3.03 4.62 0.65 2.07 5.53 
6 cm 23.89 18.78 20.08 1.15 1.28 8.09 
5 cm 6.06 3.83 13.53 1.57 2.62 1.78 
Bulk 4.22 2.69 12.11 1.06 0.75 -ve 
The deceased in this case was a 20 year old female. From the past history it was seen that 
she was a known drug abuser whose drug problem was defined as "slight". She was said to 
have taken temazepam when depressed and had taken Valium® the week before her death. 
In addition, she was known to have smoked heroin. She was not known to be on a 
methadone maintenance programme, however an empty bottle of methadone mixture was 
seized from the locus. 
From the information obtained from the hair analysis, it appears that the deceased had been 
using temazepam, diazepam, methadone and heroin in the year and month prior to death. 
The blood analysis showed the presence of methadone, temazepam, diazepam and 
desmethyldiazepam which were confirmed as being used over the past year by the hair 
analysis. No heroin was detected in blood or vitreous humor, thus without the use of hair 
analysis, this would have gone undetermined. 
Although the detection of heroin in the hair of the deceased is not relevant in terms of the 
cause of death, in cases where the subject is still alive and drug abuse is suspected, hair 
analysis is more informative than blood analysis. In particular, the roots of the hair were 
found to contain all three types of drugs indicating use of these drugs within one month 
prior to death. 
Table 6.12 contains summary information of all hair samples analysed and relates then to 
the information available from the PM and police reports. 
The results obtained for benzodiazepines, morphine and methadone were compared to the 
deceased's drug history. In this respect the hair analysis is particularly interesting as 
findings may be compared to the drug history of the deceased several months prior to 
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death. In some cases, the results obtained supported the police report, however there were 
cases where drug use was not confirmed and indeed some cases where drugs were detected 
which were not mentioned in the deceased's drug history (e. g. methadone detected in the 
hair of a subject not known to be on a methadone maintenance programme). 
Table 6.12: Comparison of Case Hair Results with PM and Police Reports 




M 6M Meth Benzo Heroin Meth Benzo Confirmed 
K96 01 x n/c x  x x  A -* 
K96 02 x n/c x   x  D -ve* 
K96 04 x n/c x  x x  A 
K96 05 x n/c x     D -ve* 
K96 07 x n/c x     D -ve* 
K96 08 x n/c x  X   D -* 
K97 09 x n/c x   X X D -ve* 
K96 11 x n/c x   x x D -ve* 
K9613    x  x  D + 
K9615    x   x A + 
K96 16 x x x   x x D -ve 
K9617    x  x x D + 
K9618    x    D + 
K96 20 x  x  x x D -ve 
K96 21        A + 
K96 22    x   x A + 
K96 23 x x x  x x  A - 
K96 24        A + 
K96 25    x  x  D + 
K96 26   x x  x x A + 
K96 29  x    x  D +* 
K96 30      x  D + 
K97 01 X X X   X X D -ve 
K97 03    x x   D +ve 
K97 05   x x x x x D +ve 
K97 06 x x x  x   D - 
K97 07    x  x x D + 
K97 08    x   x A + 
K9710 x x x  x x  A - 
K9712   x x    D + 
K97 13    x   x A + 
For key see 't'able 6.1U. 
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From Table 6.12, it can be seen that less than half of the cases correlate to the results 
expected from the PM and police reports. 8 of the 23 "known" heroin users had no 
morphine or 6MAM detected in their hair sample, however only two cases were detected 
where heroin abuse was not suspected. 
For methadone, 7 cases (47% of total positives) were found to be positive where no 
mention of methadone maintenance was given in the police report. There were 5 cases 
where the deceased was previously on a maintenance programme where no methadone was 
detected. 
The best correlation between the reports and the hair analysis results was for the 
benzodiazepines. Only 5 cases were found not to be positive where expected and only 4 
false positives were determined (no record of previous use and positive hair result). 
In terms of agreement of the comparison between the results by blood / vitreous humor and 
hair with the PM and police reports, there is little difference (39.5 % agreement for blood / 
vitreous humor and 35.5% agreement for hair). However, in terms of the determination of 
heroin abuse, hair analysis is more likely to detect the use of heroin (% agreement = 61%) 
than analysis of blood or vitreous humor (% agreement = 50%). (It should be noted that 
the cases where 6MAM was not analysed for have been omitted from the % agreement). 
6.6 CONCLUSIONS 
Post-mortem blood, vitreous humor samples were analysed for the presence of 
benzodiazepines (temazepam, desmethyldiazepam, diazepam), morphine and methadone 
using the SFE methods developed in Chapters 2,3 and 4 respectively. Metabolites of 
morphine (6MAM) and methadone (EDDP) were also detected. All three SFE methods 
were found to successfully extract the drugs from the matrices and yielded results 
comparable to those determines using SPE and LLE techniques. 
The usefulness of vitreous humor analysis as an alternative to blood was highlighted. 
Good correlations between blood and vitreous humor were seen for most of the drugs 
investigated indicating that vitreous humor can be used as an alternative sample when 
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blood is not available for analysis. Due to its relatively simple matrix, vitreous humor also 
produced cleaner extracts then blood. 
As with the blood and vitreous humor analysis, the hair extraction method was found to 
successfully recover benzodiazepines, morphine, 6MAM and methadone. Although the 
correlations between the analytical results and the PM and police reports were relatively 
poor, it was possible to use 6MAM as a marker of past heroin abuse and in some cases 
confirm past drug use up to one year prior to death. The use of hair in post-mortem cases 
is of limited use, other than in the confirmation of drug histories, however the developed 
method would be useful in determining past drug use in other areas e. g. employee and 
parolee testing. 
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7. CONCLUSIONS FROM THESIS 
The aim of this study was to develop extraction methodology using supercritical fluid 
technology for the determination of drugs of forensic interest in a range of biological 




The first sample matrix to be investigated was blood. Successful method development was 
carried out and methodology was established for all three drug types. The benzodiazepines 
were extracted using SF-CO2 with ethyl acetate as a modifier at 65 °C and 3000 psi. The 
extraction yielded >80% recoveries of temazepam, desmethyldiazepam and diazpam within 
10 minutes. 
For the extraction of morphine and methadone, it was found that both drugs extracted with 
>80% recoveries using the same conditions. SF-CO2 was still used as the main extraction 
fluid and a mixture of methanol and triethylamine was added as a modifier. The 
extractions were run at 100 °C and 3500 psi. In addition to efficiently extracting morphine 
and methadone, an additional benefit of this extraction was that it also allowed for the 
extraction of 6-monoacetyl morphine, the primary metabolite of heroin. Recoveries and 
reproducibility for the extraction of 6MAM were good. 
The second sample matrix to be investigated was vitreous humor. It was found that the 
methods which had been developed for the extraction of the drugs from blood were also 
ideal for the extractions from vitreous humor. This allowed direct comparison of the two 
sets of results obtained from blood and vitreous humor. 
The final matrix to be investigated was hair. Hair analysis is becoming of increasing 
importance in the forensic field as it provides a readily available marker of past drug use. 
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Methodology was developed from existing procedures and all three types of drugs were 
successfully extracted using the same technique. 
Extractions of post-mortem blood, vitreous humor and hair samples were carried out using 
the developed methods and were found to compare well to conventional extraction 
techniques. 
A total of 48 cases were investigated and the following comparisons were made. 
1) Vitreous humor samples were analysed and the results compared to those obtained for 
blood in order to determine the usefulness of this sample matrix. With the exception of 
desmethyldiazepam, all drugs investigated gave good correlations between blood and 
vitreous humor results, although the levels in vitreous humor were generally lower than 
the corresponding levels in blood. 
2) In order to confirm that the developed SFE methods were efficient for the extraction of 
the drugs of interest from authentic samples (all method development was carried out 
using spiked samples) some of the cases were analysed by the conventional technique 
used in the routine laboratory (SPE for benzodiazepines and morphine, LLE for 
methadone). In all cases the two methods correlated well. 
3) The results obtained for benzodiazepines, morphine and methadone were compared to 
the deceased's drug history to determine if correlations existed. Heroin abuse was 
confirmed by the presence of 6MAM in all three matrices. Hair analysis was found to 
be particularly useful as it provided a better match with the drug history than blood or 
vitreous humor. 
It has been shown, that supercritical fluid extraction is a valuable tool for the analysis of 
drugs and their metabolites in a variety of matrices. The developed SFE methods are more 
efficient and less costly in consumables than conventional extraction techniques. For the 
analysis of hair, SFE has the additional advantage of a substantial reduction in extraction 
time, as the preparative steps can be included in the methodology. 
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Appendix One: Calculation Methods Used Page261 
CALCULATION OF CONCENTRATION IN BLOOD / VITREOUS HUMOR SAMPLES 
Sample Ratio = 
Response of Drug in Sample 
Response of Internal Standard in Sample 
Standard Ratio = 
Response of Drug in Standard 
Response of internal Standard in Standard 
Drug Concentration (mg / L) = 
Sample Ratio 
x 
Concentration of Drug in Standard 
Standard Ratio Dilution Factor 
The Dilution Factor is used when the volume of the sample and standard are not the same 
e. g. 1 ml of standard and 100 µ1 of sample gives a dilution factor of 10. 
CALCULATION OF CONCENTRATION IN HAIR SAMPLES 
Drug Concentration(ng / mg) = 
Sample Ratio 
x 
Concentration of Drug in Standard (ng) 
Standard Ratio Weight of Hair Sample (mg) 
RECOVERY STUDIES 
For recovery studies, the calculations were carried out as follows: 
% Recovery = 
Extracted Standard Ratio 
x 100 Unextracted Standard Ratio 
Appendix Two: Calculation of Standard Deviation Page262 
STANDARD DEVIATION: 
In order to assess variability of data obtained, the relative standard deviation (RSD) was 




Appendix Three: Distribution of Age/Sex of Cases Nagc263 
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The distribution of age and sex of the cases investigated is shown in the above figure. lt 
can be seen that the cases were predominantly male (72%) and that the most common age 
was 29 (mean 27). 
Appendix Four: Papers in Support of this Thesis Page264 
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Supercritical Fluid Extraction of Drugs of Abuse from Conventional and 
Unconventional Toxicological Samples 
K. S. Scott and J. S. Oliver 
Department of Forensic Medicine and Science, University of Glasgow, University Place, 
Glasgow, Scotland, G12 8QQ 
This article details the supercritical fluid extraction of benzodiazepines, morphine and methadone from post- 
mortem blood, vitreous humor and hair from suspected drug abusers. 
A comparison between post-mortem blood and vitreous humor levels was made in order to investigate the use of 
vitreous humor as an alternative toxicological medium to blood. 
Hair analysis was carried out in order to evaluate the use of hair in the determination of chronic drug abuse. 
Keywords: Supercritical fluid extraction, hair, vitreous humor, blood, benzodiazepines, morphine, methadone. 
Introduction 
Most present methodology for the extraction 
of drugs of abuse from biological liquids 
involve solid phase or liquid-liquid 
extractions[ 1,2]. These methods can be time 
consuming, costly and wasteful of sample. With 
the increase in demand for efficient 
toxicological analyses the development of new 
extraction technology is of the utmost 
importance. Supercritical fluid technology has 
grown dramatically over the past decade, 
however despite this, its acceptance in routine 
forensic analysis has been limited[3,4,51. 
In addition to speed and convenience of use, 
the main advantages of supercritical fluids 
include improved efficiency, non-toxicity and 
cost-effectiveness[6]. The possibility for direct 
extraction from complex matrices, in parallel 
with a reduced risk of sample contamination 
highlights the power of supercritical fluids as a 
tool for analysis. 
As well as time of death related drug analysis, 
it can be important to obtain information 
relating to long term drug abuse. Although the 
analysis of hair has been used for this 
purpose[7.8.9], work is still required in this area 
in order to provide a validated, universally 
accepted method. 
The supercritical fluid analysis of drugs of 
abuse in hair has also been reviewed[1o]. The 
results obtained tend to be similar to those 
obtained by conventional digestion or 
methanolic extraction techniques which are time 
consuming and destructive. Here again the 
advantage of short extraction times with 
supercritical fluids is emphasised. 
Experimental 
Temazepam and prazepam were purchased 
from Wyeth Laboratory. Morphine, d3- 
morphine, methadone and d3-methadone were 
purchased from Sigma. Methanol, ethyl acetate 
and dichloromethane are HPLC grade (Lab Scan 
Analytical Sciences). Triethylamine is HPLC 
grade and Na2HPO4 GPR grade (BDH). 
BSTFA with 1% TMCS (Pierce) was used for 
the derivitisation of morphine and d3-morphine. 
The CO2 is supplied by Air Products and comes 
in 25 kg cylinders fitted with a dip-tube. 
Extrelut® (Merck) is prewashed in 
dichloromethane. Collection vials for SFE are 6 
mL HypoVialTM (Pierce) with butyl rubber septa 
(Pierce and Warriner). Columns for SFE were 
made using 3 cm x 4.6 mm i. d. stainless steel 
tubing. Water was deionised using a Milli-Q® 
water purification system (Millipore(D) 
The SFE system consists of two Gilson 306 
pumps, two rheodyne valves and a Pye series 
104 GC oven with pressure restrictor. All 
components were modified to suit the 
supercritical extractant. The CO2 pumphead 
was refridgerated to maintain the flow of liquid 
CO2 using a Gilson model SFC3 refridgeration 
unit. The extraction columns were placed over 
positions 1 and 4 in the second rheodyne and the 
extract collected by expansion into McOH in a 
HypoVialVM at the flow outlet. 
For the extraction of temazepam from blood 
and vitreous humor, the method used was that 
reported by Scott and Oliver[1II. This method 
proved ineffective in the extraction from hair. 
Methadone and morphine analysis was carried 
out using a triethylamine : methanol modifier 
which again was efficient in the extraction of 
these drugs from blood and vitreous humor but 
failed in the analysis of hair. Successful 
extraction of morphine from hair was reported 
by Cirimele, et al[10] and this method proved 
effective in the extraction of all three drug types 
from hair. 
Sample preparation 
Blood and vitreous humor 
Extrelut® was used as a support medium for 
blood and vitreous humor samples. 
Approximately 0.2 g of extrelut were placed in a 
plastic weighing boat and 100 p. L of sample 
loaded, mixed and left to dry at room 
temperature. The contents of the boat were then 
transfered to an extraction cell. 
Extraction conditions 
Condition Benzodiazepines Morphine/Methadone 
Temp: 65 °C 100 °C 
Pressure: 300 psi 3500 psi 
Modifier : Ethyl Acetate McOH: Et3N(85: 15) 
Flow: 2 mL/min 2 mUmin 
Time: 20 min 30 min 
Analysis: HPLC CC-MS 
Hair 
Hair samples were decontaminated by washing 
with H2O then methanol, then again with H20. 
In order to maximise the surface area for 
extraction, the hair was ground using either a 
mortar and pestle with liquid nitrogen or an 
analytical mill (IKA, Labortechnik) with dry ice. 
Approximately 50 mg of decontaminated ground 
hair was then placed in an extraction cell. 
Extraction conditions 
Condition All drugs 
Temp: 100 °C 
Pressure: 3500 psi 
Modifier: MeOH: Et3N: H20 (2: 2: 1) 
Flow Rate: 2 mUmin 
Cleanup: Static 10 min 
Continuous 15 min 
Extract: Add 500 pL modifier 
Static 15 min 
Continuous 30 min 
Results and Discussion 
Blood and vitreous humor 
Post-mortem blood, vitreous and hair samples 
were obtained for nine suspected drug abuse 
cases. In all nine cases, quantities of drug were 
found which could have contributed to death. 
For the hair samples, the three wash steps 
were sufficient to remove any environmental 
contamination from the hair and results reported 
are from consumed drugs only. 
Seven of the cases showed levels of morphine 
in blood from 0.07-1.20 mg/L (mean 0.57). Of 
these, five had positive vitreous humor, 0.24- 
0.44 mg/L (mean 0.35). In the case with a level 
of 0.07 mg/L blood, no morphine was detected 
in vitreous humor by GC-MS and for one of the 
cases no vitreous humor was available. 
Only two of the cases showed positive 
methadone levels in blood and vitreous humor. 
In blood, the levels were 0.20 and 0.09 mg/L 
and in vitreous humor 0.19 and 0.32 mg/L 
respectively. 
Six of the cases showed positive temazepam 
blood levels ranging from 0.13-1.22 mg/L 
(mean 0.54). Of these, three showed positive 
vitreous humor (in two, vitreous humor was not 
available and in one temazepam was not 
detected by HPLC). The positive measurements 
ranged from 0.18-0.54 mg/L (mean 0.31). Other 
benzodiazepines were found in three cases. For 
one of these cases vitreous humor was not 
available. One case showed 1.01 mg/L 
desmethyldiazepam (DMD) in blood and 0.93 
mg/L in vitreous humor. The other case 
showed 0.47 mg/L DMD plus 1.00 mg/L 
diazepam in blood and 0.18 mg/L DMD in 
vitreous humor. 
Hair 
Four cases were positive for morphine in hair 
and the values ranged from 1.09-1.50 ng/mg 
(mean 1.31). The same cases were also positive 
for methadone. Methadone concentrations 
ranged from 1.29-2.91 ng/mg (mean 2.00). In 
hair only temazepam has been analysed for at 
present. Five cases showed positive temazepam 
ranging from 0.92-111 ng/mg (mean 28.35). 
In order to determine if any relationship exists 
between blood and vitreous humor results, it 
will be necessary to review more cases. 
However, primary results have shown that in 
general, positive vitreous humor results are 
lower than the corresponding blood results. 
The results obtained from hair analysis verify 
information available on previous drug histories 
e. g. four of the cases were receiving methadone 
treament prior to death. In two of these cases 
methadone was not detected in blood or vitreous 
humor. The hair analysis was positive. 
Conclusions 
This study has demonstrated the use of 
supercritical fluids in the extraction of drugs of 
abuse from blood, vitreous humor and hair. It 
provides a fast and efficient alternative to 
conventional extraction methods. 
As only 100 µL of sample is required for 
blood and vitreous humor extractions, it is more 
economical in its use of sample than 
conventional procedures. 
It is beneficial to find that the hair extraction 
method works for all three drug types 
investigated, resulting in a requirement for only 
one extraction per case. Ordinarily, the 
digestion conditions for hair have to be carefully 
selected to ensure no artefact production. In the 
case of supercritical fluid extraction this is not 
an issue as the conditions used are relatively 
mild. 
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Development of a Supercritical Fluid Extraction Method 
for the Determination of Temazepam in Whole Blood 
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Abstract 
A supercritical fluid extraction (SFE) procedure for the analysis of 
temazepam from whole blood was developed. Quantitative 
recoveries were obtained by high-performance liquid 
chromatography using prazepam as an internal standard and 
carefully monitoring the extraction temperature and pressure. The 
results were found to compare well with those obtained by solid- 
phase extraction techniques, but they also had the advantages of 
reduced solvent consumption and minimal sample handling. The 
application of this method to authentic forensic blood specimens 
showed the SFE method to be useful as an alternative procedure for 
the extraction of temazepam in the toxicology laboratory. 
Introduction 
In western Scotland in 1994, some 141 deaths in which 
temazepam was a contributory factor were reported. Between 
1993 and 1995, an 80% increase in the number of drivers found 
with considerable levels of temazepam was observed (1). These 
figures reflect the increasing trend in temazepam abuse in 
Scotland. 
At present, temazepam analysis from biological matrices 
involves a solid-phase extraction (SPE) method. The procedure 
used is a modification of that reported by Zweipfenning et al. (2). 
Disadvantages of this procedure include the need for high-purity 
organic solvents and the resultant generation of substantial 
quantities of waste solvent. In addition, the sample preparation 
can be tedious and time consuming with increased potential for 
contamination (3). As an alternative method of sample prepa- 
ration, the use of supercritical CO2 has been investigated. 
In addition to speed and convenience, the main advantages of 
supercritical fluid extraction (SFE) are the improved efficiency, 
the nontoxicity, the cost effectiveness of the extraction fluid, 
and the possibility for direct analysis of complex matrices, thus 
reducing the risk of sample contamination (4). 
In order to develop a method for SFE, the analyst must have 
an understanding of the properties of the analyte and the com- 
" Author to wean correspondence should be addrossed. 
position of the matrix (5). As the benzodiazepines were rela- 
tively polar, it was necessary to modify the CO2 by the addition 
of an entrainer (ethyl acetate) in order for the extraction to be 
feasible. The solvating power of the supercritical fluid was 
optimized by varying the pressure and temperature to obtain 
the maximum recovery of temazepam. 
Quantitation by the SFE method was achieved by the addi- 
tion of prazepam as an internal standard. The optimum condi- 
tions for temazepam gave peak-area ratios comparable with 
those of unextracted standards as long as the temperature and 
pressure were carefully controlled. 
The developed method was first used to assess SFE in com- 
parison with SPE for the extraction of temazepam and 
prazepam standards from methanol and blood. It was then 
used to investigate the analysis of authentic forensic blood 
specimens, again by comparison with SPE. 
Experimental 
Materials 
Temazepam and prazepzm were supplied by Wyeth Labora- 
tory (Hants, U. K. ). Methanol, ethyl acetate, diethyl ether, and dichloromethane were high-performance liquid chromato- 
graphic HPLC/grade (Lab Scan Analytical Sciences, Dublin, 
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Figure 1. Peak-height ratio versus pressure. 
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Ireland), and ammonia was analytical grade (Merck, Poole, 
U. K. ). KHIPO4 was HiPerSolv grade, and Na2HPO4 was CPR 
grade (Merck). The CO2 was supplied by Air Products (Walton- 
on-Thames, U. K. ) in 25-kg cylinders fitted with a dip tube. 
Plastic syringes for SPE were 10-mL sterile Plastipak syringes 
(Becton Dickinson, Oxford, U. K. ). Glass wool for SPE was 
silanized (Jones Chromatography, Mid Glamorgan, U. K. ). 
Extrelut® (Merck) was prewashed using dichloromethane. The 
vials used for SPE' were Anchor and Trident (FBC, London, 
U. K. ) with screw caps (Merck). The vials used for SFE were 6 
mL HypoVialT`4 (Pierce, Oud-Beijerland, The Netherlands) with 
butyl rubber septa (Pierce and Warriner, Chester, U. K. ). 
Columns for the SFE were made using 3 cm x 4.6-mm internal 
diameter stainless steel tubing. Water for the HPLC mobile 
phase was deionized using a Milli-Q® water purification system 
(Millipore, Watford, U. K. ). -_ 
Apparatus 
The SFE system consisted of two Gilson (Middleton, WI) 306 
pumps, a PYE Unicam (Cambridge, U. K. ) series 104 GC oven with 
pressure restrictor, and a Spectroflow (Kratos, Manchester, U. K) 
757 UV detector. All components were modified to suit the super- 
critical extractant. The CO2 pumphead was refrigerated with a 
Gilson model SFC3 refrigeration unit to maintain the flow of 
liquid CO:. The extraction cell was placed over the loop position 
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of a Rheodyne (Cotati, CA) 7161. The extract was collected by 
expansion into methanol in a HypoVial at the flow outlet. The 
extractant was C02-ethyl acetate (95: 5) at 2 mUmin. The tem- 
perature and pressure were 65°C and 3000 psi, respectively. The 
extraction was monitored at a wavelength of 254 nm. 
The HPLC system consisted of a Gilson 305 pump and a Gilson 
115 UV detector. The column (25 cm x 4.6 mm) and guard 
column (2 cm x 4.6 mm) used were prepacked with Hypersil ODS 
(5 µm) (Capital HPLC Specialists, Bathgate, U. K). The injector 
valve was a Rheodyne 7161 with a 24-µI, sample loop. The mobile 
phase used was Na2HP04-methanol (30: 70, W. The flow rate was 
1 mUmin, and the eluent was monitored at 254 nm. 
Preparation of standards for comparison 
A series of standards ranging from 0 to 12.8 mg/L temazepam 
with 11.24 mg/L praaepam were prepared in both methanol and 
blood. Both sets were prepared by adding the appropriate vol- 
umes of each drug stock standard (12.8 mg temazepam per 
liter methanol, 56.2 mg prazepam per liter methanol) to a vial, 
evaporating at 65°C under N2, and reconstituting in 5 mL of 
either methanol or blood. 
SPE procedure 
The extraction columns were prepared by plugging the end 
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Figure S. Comparison of SPE and SFE results for the analysis of forensic toxicological case samples. 
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with approximately 10 g of Extrelut, and pipetting 0.25 mL of 
a 5% NH3 solution onto the top. Either 1 mL of standard 
blood, 0.9 mL of blank blood, and 100 uL prazepam standard 
(5 mg/100 mL in methanol) or 0.9 mL of sample blood and 
100 pL prazepam (5 mg/100 mL) were pipetted into a clean 
glass vial. To this mixture, 1 mL of phosphate buffer (A, 13.6 
g KHIP04 in 500 mL H20; B, 4g NaOH in 500 mL H20,450 
mL i and 355 mL B, pH adjusted to 4 using A or B) and 0.25 
mL of a 5% NH3 solution were added. The contents of the vial 
were mixed thoroughly, then pipetted onto the extraction 
column. After 5 min, the temazepam and prazepam were 
eluted under the influence of gravity using diethyl ether. Once 
8 mL was collected, the eluent was evaporated to dryness at 
65°C under nitrogen and reconstituted in 180 pL of HPLC 
mobile phase. 
SFE procedure 
Approximately 0.2 g of Extrelut was placed in a plastic weigh- 
ing boat. To this solution, 0.5 mL of standard blood-methanol. 
0.4 mL blank blood, and 100 pL prazeparn (5 mg/100 mL) or 
0.4 mL sample blood and 100 pL prazepam (5 mg/100 mL) were 
Table 1. Comparison of SPE and SFE Results for the 
Analysis of Forensic Toxicological Case Samples 
SPE SEE 
Case (mg/L) (mg/L) % Difference 
RTD94 266 8.04 757 5.8 
RTD9S 032 2.38 2.13 10.5 
RTD95 036 2.34 2.43 3.8 
RTD93 039 3.20 3.06 4.4 
RTD93 057 1.08 1.22 13.0 
T941297 2.43 2.51 3.3 
T941310 1.40 1.48 5.7 
1941329 2.92 3.12 6.8 
T95117 1.81 1.77 2.2 
793182 3.45 3.83 11.0 
T95 241 1.07 1.02 
_ 
4.7 
added. After mixing. the contents of the boat were allowed to dry 
at room temperature, until a friable consistency was achieved 
(approximately 1-2 h), before being transferred to an extraction 
column. It was not necessary to completely dry the samples 
but, when possible, the samples were left overnight. The column 
was sealed and placed over the loop position of the Rheodyne in 
the equilibrated SFE system. The extraction was started by 
switching the Rheodyne from load to inject and was carried out 
for 10 min. The collected extract was dried at 65°C under nitro- 
gen and reconstituted in 50 uL of HPLC mobile phase. 
Results and Discussion 
Reproducibility problems were encountered when the extrac-' 
tion conditions were not carefully controlled; in particular, 
care was required in the control of pressure. Figure 1 shows 
how small fluctuations in pressure can affect the peak-height 
ratios. The pressure chosen for the extractions was 3000 psi. 
The rate of change in peak-height ratio with pressure for the 
extracted standards compared with unextracted standards was 
less pronounced. 
Extractions were tried at various temperatures between 50 
and 100°C. The temperature for the optimum recovery of 
temazepam was found to be around 60°C. Figure 2 shows the 
variation in peak-height ratio around this value. and, from this, 
an extraction temperature of 65°C was chosen. 
In the absence of matrix interferences, the peak-area ratios 
obtained by SFE were found to be linear over the range 0-12.8 
mg/L temazepam (r2 = 0.999). Figure 3 shows that the peak- 
area ratios for both SFE and SPE compare well with those 
obtained for unextracted standards (m,,,, = 0.15, m5 = 0.134, 
mSPE = 0.158). 
As SFE exhibits its best advantages when extracting analytes 
from solids or semi-solids (6), all blood samples were dried 
before analysis. This also avoids problems that may occur 
because of Joule-Thomson cooling as the supercriti:. al fluid 
expands at the outlet. No matrix interferences 
from the blood were noted other than a slight 
decrease in the recovery of both drugs 
(80-100% compared with 90-100% from 
methanol). Again, the SFE was found to be 
linear over the range 0-12.8 mg/L temazepam 
as shown in Figure 4 (r2 = 0.995). Compar- 
ison with unextracted standards and SPE was 
favorable (m,,,, vd = 0.11, msFE = 0.111. msPE = 0.131). A comparative chromatogram of SPE 
and SFE extracted blood standards is given in 
Figure S. 
Investigation of the SFE and SPE methods 
st on authentic forensic specimens showed that 
sPE the methods correlate well. Table I and Figure 
15.00 6 show the results obtained. The SFE method 
was also found to extract other benzodi- 
'E. (SFE temazepam- azepines and their metabolites of forensic in- 
terest, including diazepam, nordiazepam, ox- 
azepam, and chlordiazepoxide. 
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Conclusion 
With careful control of temperature and pressure, both 
temazeparn and prazepam can be extracted to the same extent 
from blood with recoveries of 80-100%. Reproducible results 
can also be achieved as long as the pressure fluctuations are 
kept to a minimum (=150 psi). 
The results obtained show that the SFE method can be used 
as an alternative procedure for the extraction of temazepam 
from forensic blood samples, with the potential for use as an 
extraction procedure for other benzodiazepines of forensic sig- 
nificance. The method offers a rapid, environmentally friendly 
approach that requires minimal sample handling. 
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SUPERCRITICAL FLUID EXTRACTION AS A SAMPLE PREPARATION 
TECHNIQUE FOR THE DETERMINATION OF MORPHINE AND 6- 
MONOACETYL-MORPHINE IN POST-MORTEM BLOOD AND VITREOUS 
HUMOR. 
Karen S. Scott, John S. Oliver. Department of Forensic Medicine and Science, 
University of Glasgow, Glasgow, G12 8QQ, UK. 
Abstract 
The use of supercritical fluid extraction (SFE) was investigated for the detection of 
heroin abuse by quantifying levels of morphine and 6-monoacetyl-morphine (6- 
MAM) in post-mortem blood and vitreous humor samples. The levels achieved in 
each of the two toxicological specimens were compared on a case to case basis to 
determine if a correlation exists. 
Blood/vitreous humor samples containing deuterated morphine as the internal 
standard, were loaded on Extrelut®, dried at room temperature and then extracted 
using supercritical carbon dioxide: methanol: triethylamine (90: 8.5: 1.5) at 100°C and 
3500 psi for 20 minutes. The collected extracts were analysed by GC/MS. 
Results show that, in general, the levels of morphine obtained from blood are higher 
than the corresponding levels in vitreous humor and that correlation between the two 
sample types is good. Preliminary studies for 6-MAM again show lower levels in 
vitreous humor than in blood, with the levels being lower than the corresponding 
morphine levels in both cases. However for 6-MAM, no correlation between blood 
and vitreous humor was found. 
Introduction 
Heroin (diamorphine) abuse in the West of Scotland has been on the increase for 
several years now and has only just started to decrease with the introduction of 
methadone maintenance programmes(1). At present confirmation of heroin abuse as a 
contributory factor to death, is achieved by the detection of morphine in the blood or 
urine and circumstantial evidence obtained from the examination of postmortem 
reports, police reports and statements from friends and relatives of the deceased. 
However, in some cases the information gathered may be insufficient to confirm the 
use of heroin prior to death. Therefore, by detecting the presence of the primary 
metabolite of diamorphine (6-monoacetylmorphine) in body fluids, namely blood and 
vitreous humor, the abuse of heroin could be verified. 
Over the past few decades, supercritical fluid extraction (SFE) has been widely 
investigated in many fields of study including forensic toxicology(2,3). Although its 
use has not escalated in the routine laboratory, it has many advantages which may be 
exploited by the toxicologist. Due to difficulties in automating instrumentation for 
SFE, its advantages must be taken on a case to case basis. Extractions can be carried 
out quickly and efficiently with minimal sample handling. Unlike other types of 
extraction where selectivity is achieved using separate solvents, the same solvent can 
be used to selectively extract a wide range of sample types by simply varying the 
pressure, temperature or percentage of solvent in the supercritical fluid. Commonly 
used supercritical fluids include carbon dioxide and Xenon thus reducing and in some 
cases omitting the risks incurred on the environment by conventional liquid solvents. 
Experimental 
Sample preparation (21 
Approximately 0.2 g of Extrelut0 were placed in a plastic weighing boat. To this, 
200 tL of sample blood / vitreous humor and 100 µL of D3-morphine were added. 
After mixing, the contents of the boat were allowed to dry at room temperature, until a 
friable consistency was achieved (-1-2 hours), before being transferred to an 
extraction column. It is not necessary to completely dry the samples, but where 
possible, the samples were left overnight. The column was sealed and placed over the 
sample loop position of the Rheodyne in the equilibrated SFE system. The extraction 
was started by switching the Rheodyne from load to inject. The collected extract was 
dried at 65 °C under nitrogen then derivatised with 50 tL of BSTFA (1%TMCS) at 90 
°C for 10 minutes before injecting onto the GC-MS. 
SFE 
The SFE system consisted of two Gilson 306 pumps and a PYE series 104 GC oven 
with pressure restrictor. All components were modified to suit the supercritical 
extractant. The CO2 pumphead was refrigerated to maintain the flow of liquid CO2 
using a Gilson model SFC3 refrigeration unit. The extraction cell was placed over the 
loop position of a Rheodyne 7161. The extract was collected for 20 minutes by 
expansion into methanol in a HypoVialT"" at the flow outlet. The extractant was C02 : 
methanol : triethylamine (90 : 8.5 : 1.5) at 2 mlJmin. The temperature and pressure 
were 100 °C and 3500 psi respectively. 
GC-MS conditions 
Model: Fisons GC8000 series with MD800 EI mode (70eV) 
Column: HP-1 fused silica widebore capillary (30 m, 0.53 mm 
i. d., 0.88 µm film thickness) 
Temperature programme: 150°C-300°C @ 10°C/min, hold for 5 minutes 
Injector temperature: 225°C 
Interface temperature: 250°C 
SIM: Morphine m/z: 414,429 
6-MAM m/z: 340,399 
D3-morphine m/z: 432 
Cases 
The information available on the 20 cases studied is summarised below: 
" 13 males: Age 20-39 (mean 30); 7 females: Age 27-40 (mean 31) 
" Cause of death: 11 respiratory failure, 4 aspiration of gastric contents. All drug 
related 
" 12 known intravenous drug abusers 
" 17 sudden deaths 
" 17 with fresh needle puncture marks (not due to hospital treatment) 
" 15 with drug paraphernalia at the place of death (e. g. syringe in close 
proximity/still injected, powders/tablets in the vacinity of the body, ligature still 
tied round arm) 
" 18 poly drug deaths (8x2 drugs, 5x3 drugs, 3x4 drugs, 1x5 drugs, lx9 drugs). 
Drugs found: benzodiazepines (n=15), methadone (n=4), paracetamol (n=2), 
norpropoxyphene (n=1), amphetamines (n=1), cocaine (n=1) 
"9 cases positive for alcohol 
The morphine and 6-monoacetylmorphine levels found in each of the 20 cases are 
listed in Table 1. A plot of the concentration found in blood versus the concentration 
found in vitreous humor is shown in Figure 1. It can be seen that a correlation exists 
between the matrices for morphine (r2 = 0.697). In addition the levels found in 
vitreous humor are in general less than the corresponding blood levels (gradient = 
0.701). In contrast from Figure 2 it is apparent that no correlation exists between 
blood and vitreous humor for 6-monoacetylmorphine (r2 = 0.006). 
Case B10od 
Morphine (mg/L) 6-MAM (mg/L) 
Vitreous Humor 
Morphine (mg/L) 6-MAM (mg/L) 
1 1.18 0.51 1.22 0.42 
2 1.30 0.14 0.13 0.51 
3 0.05 0.10 0.09 1.72 
4 0.73 0.14 0.46 0.03 
5 0.81 -ve 0.42 0.73 
6 0.81 -ve 0.67 0.06 
7 1.68 0.07 1.48 0.96 
8 2.14 0.04 1.69 0.01 
9 0.48 -ve 0.07 -ve 
10 0.24 -ve 0.18 0.05 
11 0.34 -ve 0.44 -ve 
12 0.79 -ve 0.62 -ve 
13 0.45 0.08 0.16 0.02 
14 0.25 -ve 0.31 0.09 
15 0.16 0.38 0.18 -ve 
16 0.74 -ve 0.71 0.02 
17 0.25 0.23 0.23 -ve 
18 0.28 0.05 0.23 0.006 
19 0.28 0.01 0.27 0.08 
20 0.29 0.16 0.55 0.11 
Table 1 Case Results 
All 20 of the cases studied were positive for morphine, however from Table I it can 
be seen that three of the cases were not positive for 6-MAM in either blood or vitreous 
humor. In these instances, if corroborative information were not available, it would 
not be possible to state that the death was heroin related. 
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Conclusions 
In conclusion we have found SFE to be a useful tool in the analysis of morphine and 
6-monoacetylmorphine from both blood and vitreous humor samples. This in addition 
to the information available on the deceased can be used to prove that death was 
contributed to by the use of heroin. The method has been found to compare well to 
conventional solid-phase extraction methods for morphine (r2=0.99)t33 and therefore 
can be used in the toxicology laboratory. In addition we have shown that it is possible 
to use vitreous humor as a toxicological sample. This may be of use in cases where 
blood is not avalable for analysis. 
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Abstract 
The use of vitreous humor as an alternative sample to blood was investigated for the 
detection of heroin abuse by quantifying levels of morphine and 6-monoacetyl- 
morphine (6-MAM) in post-mortem samples. The levels achieved in each of the two 
toxicological specimens were compared on a case to case basis to determine if a 
correlation existed. A total of 20 positive morphine cases were examined. In general 
the levels of morphine in blood were higher than in the corresponding vitreous humor 
samples, with some correlation existing. 6-MAM was found in 15 blood samples and 
17 vitreous humor samples. Although no correlation was found between the levels of 
6-MAM in blood and vitreous humor, the latter may still be used for verification of 
heroin abuse. 
Introduction 
The use of vitreous humor as an alternative sample matrix for the determination of 
drugs has been recently reviewed by several workers. (Bermejo et al, 1992, McKinney 
et al, 1994, Samuel et al, 1994) However, without further understanding of the 
relationship between the levels obtained in conventional sample types (i. e. blood, 
urine) the interpretation of analytical results for vitreous humor is difficult. 
For several years deaths due to the abuse of heroin (diamorphine) in the West of 
Scotland have been on the increase. However, at present the confirmation of heroin 
abuse as a contributory factor to death, depends heavily on the circumstantial evidence 
obtained from the examination of postmortem reports, police reports and witness 
statements. This information is verified by quantitation of morphine in the case blood 
or, urine. In order to provide a better toxicological support for the circumstantial 
evidence it is necessary to look for a more specific diamorphine marker. The 
metabolic pathway of diamorphine is shown in Figure 1. From the half lives it is 
apparent that the routine detection of diamorphine is not practical. However, due to 
its longer half life, 6-MAM should provide a more practical diamorphine marker and 
thus it was chosen for this study. 
A recent study on the comparison of supercritical fluid extraction and solid-phase 
extraction for the detection of morphine in postmortem blood samples showed 
excellent correlation between the two methods. (Allen et al, 1997) Although the use 
of SFE in forensic toxicology is not widespread, it has many advantages which may be 
exploited by the toxicologist. In addition to speed and efficiency of extraction one of 
the main advantages of SFE is the potential for using a single solvent to selectively 
extract a wide range of sample types simply by varying the pressure or temperature of 
the supercritical fluid. Due to its practical critical temperature and pressure and low 
cost, carbon dioxide is the most commonly used supercritical fluid, thus the need for 
organic solvents is reduced. 
Experimental 
Materials 
Morphine, 6-monoacetlymorphine and D3-morphine were supplied by Sigma (Poole, 
U. K. ). Methanol, dichloromethane were high performance liquid chromatographic 
(HPLC) grade, (Lab Scan Analytical Sciences, Dublin, Ireland). BSTFA (1% TMCS) 
used as the GC-MS derivatising agent was supplied by Pierce (Rockford, IL, USA). 
Triethylamine general purpose reagent (GPR) grade was supplied by Merck (Poole, 
U. K. ). Extrelut® (Merck) was prewashed using dichloromethane. The collection 
vials for SFE, were 6mL HypoVialTM (Pierce, Oud-Biejerland, The Netherlands) with 
butyl rubber septa (Pierce and Warriner, Chester, U. K. ) 
Apparatus 
The SFE system is described elsewhere (Scott et al, 1997). The extraction was carried 
out for 20-30 minutes using C02-methanol-triethylamine (90: 8.5: 1.5) at 2.0 mL/min 
with a temperature of 100 °C and a pressure of 3500 psi. The analytes were collected 
by expansion into methanol at the flow outlet. 
The GC/MS system consisted of a Fisons GC8000 series with MD800 EI mode (70 
eV) fitted with a HP-1 fused silica widebore capillary column (30 m, 0.53 mm i. d., 
0.88 µm film thickness). The temperature was programmed from 150 °C to 300 °C at 
10 °C/minute and held for 5 minutes. The injector temperature was 225 °C and the 
interface temperature 250 °C. Selected ion monitoring was used with the following 
ions: morphine m/z 414 and 429,6-MAM m/z 340 and 399, D3-morphine m/z 432. 
Sample preparation 
Approximately 0.2 g of Extrelut0 was placed in a plastic weighing boat. To this, 200 
µL of sample blood / vitreous humor and 100 µL of D3-morphine were added. After 
mixing, the contents of the boat were allowed to dry at room temperature, until a 
friable consistency was achieved (-1-2 hours), before being transferred to an 
extraction column. The column was sealed and placed over the loop position of the 
Rheodyne in the equilibrated SFE system. The extraction was started by switching the 
Rheodyne from load to inject. The collected extract was dried at 65 °C under nitrogen 
then derivatised with 50 µL of BSTFA (1%TMCS) at 90 °C for 10 minutes before 
injecting onto the GC-MS. 
Cases 
The information available on the 20 cases studied is summarised in Table I. Using 
only this information it should be possible to predict whether 6-MAM will be present 
in the blood and vitreous humor. For example in case 1, the deceased was a known 
intravenous heroin abuser who died suddenly. Fresh needle puncture marks were 
found on the body and a syringe was found in close proximity to the body. Therefore, 
in this case, we would expect to find traces of 6-MAM. In contrast with case 15, there 
was no evidence of heroin abuse and thus we would not expect to find morphine or 6- 
MAM. 
Results and discussion 
The levels of morphine and 6-monoacetylmorphine found in each of the 20 cases are 
listed in Table II. A plot of the morphine concentration found in blood versus the 
concentration found in vitreous humor is shown in Figure 2. It can be seen that a 
correlation exists between the matrices for morphine (r2 = 0.697). For the 17 sudden 
death cases only, the correlation coefficient is 0.885, indicating a dependance on the 
rate of death. The levels found in vitreous humor are in general less than the 
corresponding blood levels (gradient = 0.701 (0.811 for sudden deaths)). In contrast 
from Figure 3 it is apparent that no correlation exists between the levels found in 
blood and vitreous humor for 6-monoacetylmorphine (r2 = 0.006) even when the 
sudden deaths are taken separately (r2 = 0.03). 
All 20 of the cases studied were positive for morphine, however from Table I it can be 
seen that three of the cases were not positive for 6-MAM in either blood or vitreous 
humor (9,11,12) Therefore, in the absence of corroborative information, it would not 
be possible to state that the death was heroin related in these cases. On the other hand, 
the circumstantial evidence does not imply death related to heroin overdose in cases 2, 
4,15 and 19, yet the results show that these cases were in fact heroin related due to the 
presence of 6-MAM in the blood / vitreous humor. 
Conclusions 
SFE can be successfully used for the quantitation of 6-MAM in both blood and 
vitreous humor samples. The detection of this compound is useful in the confirmation 
of death due to heroin overdose. However, due to the short half life of 6-MAM it is 
necessary to review the case notes relating to a particular toxicology file before 
making a judgement as to the contribution of drugs to the death. The good correlation 
between blood and vitreous humor levels for morphine, indicates that this is an ideal 
matrix for use when blood is not available or is badly denatured. For the 
determination of 6-MAM, it has been shown that in general higher levels are 
measured in this matrix, however no correlation between the two matrices exists and 
thus further work will need to be carried out in order to determine the value of 
vitreous humor as an alternative for the quantitation of 6-MAM. 
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